The human RNase MRP complex : composition, assembly and role in human disease by Eenennaam, Hans van
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/19147
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
The human 
RNase MRP 
complex
Composition, assembly and 
role in human disease
T
h
e
 h
u
m
a
n
 R
N
a
se
 M
R
P
 co
m
p
le
x
 
 
 
Hans van Eenennaam
H
a
n
s va
n
 E
e
n
e
n
n
a
a
m
The human 
RNase MRP 
complex
Composition, assembly and 
role in human disease
Hans van Eenennaam, 2002
The human RNase MRP complex
Composition, assembly and role in human disease
een wetenschappelijke proeve op het gebied van de
Natuurwetenschappen, Wiskunde en Informatica
PROEFSCHRIFT
ter verkrijging van de graad van doctor
aan de Katholieke Universiteit Nijmegen,
volgens besluit van het College van Decanen
in het openbaar te verdedigen op
vrijdag 14 juni 2002
des namiddags om 1:30 uur precies
door
Hans van Eenennaam
geboren op 3 november 1973
te Middelburg
Cover illustration
Statue of the Dwarf Seneb and his family, 
painted limestone, height 34 cm, width 22.5 cm, 
Giza, Tomb of Seneb, Late Fifth - Early Sixth 
Dynasty.
From: The Cairo museum Masterpieces of 
Egyptian Art, Francesco Tiradritti, Thames & 
Hudson Ltd, London, 1998
voor mijn ouders
Promotor
Prof. Dr. W.J. van Venrooij
Co-promotor
Dr. G.J.M. Pruijn
Manuscriptcommissie
Prof. Dr. L.B.A. van de Putte
Prof. Dr. F.P.J.T. Rutjes
Prof. Dr. H.F. Tabak (Universiteit van Amsterdam)
ISBN 90-9015696-8
© 2002 by Hans van Eenennaam
The research described in this thesis was performed at the Department of Biochemistry, Faculty 
of Science, University of Nijmegen, the Netherlands. This work was supported in part by the 
Netherlands Foundation for Scientific Research (NWO-CW).
Table of contents
hoe
als je je
met zorgeloosheid
kon omringen
en dat dat
je ruimte
was
(Bert Schierbeek)
Chapter 1   General introduction .................................................................................. 9
Part I
Chapter 2   hPop4: a new protein subunit of the human RNase MRP............................ 25
                  and RNase P ribonucleoprotein complexes
Chapter 3   hPop5, a protein subunit of the human RNase MRP................................... 39
                  and RNase P endoribonucleases
Part II
Chapter 4   Basic domains target protein subunits of the RNase MRP ........................... 55
                  complex to the nucleolus independently of complex association
Chapter 5   RNA-protein interactions in the human RNase MRP .................................. 71
                  ribonucleoprotein complex
Chapter 6   Identity of the RNase MRP and RNase P associated.................................... 91
                  Th/To-autoantigen. 
Part III
Chapter 7   Autoantibodies against small nucleolar ribonucleoprotein ........................ 107
                  complexes and their clinical associations. 
Chapter 8   Mutations in the RNA component of the RNase MRP cause a ................... 121
                  pleiotropic human disease, cartilage-hair hypoplasia. 
Part IV
Chapter 9   General discussion.................................................................................. 137
                  Samenvatting/Summary.......................................................................... 151
                  References.............................................................................................. 155
                  List of publications................................................................................. 162
                  Dankwoord en acknowledgements .......................................................... 163
                  Curriculum vitae .................................................................................... 167
General introduction
Adapted from IUBMB Life (2000) 49: 265-272
Chapter 1
11
1
G e n e r a l  i n t r o d u c t i o n
(1,2). These processing and modification events 
are mediated by small nucleolar RNAs and their 
associated proteins (the so-called small nucleo-
lar ribonucleoproteins or snoRNPs). Although 
snoRNAs are heterogeneous in size, snoRNAs 
can be classified in three distinct groups based 
on conserved sequence elements: box C/D 
snoRNAs, box H/ACA snoRNAs and RNase 
MRP/RNase P RNAs ((3), reviewed in ref. (4,5)).
Small nucleolar 
ribonucleoprotein particles
In eukaryotes the 5.8S, 18S and 25/28S 
rRNAs are transcribed by RNA polymerase I 
as one long precursor. The processing of this 
precursor not only involves endo- and exonu-
cleolytic cleavages, but also ribose methylation 
and conversion of uridines to pseudouridines 
Nowadays, it is generally assumed that the ‘RNA world’ was one of the early phases in the evolution of life. At that stage of evolu-tion ribonucleic acids (RNAs) were thought to play a key role in 
the catalysis of chemical reactions and its own replication. In the current 
phase of evolution, one of the major functions of RNA is the transfer of 
information stored in genes, from DNA (deoxyribonucleic acid) to proteins. 
During this process, a copy of the DNA is made in the form of messenger 
RNA (mRNA). This messenger RNA is subsequently transported to the site of 
protein synthesis, where the message is translated and the encoded protein 
is synthesised. In the latter process, two other classes of RNA are involved. 
The transfer RNAs (tRNA) delivers the amino acids to the ribosome. This 
synthesising machinery binds the incoming amino acids to the growing 
polypeptide chain. The ribosome itself contains numerous proteins and 
four RNAs, called ribosomal RNAs (rRNA).
Before these different RNAs (mRNA, tRNA and rRNA) can function in the 
above-described processes, they undergo a maturation process directly after 
their synthesis. In eukaryotes all these RNAs are cleaved and/or undergo 
modifications such as ribose-methylation and conversion of a uridine to a 
pseudouridine. The cleavage generating the mature 5’-end of tRNAs and the 
cleavages and modifications needed for the complete maturation of rRNAs 
are mediated by other RNAs that are primarily found in the nucleolus and 
therefore designated as small nucleolar RNAs or snoRNAs.
In this chapter our knowledge on the structure and function of these small 
nucleolar RNAs, with emphasis on the RNase MRP and RNase P complexes, 
will be summarised.
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Box C/D snoRNPs
The box C/D snoRNAs contain the con-
served C (consensus sequence: RUGAUGA) and 
D (consensus sequence: CUGA) boxes, which 
are frequently followed or preceded by a stem 
structure (see Figure 1A). Imperfect copies 
of box C/D sequences (referred to as box C’ 
and D’) have been described and are located 
between box C and box D (6-8). Most of the 
box C/D snoRNAs, e.g. U24-U63, harbour an 
extended region (10-21 nucleotides) of base 
complementarity to rRNA, thereby positioning 
box D and/or D’ exactly 5 nucleotides from the 
nucleotide that has to be modified via 2’-O-
ribose methylation (Figure 1A) (6,9).
At present 51 of the 55 ribose methylation 
sites in yeast ribosomal RNA have been assigned 
to 41 different guide snoRNAs (10). In mam-
mals 105-107 ribose methylation sites have 
been mapped and at present only 14 ribose 
methylations remain without identified cog-
nate guide snoRNA (2,11).
A small group of box C/D snoRNAs lack 
sequence complementarity to rRNA and these 
snoRNAs have been demonstrated to function 
in endonucleolytic processing of pre-rRNA. 
This group includes U3, U8, U13 and U22 
snoRNA (reviewed in ref. (4,5,12))
Three proteins have been shown to be 
specifically associated with all box C/D 
snoRNAs: fibrillarin, Nop56 and Nop5/58 
(13-15). Although no clear function has been 
demonstrated for these proteins, sequence and 
structure homology between known methyl-
transferases and fibrillarin strongly suggest 
that fibrillarin is the 2’-O-methyltransferase 
enzyme (16).
Box H/ACA snoRNPs
The box H/ACA snoRNAs possess 5’ and 
3’ hairpin domains, connected and followed 
by single-stranded hinge and tail regions that 
carry the conserved H (AnAnnA) and ACA 
boxes, respectively (Figure 1B). Two short 
“rRNA recognition motifs” present in the 
snoRNA are able to base pair with rRNA 
sequences flanking the uridine to be converted 
into pseudouridine (Figure 1B) (3,17).
At present, 42 of the 91-93 pseudouri-
dines present in mammalian rRNAs can be 
explained by the identification of 40 box 
H/ACA snoRNAs, e.g. U64-U72 ((2,11) and refe-
rences therein).
Four proteins have been shown to be spe-
cifically associated with box H/ACA snoRNAs: 
hGar1, NAP57/dyskerin, hNHP2 and hNOP10 
(18-20). The homology between NAP57/
dyskerin and pseudouridine synthases involved 
in tRNA and bacterial rRNA modifications 
strongly suggests that NAP57/dyskerin repre-
sents the pseudouridine synthase associated 
with the box H/ACA snoRNPs (21).
RNase MRP/RNase P
The RNase MRP and RNase P complexes 
are the only known representatives of the third 
class of small nucleolar RNPs. Both ribonucleo-
protein particles function as endonucleases and 
have been shown to be involved in the process-
ing of pre-rRNA and pre-tRNA, respectively. A 
more detailed overview of these complexes is 
given below.
RNase MRP and RNase P 
ribonucleoprotein 
particles
Function and subcellular localisation of 
RNase MRP
The RNase MRP (for Mitochondrial RNA 
Processing) was originally identified in mouse 
cells by virtue of its ability to cleave the mito-
chondrial RNA that functions as a primer for 
mitochondrial DNA replication in vitro (22). 
Initiation of mitochondrial DNA replication 
occurs at two origins of replication (OH and 
OL). OH initiates the replication of the heavy 
strand of mtDNA, whereas OL is involved in the 
replication of the complementary light strand. 
Initiation of the replication of the heavy strand 
is a two step process (reviewed in ref. (23)). 
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Figure 1. Conserved features of the box C/D and box H/ACA snoRNAs (87).
A. Box C/D snoRNAs are characterised by conserved boxes C or C’ and boxes 
D or D’ and an extended region of base complementarity to rRNA, that fixes box 
D or D’ five nucleotides from the nucleotide that has to be 2’-O-ribose methyl-
ated. B. Box H/ACA is characterised by box H and ACA positioned in the hinge 
or tail region of these snoRNAs. Two rRNA recognition motifs basepair with the 
rRNA flanking the uridine that has to be converted to a pseudouridine.
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Figure 2. → Function of RNase MRP and RNase P complexes. 
A. RNase MRP has been shown to function in the processing 
of mitochondrial RNA that functions as a primer for DNA rep-
lication. The parental mtDNA are indicated with H-strand and 
L-strand, for heavy- and light-strand, respectively. Transcription 
starts from the Light Strand Promoter (LSP) and is initiated by 
a mitochondrial transcription factor (mtTFA) and mitochon-
drial RNA polymerase (mtRPOL). After transcription of the 
heavy strand origin of replication (O
H
), the transcript remains 
bound to the DNA duplex and is subsequently cleaved by 
RNase MRP to form primers that function in the inititation 
of DNA synthesis by DNA polymerase γ (reviewed in ref. 
(23,88)). (Continued on next page)
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First, RNA transcription of the light strand 
is initiated at the light-strand promoter (LSP) 
thereby forming a three stranded R-loop (RNA 
transcript with mitochondrial DNA) (24,25); 
see Figure 2A. Secondly, the RNA transcript is 
cleaved by RNase MRP to generate RNA mole-
cules that subsequently function as primers for 
the DNA synthesis of the heavy strand by DNA 
polymerase γ.
Biochemical purification of the RNase MRP 
activity from mitochondria showed that this 
enzyme is a ribonucleoprotein particle, that 
the RNA component is essential for its activity 
and that the RNA component is encoded in the 
nucleus (26,27).
In addition to its mitochondrial function, 
evidence for the involvement of the RNase 
MRP complex in the biogenesis of ribosomes 
has been obtained in the yeast Saccharomyces 
cerevisiae (28-30). RNase MRP was shown to 
cleave the precursor of ribosomal RNA at site 
A3 within the first internal transcribed spacer 
(ITS1) (see Figure 2B). Under normal growth 
conditions, two forms of 5.8S rRNA are pro-
duced, a long form and a short form, the latter 
being approximately 10 times more abundant 
than the former. When the RNase MRP acti-
vity is abrogated by mutation or depletion of 
one of its constituents, cleavage at site A3 of 
pre-rRNA is inhibited, leading to accumulation 
of the long form of 5.8S rRNA (28,29,31-38). 
Although no clear function of the two forms 
of 5.8S rRNA has been described, it has been 
shown that inhibition of 5.8S(S) rRNA synthe-
sis thereby enhancing the amount of 5.8S(L) 
rRNA, results in a change in the expression of 
several proteins, suggesting that these forms of 
5.8S rRNA play a role in the selective transla-
tion of (some) proteins (29). The identity of the 
proteins that are either up- or downregulated 
has not been investigated, yet.
Genetic depletion of either RNA or protein 
components of the RNase MRP complex demon-
strated that the RNase MRP complex is essen-
tial for yeast viability. However, it was shown 
that cleavage at site A3 in the pre-rRNA is 
not (39), suggesting that RNase MRP exhibits 
another, as yet unidentified, function that is 
essential for viability. The mitochondrial func-
tion of RNase MRP is probably also not essen-
tial for viability because yeast cells without 
mitochondrial DNA form petite colonies on a 
fermentable medium and are viable (reviewed 
in ref. (40)).
Recent findings in yeast suggest that the 
RNase MRP complex may also play a role in cell 
cycle control (41). Yeast cells containing muta-
tions in the gene encoding the RNase MRP spe-
cific protein subunit Snmlp show defects in 
plasmid segregation, which is suggested to be 
caused by telophase arrest. This effect has also 
been found with an RNase MRP RNA mutant, 
suggesting some role for RNase MRP in the 
breakdown of the mitotic spindle and closing 
steps of mitosis (41). Whether this cell cycle 
arrest is directly or indirectly caused by the 
defect of these mutants in pre-rRNA processing 
is at present unclear.
Subcellular partitioning and in situ hybri-
disation experiments confirmed the presence 
of RNase MRP in mitochondria and nucleoli 
(42,43), with the vast majority being localised 
in the nucleolus. The central region of the 
RNase MRP RNA (Figure 3A) is important for 
its mitochondrial localisation (42), whereas the 
5’ located P3 domain of the RNase MRP RNA 
(see below) is necessary for its nucleolar locali-
sation (44). These data suggest that two differ-
ent structural domains within the RNase MRP 
RNA, which is transcribed by RNA polymerase 
III in the nucleoplasm, mediate its transport to 
these different subcellular compartments.
Function and subcellular localisation of 
RNase P
The characterisation of the first tRNA pre-
cursor soon led to the identification of the 
enzymatic activity that processed the 5’ end of 
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Figure 2 (Continued) B. RNase MRP and RNase P have been shown to function in the processing of precursor rRNA in yeast. The 
35S (primary) transcript, as is depicted at the top, is processed to mature 25S, 18S, and 5.8S rRNAs (from (4)). The cleavage sites 
(A0 through E), the relative positions of the rRNA sequences (black boxes), the external transcribed spacers (5’ETS and 3’ETS), 
and the internal transcribed spacers (ITS1 and ITS2) are indicated. The small white box marks the sequence in the long form of 
5.8S rRNA, 5.8S(L), that is absent in the short form of 5.8S rRNA, 5.8S(S). RNase MRP is involved in the cleavage event at site A3 
in ITS1, whereas RNase P might be involved in the processing of ITS2 (reviewed in ref. (89)). (Continued on next page).
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Figure 2. (Continued). C. Processing of precursor tRNA. 
RNase P mediates the removal of the 5’ leader sequence of 
precursor tRNA. The 5’ leader, 3’ trailer, and intron elements 
are indicated (the latter being present in only a subset of pre-
tRNAs). Although end maturation precedes intron removal in 
this representation, the actual order of these events may be 
reversed (reviewed in ref. (53)).
C
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precursor tRNA in E. coli (45). Purification of 
the RNase P enzyme from E. coli showed that 
the enzyme is a ribonucleoprotein particle (46). 
The RNA subunit (M1 RNA) of E. coli RNase P 
is encoded by the rnpB gene and is 377 nucleo-
tides long (47). The protein component of the 
E. coli RNase P complex is encoded by the 
rnpA gene, consists of 119 amino acids and 
is called C5. (48). Although both components 
of the bacterial RNase P complex are neces-
sary for its pre-tRNA processing activity in 
vivo (49), enzymatic activity of the RNA com-
ponent alone could be demonstrated in vitro 
under conditions of high ionic strength (50).
Nowadays, RNase P complexes in bacteria, 
yeast and human have been identified (reviewed 
in ref. (51,52)) and all are able to process the 
precursor of tRNA. Processing of pre-tRNA 
in yeast and human includes multiple steps 
(Figure 2C). After removal of the 5’-leader and 
3’- trailer sequence by either endonuclease or 
exonuclease activity, the CCA trinucleotide is 
added to the 3’ end and nucleotides are modi-
fied (reviewed in ref. (53)). Before export to 
the cytoplasm can occur intervening sequences 
(introns), if present, will have to be removed.
Besides the tRNAs encoded in the nucleus, 
human and yeast cells both contain mitochon-
drially encoded tRNAs. Although the removal 
of the 5’-leader sequences of mitochondrial 
pre-tRNAs initially was appointed to a protein 
enzyme (54,55), recent data indicate that the 
mitochondrial RNase P activity is contained 
in a ribonucleoprotein complex, containing 
an RNA component identical to the nuclear 
RNase P RNA (43). At this moment it is unclear 
whether the same set of proteins is associated 
with both nuclear and mitochondrial RNase P 
complexes.
An additional function of the RNase P com-
plex has been reported a few years ago. Yeast 
cells containing mutations in the RNase P RNA 
showed, besides accumulation of pre-tRNA, 
accumulation of an aberrant form of 5.8S rRNA 
(56). This aberrant form of 5.8S rRNA was 
shown to have a 35 nucleotide extension at 
the 3’ end of the 5.8S rRNA, indicating that 
RNase P might also function in the cleavage of 
pre-rRNA in ITS2 (see Figure 2B).
In situ hybridisation experiments using 
both anti-sense oligonucleotides and nick-
translated DNA probes have revealed that the 
human RNase P complex is localised through-
out the cytoplasm and the nucleus (57,58) as 
well as in structures at the edge of the nucleolus 
known as perinucleolar compartments (PNCs) 
(59). These PNCs have been proposed to func-
tion in the biogenesis of RNA polymerase III 
transcripts and not to reflect active RNase 
P complexes (reviewed in ref. (53)). Micro-
injection of rhodamine-labeled RNase P RNA 
showed an initial localisation of RNase P RNA 
to the nucleolus followed by a redistribution 
throughout the nucleus (58). Deletion mutant 
analyses of the RNase P RNA suggested that 
the 5’ located P3 domain, which displays a 
predicted secondary structure similar to that 
of the RNase MRP RNA, is required for its 
nucleolar localisation (Figure 3B) (58). Further-
more, these experiments demonstrated that the 
3’-part of the RNase P RNA is important for 
the nucleoplasmic localisation observed after 
the initial nucleolar accumulation. In summary, 
the human RNase P complex has been shown 
to function in the processing of pre-tRNAs in 
both nucleus and mitochondria, which is con-
sistent with the reported subcellular localisa-
tions.
In the yeast Saccharomyces cerevisiae a dif-
ferent subcellular localisation has been reported 
for the RNase P complex. In situ hybridisation 
experiments in yeast indicated that RNase P 
RNA is predominantly found in the nucleolus 
(60). A nucleolar localisation has also been 
reported for some pre-tRNAs, suggesting that 
the removal of the 5’ leader of pre-tRNA in 
yeast may occur in the nucleolus (60). A nucleo-
lar localisation of RNase P is also consistent 
with its proposed role in the processing of pre-
rRNA in the ITS2 which also proceeds in this 
compartment (56).
Th/To autoantibodies facilitated the 
identification of human RNase MRP 
and P RNAs
The finding that patients with certain con-
nective tissue diseases produce autoantibodies 
directed against the human RNase P complex 
resulted in the identification of the RNA com-
ponent of human RNase P (also called H1 or 
8-2 RNA) (61-63). The identified RNA mole-
cule is 340 nucleotides long, is synthesised by 
RNA polymerase III and has a pppG 5’-end. 
The same autoimmune sera also immunopre-
cipitated the RNA component of the human 
RNase MRP particle (also called Th or 7-2 
RNA), which consists of 267 nucleotides, is also 
synthesised by RNA polymerase III and also 
has a pppG 5’-end (62,64-66). Patient antibo-
dies that recognise both RNase MRP and RNase 
P complexes are designated as anti-Th/To. The 
anti-Th/To specificity has been observed in 
4-13% of scleroderma patients (67,68). An ana-
lysis of clinical parameters showed that anti-
Th/To antibodies are predominantly found in 
scleroderma patients with limited cutaneous 
involvement and in certain patients with pri-
mary Raynaud’s phenomenon whose disease 
evolved to limited cutaneous involvement (67). 
The cumulative survival of patients with these 
antibodies was only 78% at 10 years, compared 
to 91% for patients that do not have anti-Th/To 
specificity.
The observation that patient antibodies 
often recognise both RNase MRP and RNase P 
complexes, strongly suggested that these com-
plexes are structurally related. Although the 
RNA components of RNase P and RNase MRP 
are poorly conserved at the sequence level, 
both experimental and phylogenetic data sug-
gest that they fold into similar secondary struc-
tures, as illustrated in Figure 3 (69,70).
These similar secondary structures are also 
referred to as cage-shaped structures (69) and 
correspond to the first three stem-loop struc-
tures, designated as P1-P3, and a long-range 
interaction (P4); see Figure 3. The similarity 
between the P3 domains of RNase MRP and 
RNase P RNAs is not restricted to their secon-
dary structures, because experiments with 
yeast mutants, in which the P3 domains of 
RNase MRP and RNase P had been swapped, 
demonstrated that such mutations did not lead 
to loss of function or specificity (71).
Because the Th/To-patients’ sera examined 
were unable to immunoprecipitate the RNA 
components of the RNase MRP and RNase P 
complexes from deproteinised cell extracts, it 
was concluded that these particles share at 
least one autoantigenic polypeptide (65). Using 
35S-methionine or 3H-leucine labelled HeLa cell 
extract, the autoantigenic protein was found 
to have a molecular weight of approximately 
40 kDa (68,72,73) and for this reason it was 
designated Th-40. Crossreactivity of antibodies 
raised against the E. coli RNase P protein with 
the Th-40 autoantigen strongly suggested that 
the Th-40 autoantigen represents the human 
18 C h a p t e r  1 19
1
G e n e r a l  i n t r o d u c t i o n
homologue of this prokaryotic RNase P pro-
tein (74). UV-crosslinking analysis showed that 
the autoantigenic Th-40 polypeptide could be 
UV-crosslinked to stem-loop P3 of RNase MRP 
and RNase P RNA (75,76). As described above, 
deletion of the P3 domain in RNase P and 
RNase MRP RNA resulted in loss of nucleolar 
localisation, suggesting an important role for 
the Th-40 autoantigen in the subcellular locali-
sation of these enzymes (44,58).
RNase MRP and RNase P protein subunits
Screening of a yeast library with tempe-
rature-sensitive mutants for strains that con-
tained an altered ratio of 5.8S(L) to 5.8S(S) 
at the non-permissive temperature, resulted 
in the identification of the first protein asso-
ciated with both RNase MRP and RNase P in 
yeast (37). This protein was designated Pop1 
for “Processing of precursor”. Subsequently, 
other protein subunits of the RNase MRP com-
plex were identified as suppressors of tem-
perature-sensitive RNase MRP RNA mutants: 
Snm1p, Pop3p and Pop4p (32,34,35). Charac-
terisation of these proteins showed that only 
Snm1p appeared to be specifically associated 
with the RNase MRP complex, whereas Pop3p 
and Pop4p were also found to be associated 
with the RNase P complex. The yeast Rpp1p 
and Rpp2p proteins were identified as homo-
logues of two human RNase P proteins, but 
were also found associated with the RNase 
MRP complex (33,36). Purification of the RNase 
P complex from yeast resulted in the identifica-
tion of 4 additional protein subunits (Pop5p, 
Pop6p, Pop8p and Rpr2p) of which only the 
Rpr2p protein appeared to associate specifi-
cally with the RNase P complex (38).
The characterisation of the first protein 
shared by RNase MRP and RNase P in yeast 
(37) facilitated the cloning of the first cDNA 
encoding a human RNase MRP/RNase P pro-
tein subunit: hPop1 (77). More recently, cDNAs 
encoding several other human protein subunits 
have been isolated after the biochemical purifi-
cation of the RNase P complex from HeLa 
cells: Rpp14, Rpp20, Rpp29, Rpp30, Rpp38, 
and Rpp40 (78-80). One additional protein 
copurified with RNase P activity from HeLa 
cells (Rpp25), which has been recently identi-
fied (78, Guerrier-Takada, personal communi-
cation).
The identification of protein subunits spe-
cific for either RNase MRP or RNase P in yeast 
(Snm1p and Rpr2p, respectively) suggests that 
such protein subunits are likely to exist in 
human cells as well (32,38). Indeed, the human 
homologue of the RNase P specific protein 
subunit (Rpr2p) has recently been identified: 
Rpp21 (81).
Screening of cDNA libraries in a yeast two 
hybrid system using Rpp14, Rpp20, Rpp21, 
Rpp29, Rpp30, Rpp38, Rpp40 and hPop1 as 
bait identified three putative new protein com-
ponents of the RNase MRP and P complexes: 
small heat shock protein 27 (Hsp27), human 
LIM domain-containing protein (LIMD1) and 
an exoribonuclease (OIP2) (82). It was shown 
that Hsp27 is able to bind Rpp20 and that addi-
tion of Hsp27 stimulates RNase P activity in 
vitro. However, a stable association between 
Hsp27 and the RNase P holoenzyme could 
not be demonstrated. The significance of the 
interactions of LIMD1 and OIP2 with Rpp14 
remains to be elucidated.
The protein subunits of RNase MRP and 
RNase P for which sequence information has 
been obtained by cDNA analysis lack all of 
the currently known RNA-binding motifs (38). 
However, in all yeast RNase MRP and RNase 
P proteins except Rpp1p, a motif can be dis-
cerned in which two neighbouring lysine resi-
dues are preceded or followed by an additional 
lysine at a distance of three to eight interven-
ing residues. Although the relevance of this 
finding is unclear, this motif has been sug-
gested to be implicated in RNA association, 
protein-protein interactions, or nuclear loca-
lisation (38). In most of the known protein 
subunits of human RNase MRP and RNase P, 
similar lysine-rich motifs can be discerned. 
Most of these proteins are (highly) basic and 
have predicted pI values between 7.5 and 11. 
In addition, one single acidic protein has been 
identified in both human and yeast RNase 
MRP/RNase P: Rpp40 and Pop8p, respectively 
(38,80). Recently, the functional significance of 
sequence elements rich in basic amino acids for 
some of the RNase P and RNase MRP protein 
subunits has been demonstrated (83). Muta-
Figure 3. Secondary structures of human RNase MRP RNA (A) and RNase P RNA (B). The secondary structure of RNase MRP RNA 
is based on phylogenetic comparison and chemical modification data (70). The secondary structure of RNase P RNA is based on 
phylogenetic comparison of vertebrate RNase P RNAs (90,91). The structurally conserved 5’-located P3 domain is indicated in bold.
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tional analysis of the basic domains in the 
Rpp38 and Rpp29 proteins suggested that they 
are required for their nucleolar accumulation 
and that the Rpp14 protein subunit, which 
lacks such clusters of basic amino acids, is 
transported to the nucleus and nucleolus by a 
‘piggyback’ mechanism (83).
After purification of the human RNase P 
from HeLa cells, the purified RNase P complex 
was shown to contain ATPase activity. Interes-
tingly, the Rpp20 protein subunit has signifi-
cant homology with a putative ATP binding 
cassette in an ABC transporter ATPase from 
Arabidopsis thaliana. The recombinant Rpp20 
protein appeared to display ATPase activity 
and deletion of the putative ATP binding cas-
sette resulted in a decreased ATPase activity 
(84). It is still unknown whether human RNase 
MRP, which also contains Rpp20, displays 
ATPase activity as well.
Interactions between RNase MRP and 
RNase P subunits
UV-crosslinking experiments have pro-
vided insight into the intermolecular interac-
tions occurring in the RNase MRP and RNase P 
particles. Using this technique, in combination 
with patients’ autoantibodies directed to the 
RNase MRP and RNase P particles, Yuan and 
coworkers showed that the major autoantigenic 
polypeptide, Th-40, is bound to the P3 domain 
of RNase MRP and RNase P RNA (Figure 3) 
(75). Analysis of randomised mutants of the P3 
domain of RNase P RNA in yeast showed that 
four conserved nucleotides in this domain are 
important for viability and yeast three-hybrid 
studies showed that in these mutants the inter-
action between the P3 domain and Pop1 is 
abolished (85). Three-hybrid studies using the 
human RNase P RNA allowed the identification 
of interactions of Rpp21, Rpp29, Rpp30 and 
Rpp38 proteins, but not hPop1 with this RNA, 
suggesting that the latter interaction is not 
evolutionarily conserved (86). In addition, UV-
crosslinking experiments showed that Rpp21, 
Rpp29 and Rpp30, but not Rpp38, directly 
interacts with the P3 domain of RNase P RNA 
(86).
Yeast two-hybrid analyses using Rpp14, 
Rpp20, Rpp21, Rpp29, Rpp30, Rpp38, Rpp40 
and hPop1 indicated that Rpp30 strongly inter-
acts with Rpp14. Similarly, a strong interac-
tion could be demonstrated between Rpp40 
and Rpp21. Furthermore, several weak interac-
tions between the other protein components 
could be detected. The observation that not all 
of these two-hybrid interactions are recipro-
cal, i.e. are also detected when the DNA-bind-
ing and transcription activation domains are 
interchanged, complicates the interpretation of 
these data (82).
Recently, recombinant Rpp14 and Rpp21 
proteins were shown to interact with pre-tRNA 
suggesting that these proteins may be involved 
in recognition and/or the cleavage of pre-tRNA 
(81).
Outline of this thesis
The RNase MRP complex has been shown 
to cleave precursor rRNA and mitochondrial 
RNA needed for mitochondrial DNA replica-
tion. At the start of this project, in 1997, the 
RNA component and one protein subunit of the 
human RNase MRP complex had been cloned. 
Furthermore, a protein of 40 kDa (Th-40), 
which was recognised by autoantibodies of 
scleroderma patients, had been reported to be 
associated with the human RNase MRP com-
plex. The goal of this project was to identify 
new protein subunits of the RNase MRP com-
plex, to shed more light on the identity of 
Th-40 autoantigen, to obtain more information 
on the architecture of the RNase MRP complex 
and to study the relation between the RNase 
MRP complex and the related RNase P com-
plex.
The results reported in this thesis are divided 
into three parts:
I novel protein components of the RNase 
MRP complex
II assembly of the RNase MRP complex
III RNase MRP and human disease
In Part I the identification and cDNA 
cloning of two novel protein components of 
the human RNase MRP complex is described. 
These two novel human protein subunits were 
identified by virtue of their homology with 
two yeast RNase MRP proteins. Biochemical 
analyses showed that these proteins are also 
shared by the human RNase P complex. The 
cloning of hPop4 is reported in Chapter 2 and 
the cloning of hPop5 in Chapter 3.
In Part II various data are described 
which are aimed at the elucidation of the assem-
bly pathway and architecture of the human 
RNase MRP complex. First (Chapter 4) the 
subcellular localisation and complex associa-
tion of three protein subunits of the human 
RNase MRP and RNase P complexes are stu-
died by deletion mutagenesis. In addition, the 
effects of these deletions on the RNase P acti-
vity have been determined. In the next chapter 
(Chapter 5) the development of a reconsti-
tution assay for the RNase MRP complex is 
described as well as the application of this 
assay to study the role of structural elements of 
the RNase MRP RNA in the association of dif-
ferent protein subunits. UV-crosslinking analy-
ses were performed to identify proteins that 
directly interact with the RNase MRP RNA. In 
the last chapter of this part (Chapter 6) the 
paradoxical differences between our data pre-
sented in Chapter 5 and literature data on the 
Th-40 autoantigen are studied. The identity 
of the Th-40 autoantigen is elucidated and an 
explanation for the apparent controversy is 
provided.
In Part III the relationship between the 
RNase MRP complex and certain human disea-
ses is studied. The RNase MRP complex has 
been found to be an autoantigen targeted by 
autoantibodies in patients suffering from cer-
tain connective tissue diseases. In Chapter 7 
a relatively large collection of patient sera was 
screened for the presence of autoantibodies 
directed against nucleolar components, inclu-
ding the three classes of small nucleolar ribo-
nucleoprotein complexes (box C/D snoRNPs, 
box H/ACA snoRNPs and RNase MRP/P). In 
addition, clinical data were collected by chart 
review and the relevance of these autoantibo-
dies for diagnosis and prognosis is discussed. In 
Chapter 8 the role of the RNase MRP complex 
in a completely different disease is discussed. 
Genetic analyses of patients suffering from 
the inherited disease cartilage hair hypoplasia 
(characterised by dwarfism) demonstrated that 
these patients have mutations in the gene 
encoding the RNA component of the RNase 
MRP complex.
Finally, the results obtained in this project 
are discussed in Chapter 9. A summary com-
pletes this thesis.
Part I
Novel components of the RNase MRP complex
hPop4: A new protein subunit of the 
human RNase MRP and RNase P 
ribonucleoprotein complexes
Hans van Eenennaam
Ger J.M. Pruijn
Walther J. van Venrooij
Nucleic Acids Research (1999) 12: 2465-2472
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Introduction
In eukaryotes the 5.8S, 18S and the 25S/28S 
rRNAs are transcribed as one long precursor 
by RNA polymerase I. The maturation of this 
precursor not only involves endo- and exo-
nucleolytic cleavages, but also methylation 
and pseudouridinylation (1). Proper proces-
sing of the precursor rRNA requires a group 
of small nucleolar ribonucleoprotein particles 
(snoRNPs). These snoRNPs consist of proteins 
associated with so-called snoRNAs, which are 
Abstract
RNase MRP is a ribonucleoprotein particle involved in the proces-sing of pre-rRNA. The RNase MRP particle is structurally highly related to the RNase P particle, which is involved in pre-tRNA 
processing. Their RNA components fold into a similar secondary structure 
and they share several protein subunits.
We have identified and characterized human and mouse cDNAs that encode 
proteins homologous to yPop4p, a protein subunit of both the yeast RNase 
MRP and RNase P complexes. The human Pop4 cDNA encodes a highly 
basic protein of 220 amino acids. Transfection experiments with epitope-
tagged hPop4 protein indicated that hPop4 is localized in the nucleus and 
accumulates in the nucleolus. Immunoprecipitation assays using extracts 
from transfected cells expressing epitope-tagged hPop4 revealed that this 
protein is associated with both the human RNase MRP and RNase P 
particles. Polyclonal rabbit antibodies raised against recombinant hPop4 
recognized a 30 kDa protein in total HeLa cell extracts and specifically co-
immunoprecipitated the RNA components of the RNase MRP and RNase P 
complexes. Finally we showed that anti-hPop4 immunoprecipitates possess 
RNase P enzymatic activity. Taken together, these data show that we have 
identified a protein that represents the human counterpart of the yeast 
Pop4p protein.
heterogeneous in size and contain structural 
elements. Based on their structural elements 
the snoRNAs can be divided into three groups: 
Box C/D snoRNAs, Box H/ACA snoRNAs and 
RNase MRP/RNase P (5). While most Box C/D 
snoRNAs have been demonstrated to function 
in ribose methylation (92) and Box H/ACA in 
pseudouridinylation of the rRNAs (93), RNase 
MRP and RNase P function as endonucleases 
(56,94).
Originally the RNase MRP has been identi-
fied as an endoribonuclease able to cleave, in 
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vitro, mitochondrial RNA that functions as a 
primer for mitochondrial DNA replication (22). 
Most of the RNase MRP is, however, not loca-
lized in the mitochondria but is found in the 
nucleolus of cells (26,72). Genetic and biochem-
ical experiments in Saccharomyces cerevisiae 
have shown that the RNase MRP is involved 
in the formation of the short form of the 5.8S 
rRNA (5.8S (S)), by catalyzing the cleavage at 
site A3 in the Internal Transcribed Spacer 1 
(ITS1) of pre-rRNA (28-30,37). An involvement 
of RNase MRP in mitochondrial DNA replica-
tion in vivo has not been demonstrated yet.
The sensitivity of RNase MRP function to 
both ribonucleases and proteases demonstrates 
a requirement for both RNA and protein sub-
units for catalytic activity (26). The RNA sub-
unit of the RNase MRP has been cloned from 
several species including human (66), mouse 
(27), rat (95), cow (96), toad (97), yeast (98), 
Arabidopsis and tobacco (99). The RNA subunit 
of RNase MRP is related to the RNA subunit of 
RNase P, an endoribonuclease involved in the 
processing of the 5’-end of precursor-tRNAs 
(100,101) and also suggested to be involved 
in processing of the precursor-rRNA in Inter-
nal Transcribed Spacer 2 (ITS2) (56). Both 
RNA components have similar secondary struc-
ture elements, in particular the so-called cage-
shaped domain (69,70) which contains many 
conserved nucleotides, supporting the idea 
that the RNase MRP and RNase P RNAs have 
evolved from a common ancestor (102,103). The 
identification of these RNAs via anti-Th/To sera 
from patients suffering from the connective 
tissue diseases systemic lupus erythematosus 
(SLE) and scleroderma, which immunopre-
cipitate both RNA components, has led to 
alternative names for these RNA components: 
RNase MRP is also referred to as Th or 7-2 
RNA and RNase P RNA as H1 or 8-2 RNA 
(61,62,64,65,104).
The close relationship between the RNase 
MRP and RNase P is also supported by the 
fact that both particles contain similar protein 
subunits. Recently, purification of the RNase P 
particle from S. cerevisiae led to the identifica-
tion of 9 protein subunits copurifying with 
the RNase P RNA (38). All these proteins are 
encoded by genes essential for RNase P acti-
vity and for cell viability. Four of these pro-
tein subunits: Pop1p (37), Pop3p (35), Pop4p 
(34) and Rpp1p (33), had been identified before 
and all four appeared to be components of both 
the RNase P and RNase MRP particle. Other 
subunits shared by both particles are Pop5p, 
Pop6p, Pop7p/Rpp2p and Pop8p. Yeast RNase 
MRP and RNase P also contain at least one pro-
tein subunit specifically associated with each 
of these particles, which are designated Snm1p 
(32) and Rpr2p (38), respectively.
The human RNase P particle has also been 
purified from HeLa cells, which resulted in the 
cDNA cloning of four RNase P protein subunits 
(78,80). Rpp20, Rpp30, Rpp38 and Rpp40 have 
been characterized and sequence comparison 
revealed that Rpp20 is the human homologue 
of Pop7p/Rpp2p while Rpp30 is the human 
homologue of Rpp1p (33,36,38,80). The first 
human protein subunit characterized was the 
hPop1 protein (77), the homologue of the yeast 
Pop1p. For hPop1, Rpp30 and Rpp38 it has 
been established that they are subunits of both 
RNase MRP and RNase P (77,105) and this is 
likely to be the case for Rpp20 as well.
 In this report we describe the identifica-
tion of the human and mouse homologues of 
the yeast Pop4p. A complete cDNA encoding 
the human homologue of yPop4 was cloned 
and characterized. This cDNA encodes a novel 
nucleolar 30 kDa protein, that is associated 
with both RNase MRP and RNase P. Polyclonal 
rabbit antibodies were raised against hPop4, 
and used to confirm the association of hPop4 
with these two ribonucleoprotein complexes.
Results
Identification of putative human and 
mouse Pop4p homologues
Recently, the cDNA cloning and character-
ization of Pop4p from S. cerevisiae has been 
described (22). This protein was shown to 
be a subunit of both the yeast RNase MRP 
and RNase P particles and to be essential for 
5.8S rRNA and pre-tRNA processing. The open 
reading frame (ORF) of the yeast Pop4 cDNA 
encodes a protein comprised of 279 codons 
with a predicted molecular weight of 33 kDa.
The amino acid sequence of yeast Pop4p, 
hereafter designated yPop4, was compared 
with protein and ‘translated nucleic acid’ 
sequence databases to identify homologous 
sequences that might represent mammalian 
homologues of yPop4. Six overlapping nucleic 
acid sequence entries, corresponding to human 
Expressed Sequence Tags (ESTs), were 
retrieved. Using these ESTs a cDNA sequence 
could be constructed of 1133 nucleotides, con-
taining an ORF encoding a protein of 220 amino 
acids. For reasons documented below this pro-
tein will be referred to as hPop4.
Besides the human ESTs retrieved from the 
sequence databases using the yPop4 amino acid 
sequence, five mouse ESTs were selected. The 
combination of these five ESTs also allowed 
the derivation of a cDNA sequence, which in 
this case was comprised of 1433 nucleotides, 
containing an ORF encoding a protein of 221 
amino acids. The latter protein will be referred 
to as mPop4, since its amino acid sequence 
is highly homologous to that of hPop4 (see 
below).
No in-frame stop codon was found upstream 
of the first ATG in the human cDNA sequence, 
which might implicate that the cDNA did 
not represent the complete mRNA. However, 
since such an in-frame stop codon is present 
upstream of the first ATG in the mPop4 cDNA 
sequence and since the amino acid sequences 
derived from the hPop4 and mPop4 cDNA 
are highly homologous, it is reasonably to 
assume that the first ATG in the human cDNA 
sequence represents the start codon of the 
hPop4 mRNA.
Cloning of hPop4 cDNA
To clone a cDNA encoding the complete 
open reading frame of hPop4, two oligonu-
cleotides were designed based on the cDNA 
sequence derived from the human ESTs. These 
oligonucleotides were used as PCR primers to 
amplify the hPop4 ORF using DNA from both 
human placenta and teratocarcinoma cDNA 
libraries as template. Sequencing of several 
clones resulting from this procedure revealed 
that clones derived from both cDNA libraries 
were completely identical, thereby ruling out 
the introduction of PCR artifacts. Nevertheless, 
in these cDNA clones minor differences were 
found in comparison to the sequence derived 
from the human ESTs. Nucleotides 100-104 of 
the cDNA sequence (numbering according to 
EMBL/Genbank database entry with accession 
number Y18863) are 5’-GCGGG-3’, while the 
EST sequence contains an additional nucleo-
tide in this segment 5’-GCGGGG-3’. The result-
ing frame shift is restored by the presence of 
an additional C-residue at position 139 in the 
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cDNA. Finally, a C-residue was found at posi-
tion 162 of the cDNA rather than a G at this 
position in the EST sequence, resulting in an 
alanine codon instead of a glycine at position 
46 in the amino acid sequence. Although we 
can not exclude the possibility that these dif-
ferences represent genetic polymorphisms, it 
is more likely that they are due to sequencing 
errors, which are known to occur relatively 
frequently in EST sequences. In the complete 
hPop4 cDNA sequence the coding sequence 
corresponds to the sequence determined in this 
study while the UTRs are derived from the 
EST sequences. At position -20 relative to the 
start of the poly(A)-tail a putative polyadenyl-
ation signal can be found. In conclusion, the 
combined cDNA is 1133 nucleotides long and 
encodes a protein of 220 amino acids, with a 
predicted molecular weight of 25.4 kDa and a 
predicted pI of 10.9.
To investigate whether the size of the 
hPop4 cDNA was in accordance with the size of 
the mRNA, the latter was analyzed by northern 
blot hybridization using total RNA extracted 
from a human melanoma cell line. A probe 
derived from nucleotides 100-590 of the cDNA 
sequence hybridized to a single mRNA species 
of about 1.3 kb, which is in good agreement 
with the length of the cDNA (data not shown).
In Figure 1 an alignment is shown of the 
amino acid sequences derived from the human, 
mouse and yeast Pop4 cDNAs. The homology 
between human and mouse Pop4 proteins is 
high (83% identity; 90% similarity), while the 
homology between human and yeast Pop4 is 
much lower, but still significant (29% identity; 
49% similarity). The amino acid conservation 
between mammalian and yeast Pop4 proteins is 
most extensive in three blocks in the C-termi-
nal half of the Pop4 protein.
In the hPop4 protein sequence a cluster-
ing of basic amino acids is evident between 
residues 53 and 85, which may contain a func-
tional bipartite nuclear localization sequence 
(NLS), as in this region three partly overlap-
ping elements matching the bipartite NLS con-
sensus sequence can be discerned.
hPop4 accumulates in the nucleoli
To investigate the subcellular localization 
of hPop4, a VSV-G tag sequence (106) was fused 
to either the 5’-end or the 3’-end of the hPop4 
cDNA and cloned in the mammalian expression 
vector pCI-neo. The resulting constructs (VSV-
hPop4 and hPop4-VSV) were used to transfect 
HeLa cells and after overnight culturing the 
localization of the VSV-tagged hPop4 protein 
was determined via indirect fluorescence con-
focal microscopy, using a monoclonal anti-
VSV-tag antibody. The results, which were 
identical for both constructs, showed a strong 
nucleolar and a weak, homogeneous nucleo-
plasmic staining pattern (Figure 2, panel B). 
Since the anti-VSV-tag antibody in non-trans-
fected cells generated no signal above back-
ground, the observed staining appeared to be 
specific for the hPop4-VSV protein expressed 
in transfected cells. To confirm that the nuclear 
regions most intensely stained by the anti-
VSV-tag antibodies represented nucleoli and to 
investigate whether hPop4 co-localized with 
hPop1, double immunostaining with affinity-
purified anti-hPop1 antibodies (77) was per-
formed (Figure 2, panels A-C). Note that hPop1 
is also an RNase MRP and RNase P subunit and 
therefore co-localization of hPop1, which has 
previously been shown to accumulate in the 
nucleolus, and hPop4-VSV would be consistent 
with an association of hPop4-VSV with these 
ribonucleoprotein complexes. Indeed a full 
co-localization of hPop4-VSV and hPop1 was 
observed (Figure 2, panel C). In conclusion, 
transiently expressed hPop4-VSV localizes to 
the nucleus and strongly accumulates in the 
nucleolar compartment.
hPop4 is associated with both the RNase 
MRP and RNase P particles
To determine whether the hPop4 protein 
is indeed a subunit of the human RNase MRP 
and the related RNase P particle, immunopre-
cipitation experiments were performed with 
epitope-tagged hPop4 protein. HeLa cells were 
transfected with both VSV-tagged hPop4 con-
structs and the corresponding empty vector 
(pCI-neo) as a control. Cell extracts prepared 
from these cells were used for immunoprecipita-
tion with anti-VSV antibodies, anti-fibrillarin (a 
protein associated with Box C/D snoRNPs) anti-
bodies, and a patient serum, known to immu-
noprecipitate both RNase MRP and RNase P 
complexes (anti-Th/To). RNAs were extracted 
from immunoprecipitates and from total cell 
extracts, fractionated by gel electrophoresis 
and analyzed by northern blot hybridization 
using probes specific for RNase MRP, RNase P, 
A
B
C
Figure 2. Subcellular localization of hPop4. Double immunoflu-
orescence and confocal microscopy was performed on HeLa 
cells, which were transiently transfected with hPop4-VSV. Cells 
were fixed with methanol and stained with affinity-purified 
anti-hPop1 (77) (A) and anti-VSV (B) antibodies. C. superim-
position of panels A and B.
Figure 1. Alignment of amino acid sequences derived from human, mouse and yeast Pop4 cDNAs. Amino acids that are identical 
in at least two of three proteins are marked by a black box, while amino acids with a conserved character are marked with a gray 
box. Dashes indicate the absence of corresponding amino acids.
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AIISVTKSKCPSYVGITGILLQETKHIFKIITKE DRLKVIPKLNCVFTVE
ELWKQYIRDLCNGLK PDTQPQMIQAKLLKADLHG
I Y FVPM ELW NYIKEL N K N L KL AD G
AIISVTKSKCPSYVGVTGILLQETKHVFKIITRE DHLKVIPKLNCVFTIEI
ALL VTKSK T IGL GIVI DS K F MI K D IK IPK VF EI
D
KGLSAKQRRDMRLF
E D QLEK K L EY K KK K KE L
DIKPEQ QRYSLFLPLH ELWKQYIRDLC GLK PDTQPQMIQAKLLKADLHG
DIKPEQ QRYSLFLPLH
K R KKKK KGLSARQRRELRLF
PHMS E E LQR KAVILEYFTR K R R KKK
FISY IYGSKFQLRSSERSAKKFKAKGTIDL
D FISY IYGSKFQLRASERSAKKFKAKG IDL
D L Y I G RF RS DRAGRKFKSR DM
MKS IYHALS KEA D D VQPSGA QRAEAFVRAFLK S
MK IYHA S KEA D D VQ G QRAEAFVRAFLKQS
T I L K D E L PT G QR Q K L N
PRMS Q E QLQR KAVVLEYFTR
hPop4 1 --- V Q N S ------------- ------ R
mPop4 1 --- AA F H K H ------------- EL S------
yPop4 1 MDRTQ F KDC FT CLE P KPFNENRFQDTLL L D GLTSRL Q RKS LN D L
hPop4 39 T P AR D ---------- H - KE A
mPop4 39 I Q DC SH ---------- L P P P S
yPop4 61 QKVSQL SA K RDYQRINKNS IA R INNC KNT CL LAYENKITD DL H
hPop4 88 ------- - S --
mPop4 89 ------- - --
yPop4 121 Y EEKHPTIYESLPQ VD YK I L IT NLKTF GS ALL SM YN
hPop4 138 --- T------
mPop4 139 --- ------
yPop4 181 R NK L Q W Q F I V GNII E C KGT QF PISDDD
hPop4 189 G - ------
mPop4 190 D - ------
yPop4 241 SA R S L D KY V RCD LYYIQN
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U3 (a Box C/D snoRNA) and U1 RNA. As is 
shown in Figure 3 (lane 3) the RNase MRP 
and RNase P RNAs are both precipitated by 
the anti-VSV-tag antibody from a cell extract 
containing VSV-tagged hPop4 protein. Identi-
cal results were obtained for both VSV-tagged 
hPop4 constructs. The specificity of this result 
was established by the lack of co-precipitation 
of U1 and U3 RNA and by the inability of 
the anti-VSV-tag antibody to co-precipitate 
RNase MRP or RNase P RNA from extracts of 
control cells (transfection with pCI-neo vector; 
Figure 3, lane 7). As expected, the anti-Th/To 
patient serum immunoprecipitated both the 
RNase MRP and RNase P RNAs from both 
types of cell extracts (lanes 2 and 6). The spe-
cific immunoprecipitation of U3 RNA by the 
anti-fibrillarin antibodies (lanes 4 and 8) and 
the lack of immunoprecipitation of U1 RNA 
(lanes 2-4 and 6-8) further substantiated the 
specificity of the assay. Taken together, these 
results indicate that the VSV-tagged hPop4 pro-
tein associates with both the RNase MRP and 
RNase P particles.
Anti-hPop4 antibodies immunoprecipi-
tate both RNase MRP and RNase P par-
ticles
To exclude the possibility that association 
of hPop4-VSV with the RNase MRP and 
RNase P particles was due to overexpression of 
the protein in the transiently transfected HeLa 
cells, a polyclonal antiserum was raised against 
recombinant hPop4 to study the endogenous 
non-tagged hPop4 protein. The hPop4 protein 
was expressed as a fusion protein with Glutha-
tione S-Transferase (GST) in Escherichia coli, 
which was designated GST-hPop4. After purifi-
cation using Gluthathione-Sepharose-4B beads, 
GST-hPop4 (Figure 4, lane 1) was used to immu-
nize rabbits. Western blot analysis showed that 
the resulting rabbit antisera, in contrast to 
the corresponding pre-immune sera, recog-
nized not only the recombinant GST-hPop4, 
but also the hPop4 protein expressed in HeLa 
cells (Figure 4). Besides the band representing 
the GST-hPop4 protein, some faster migrating 
bands in the recombinant material were recog-
nized by the anti-hPop4 antisera as well. These 
bands are most probably due to proteolytic 
degradation of the GST-hPop4 protein during 
the purification and may in part be stained 
due to anti-GST activity in the sera. Note that 
the endogenous hPop4 protein of HeLa cells 
migrated at approximately 30 kDa in SDS-PAGE 
gels.
To investigate whether hPop4 is a subunit 
of both the endogenous RNase MRP and 
RNase P particles, immunoprecipitations were 
performed with this anti-hPop4 antiserum 
using total HeLa cell extracts. The co-preci-
pitating RNAs were isolated and analyzed by 
northern blot hybridization using probes spe-
cific for RNase MRP, RNase P and U3 RNA. As 
depicted in Figure 5 (lane 4) the anti-hPop4 
antiserum efficiently immunoprecipitated both 
the RNase MRP and RNase P RNA components, 
while the pre-immune serum did not immuno-
precipitate any of the RNAs analyzed (Figure 
5, lane 5). The specificity of the antiserum was 
substantiated by the observations that a con-
trol polyclonal rabbit antiserum (lane 3) did not 
detectably precipitate RNAs, while a patient 
anti-Th/To antiserum as well as rabbit anti-
hPop1 antiserum did co-immunoprecipitate the 
RNase MRP/RNase P RNAs (lanes 2 and 6).
In conclusion, these results fully support 
previous findings that hPop4 is a component 
of both RNase MRP and RNase P.
Figure 3. VSV-tagged hPop4 associates with RNase MRP and 
RNase P. HeLa cells were transfected with hPop4-VSV cDNA 
construct and the empty vector as a negative control. After 
overnight culturing, cell extracts used for immunoprecipitation 
with anti-Th/To, anti-VSV-tag and anti-fibrillarin (anti-fib) anti-
bodies. RNAs were isolated from the immunoprecipitates 
(lanes 2-4 and 6-8) and from the total cell extracts (lanes 1 
and 5) and analyzed by northern blot hybridization using spe-
cific probes for RNase P, RNase MRP, U3 and U1 RNA, as indi-
cated on the right. Lanes 1-4, material from cells expressing 
hPop4-VSV. Lanes 5-8, material from control cells transfected 
with pCI-neo. The amounts of the RNAs analyzed in lanes 1 
and 5 corresponds to 10% of the amounts of extracts used for 
immunoprecipitations (10% input). The faint U1 snRNA band 
observed in lane 3 is due to some non-specific co-precipitation 
with the anti-VSV antibody.
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Figure 4. Western blot analysis of rabbit antiserum raised 
against GST-hPop4. Rabbit antisera were raised against recombi-
nant GST-hPop4 fusion protein expressed in E. coli. GST-hPop4 
protein (lane 1 shows the recombinant protein preparation 
stained with Coomassie Brilliant Blue) was separated by 13% 
SDS-PAGE and transferred to nitrocellulose filters. After incu-
bation with anti-hPop4 antiserum (lane 3) or pre-immune 
serum (lane 2), bound antibodies were visualized with horse-
radish peroxidase-conjugated goat anti-rabbit antibodies and 
chemiluminescence. The reactivity of the antiserum with pro-
teins from a total HeLa extract was analyzed also by western 
blotting: anti-hPop4 (lane 5) and pre-immune serum (lane 4). 
On the left, the molecular weights of protein markers are indi-
cated. The full-length GST-hPop4 protein band is indicated with 
an asterisk, while the blue arrow points to the HeLa hPop4 
protein.
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Figure 5. Anti-hPop4 antiserum co-immunoprecipitates the 
RNA components of RNase MRP and RNase P. RNPs were 
immunoprecipitated from a total HeLa cell extract using 
anti-Th/To (lane 2), anti-Ro52 (lane 3), anti-hPop4 (lane 4), 
pre-immune (lane 5) and anti-hPop1 (lane 6) antisera. Co-
precipitating RNAs and RNA from total extract were isolated, 
resolved by denaturing polyacrylamide gel electrophoresis and 
analyzed by northern blotting using riboprobes specific for 
human RNase P, RNase MRP and U3 RNA, as indicated on the 
right. The signals marked with an asterisk, are due to incom-
plete removal of the RNase P probe prior to the incubation 
with the U3 RNA probe.
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Anti-hPop4 antibodies immunoprecipi-
tate RNase P enzymatic activity
Having demonstrated that the anti-hPop4 
antibodies specifically immunoprecipitate the 
RNase MRP and RNase P RNAs from total 
HeLa cell extracts, we analyzed whether the 
immunoprecipitates contained any RNase P 
enzymatic activity. Immunoprecipitates were 
incubated with a 32P-labeled pre-tRNA. The 
products of this reaction were resolved on a 
denaturing polyacrylamide gel and visualized 
using autoradiography. The results in Figure 6 
show that the anti-hPop4 antibodies are indeed 
able to immunoprecipitate the enzymatically 
active RNase P complexes, as the pre-tRNA is 
specifically cleaved into mature tRNA and the 
5’-leader. The capability to immunoprecipitate 
this activity was indistinguishable from that of 
the anti-hPop1 antiserum, which was used as 
a positive control. In contrast, the pre-tRNA 
incubated with the immunoprecipitate of either 
the pre-immune serum or a control antiserum 
was not processed (lanes 2 and 4). We con-
clude that the hPop4 protein is associated with 
a catalytically active form of RNase P.
Discussion
We have identified and cloned a new sub-
unit of the human RNase MRP particle, which 
is also associated with the evolutionarily related 
RNase P particle. The new subunit exhibits 
homology to the yeast Pop4 protein and was 
therefore designated hPop4. We showed that 
the subcellular localization of hPop4 is primar-
ily nucleolar and that this protein is associated 
with catalytically active RNase P particles.
Amino acid sequence of hPop4
While a high degree of amino acid sequence 
conservation was observed between the human 
and putative mouse Pop4 polypeptides, the 
human and yeast Pop4 sequences are only 
moderately homologous (29% identity), which 
is, however, slightly higher than the degree 
of sequence conservation observed for other 
RNase MRP/RNase P proteins, like hPop1/Pop1 
(22% identity) (77), Rpp30/Rpp1 (23% iden-
tity) (33) and Rpp20/Rpp2 (14% identity) (36). 
Sequence analysis did not reveal the presence 
of known protein sequence motifs in the mam-
malian Pop4 polypeptides, apart from putative 
nuclear localization sequences. The most con-
served regions are found in the C-terminal half 
of the protein. Within this region an evolution-
arily conserved cluster of basic amino acids is 
found near the C-terminus. Recently, Chamber-
lain et al. (38) identified an element consisting 
of two contiguous lysine residues preceded or 
followed by an additional lysine at a distance 
of 3-8 intervening residues, which is found 
in all known RNase P proteins, except Rpp1p 
(33,38). Several sequences corresponding to 
this element are present in hPop4 and mPop4 
and a few of such elements are found at an 
equivalent position in yeast. This element is 
also found in some ribosomal proteins and 
might be involved in protein-RNA association 
or protein-protein interactions.
Interestingly, the phenylalanine at position 
207 of yPop4, which has been demonstrated 
to be mutated in the yeast strain that led to 
the identification of this protein (34), is not 
conserved in the human and mouse Pop4 pro-
teins. The substitution of the phenylalanine by 
either a leucine or a serine in yPop4 enabled 
the protein to suppress the rrp2-2 phenotype, 
which is due to a mutation in the RNA compo-
nent of the RNase MRP. The authors suggested 
that this amino acid substitution somehow com-
pensated the functional defect of the base sub-
stitution in the RNA component of RNase MRP. 
The proposed direct interaction between the 
yPop4 protein and the RNase MRP RNA may 
not be found for the human RNase MRP RNA 
and hPop4, as the region of the RNase MRP 
RNA that is mutated in the rrp2-2 strain is not 
present in the human RNase MRP RNA (28).
The hPop4 sequence described in the pre-
sent study is further supported by a recent 
paper, in which the cDNA sequence of a protein 
called Rpp29 has been described. Rpp29 has 
been isolated as a protein subunit of the human 
RNase P particle, which is homologous to yeast 
Pop4p (79). Sequence comparison revealed 
that Rpp29 is almost identical to hPop4, as 
might be anticipated by their mutual homo-
logy with yPop4. Only two differences were 
observed between the hPop4 and Rpp29 pro-
tein sequences. Human Pop4 contains a serine 
at position 38 and a leucine at position 76, 
while in the sequence of Rpp29 these amino 
acids are substituted by a threonine and a 
phenylalanine, respectively. The presence of 
the serine and the leucine at these positions 
in hPop4 is supported by the identity of 
the equivalent amino acids in the predicted 
sequence for mPop4, which are also a serine 
and a leucine (Figure 1). Based upon both their 
sequences (the hPop4 and Rpp29 cDNAs differ 
only by 6 nucleotides) and biochemical charac-
teristics it is highly likely that hPop4 and 
Rpp29 represent the same protein. At present, 
it is unclear whether the small sequence dif-
ferences between hPop4 and Rpp29 are due 
to imperfect cDNA sequences or to a genetic 
polymorphism.
Nucleolar accumulation of hPop4
The nucleolar accumulation observed for 
VSV-tagged hPop4 is in agreement with the 
association of the hPop4 protein with the RNase 
MRP and RNase P particles. Previously, it has 
been proposed that accumulation of proteins 
in the nucleoli is a two-step process (107-109). 
First, a nucleolar protein is transported from 
the cytoplasm to the nucleoplasm, which is 
dependent on an NLS, and subsequently func-
tional domains that interact specifically with 
other nucleolar components mediate nucleolar 
entry. The subcellular localization of the RNase 
MRP particle has been determined to be pri-
marily nucleolar, while only a minority of 
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Figure 6. Anti-hPop4 antibodies immunoprecipitate enzymati-
cally active RNase P. Anti-hPop1 (lane 1), pre-immune (lane 
2), anti-hPop4 (lane 3) and anti-Ro52 (lane 4) sera were used 
for immunoprecipitations from total HeLa cell extract. Immu-
noprecipitates were assayed for RNase P enzymatic activity 
by incubating with a 32P-labeled pre-tRNA substrate. Subse-
quently, the RNAs were isolated and resolved by denaturing 
polyacrylamide gel electrophoresis and visualized by autora-
diography. On the right, the positions of the pre-tRNA, the 
mature tRNA and the 5’-leader sequence are indicated.
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RNase MRP complexes has been reported to 
reside in the mitochondria (26,72,110). We 
could, however, not detect any staining above 
background in the cytoplasm of HeLa cells, 
in agreement with biochemical fractionation 
data which did not show a significant portion 
of the RNase MRP RNA in the mitochondria 
of HeLa cells (72). RNase P has been reported 
to be localized in both the nucleoplasm and 
nucleolus and recent studies indicate that the 
majority of RNase P is localized in the nucleo-
lus (60), strongly suggesting that at least some 
aspects of pre-tRNA processing occur in the 
nucleolar compartment.
hPop4 is shared by RNase MRP and 
RNase P
In yeast Pop1p, Pop3p, Pop4p, Pop5p, 
Pop6p, Pop7p/Rpp2p, Pop8p and Rpp1p are 
protein subunits associated with both RNase 
MRP and RNase P (36,38). In addition, two 
yeast proteins have been identified, which are 
specifically associated with either RNase MRP 
(Snm1p) (32) or RNase P (Rpr2p) (38). Presently 
such particle-specific proteins have not been 
identified in mammals yet.
In agreement with the association of yeast 
Pop4 with both particles, we showed that its 
human counterpart, hPop4, is also a subunit 
of both RNase MRP and RNase P and is associ-
ated with catalytically active RNase P. Also the 
Rpp29 protein, which is most likely identical to 
hPop4, has recently been reported to be associ-
ated with (catalytically active) RNase P (79). 
The capability to immunoprecipitate enzymati-
cally active RNase P has been reported before 
for antibodies directed against the hPop1, 
Rpp20, Rpp30, Rpp38 and Rpp40 protein sub-
units of RNase P (77,78,80).
The hPop4 protein is probably not directly 
bound to the RNase MRP and RNase P RNA 
components, since recent immunoprecipita-
tion experiments using the anti-hPop4 antise-
rum failed to detect a radiolabeled polypeptide 
comigrating in SDS-PAGE with hPop4 after UV-
crosslinking of RNase MRP particles recon-
stituted with radiolabeled RNase MRP RNA 
(our unpublished observations). With the latter 
type of experiments we recently identified 
three human proteins with apparent molecular 
weights of 20, 25 and 40 kDa, that directly 
interact with the RNase MRP RNA (105). These 
data suggest that the association of the hPop4 
protein with these ribonucleoprotein particles 
might be mediated by protein-protein interac-
tions. Further studies will be required to eluci-
date the molecular interactions that determine 
RNase MRP architecture.
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Materials and Methods
Accession number
The hPop4 cDNA described in this report has been 
deposited in the EMBL database under accession number 
Y18863.
cDNA cloning and sequence analysis
Database searches were done using the BLASTN 2.0.5 
program (111). The accession numbers of the over-
lapping human Expressed Sequence Tags (ESTs) are 
N40691, AA134865, W74573, AA308539, AA132996 
and AA576911. The accession numbers of the overlap-
ping mouse ESTs are W66853, W46039, AA1990967, 
AA929907 and W15729.
Oligonucleotides were designed based on the human 
EST sequences to amplify the open reading frame 
of hPop4: pop41 [5’-GCG-GAT-CCC-TCG-AGA-TGA- 
AGA-GTG-TGA-TCT-ACC-ATG-CAT-TG-3’] and pop42 
[5’-GCG-GAT-CCC-CCG-GGT-CAT-CTA-GAC-AGG-TCA-ATC-
GTT-CCC-TTC-GC-3’]. The polymerase chain reaction 
was performed on 200 ng denatured DNA from λgt11 
human placenta (Clontech) and teratocarcinoma cDNA 
libraries (112). The amplified fragments were ligated 
in the PCR-II-TOPO vector (Invitrogen) and sequenced 
using the dideoxynucleotide chain termination method.
Transfection constructs
Vesicular stomatitis virus G epitope (106) (VSV-G)-
tagged (hereafter referred to as VSV-tagged) cDNAs were 
constructed as follows. The VSV-55k and 55k-VSV cDNA 
constructs, as described in (113), contain a XhoI and a 
XbaI-site, respectively, between the 55k open reading 
frame (ORF) and the VSV-tag sequence, which is posi-
tioned either at the N-terminal or at the C-terminal side 
of the ORF. Digestion by either XhoI/SmaI or XhoI/XbaI 
results in release of the 55k-cDNA from these plasmids. 
The VSV-tagged constructs of hPop4 were constructed by 
isolation of the hPop4 ORF from the hPop4/PCR-II-TOPO 
construct by either XhoI/SmaI or XhoI/XbaI digestion 
and ligation into the XhoI/SmaI or XhoI/XbaI digested 
VSV-55k or 55k-VSV constructs. The integrity of the 
resulting constructs was checked by DNA sequencing. 
The pCI-neo plasmid (Promega), which has been used 
previously to prepare VSV-55k and 55k-VSV, was used 
as a control in the transfection experiments.
Transient Transfection of HeLa cells
HeLa monolayer cells were grown to 80% confluency 
by standard tissue culture techniques and subsequently 
3x106 cells were transfected with 10 µg plasmid DNAs 
in a total volume of 400 µl of Dulbecco’s modified Eagle’s 
medium containing 10% fetal calf serum. Electropora-
tion was performed at 276 V and a capacity of 950 µF 
with a Gene Pulser II (BioRad). After electroporation, 
cells were resuspended in 10 ml of Dulbecco’s modified 
Eagle’s medium containing 10% fetal calf serum and 
grown overnight either on coverslips or in flasks.
Cells grown on coverslips were washed twice with 
phoshate-buffered saline (PBS), fixed with methanol 
(5 min at -20°C) and used for immunofluorescence 
assays.
Cells grown in flasks were harvested, washed once 
with PBS and used to prepare extracts for immunopre-
cipitation assays.
Immunofluorescence
Indirect immunofluorescence assays were performed 
on hPop4-VSV transfected HeLa cells. Fixed cells were 
incubated with affinity-purified rabbit anti-hPop1 anti-
bodies ((77), diluted 1:100 in PBS) and affinity-purified 
mouse anti-VSV tag antibodies (Boehringer, diluted 1:50 
in PBS) for 1 h at room temperature, washed with PBS 
and subsequently incubated with swine-anti-rabbit cou-
pled to FITC (diluted 1:50 in PBS) and rabbit-anti-mouse 
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coupled to TRITC (diluted 1:50 in PBS) for 1 h at room 
temperature. Cells were mounted with PBS/glycerol con-
taining Mowiol and bound antibodies were visualized 
by confocal microscopy.
Preparation of HeLa cell extracts
Extracts of HeLa cells were prepared by resuspen-
ding cell pellets in buffer A (25 mM Tris-HCl pH 7.5, 
100 mM KCl, 1 mM dithioerythritol, 2 mM EDTA, 
0.5 mM phenylmethylsulfonyl fluoride, 0.05% NP-40) 
and lysis by sonification using a Branson microtip (three 
times 20 s). Insoluble material was removed by centrifu-
gation (12,000 g, 15 min) and supernatants were used 
directly for immunoprecipitations.
Anti-hPop4 antiserum
To raise a polyclonal anti-hPop4 antiserum, the hPop4 
protein was expressed as a fusion protein with Glu-
thatione S-Transferase (GST) in E.coli and purified as 
described previously (114). Rabbits were immunized 
with this material according to standard procedures 
(115). For each immunization 200 µg of GST-hPop4 was 
used.
Western blot analysis
For western blot analysis the anti-hPop4 and pre-
immune sera were used in a 500-fold dilution in the 
presence of 1% normal goat serum. Detection was per-
formed using horseradish peroxidase-conjugated goat-
anti-rabbit IgG (Dako Immunoglobulins) as secondary 
antibody and visualization by chemiluminescence.
Immunoprecipitation and pre-tRNA processing assay
Monoclonal anti-VSV-tag (Boehringer) and anti-fibril-
larin ASWU1 (a kind gift of Dr. M. Monestier) antibo-
dies, patient anti-Th/To serum, and rabbit anti-hPop4, 
anti-hPop1, anti-Ro52 and pre-immune serum from the 
rabbit immunized with hPop4 protein were coupled to 
protein A-agarose beads (Biozym) in IPP500 (500 mM 
NaCl, 10 mM Tris-HCl pH 8.0, 0.05% NP-40) by incuba-
tion for 2 h at room temperature. Beads were washed 
twice with IPP500 and once with IPP150 (150 mM NaCl, 
10 mM Tris-HCl pH 8.0, 0.05% NP-40). For each immu-
noprecipitation cell extract was incubated with the anti-
body-coupled beads for 2 h at 4°C. Subsequently, beads 
were washed three times with IPP150.
To analyze co-precipitating RNAs, the RNA was iso-
lated by phenol-chloroform extraction and ethanol 
precipitation. RNAs were resolved on a denaturing poly-
acrylamide gel and blotted to a Hybond-N membrane 
(Amersham). Northern blot hybridizations with ribo-
probes specific for human RNase P, RNase MRP, U3 and 
U1 RNAs were performed as previously described (116).
To assay for RNase P enzymatic activity in the immu-
noprecipitates, an internally 32P-labeled pre-tRNA sub-
strate (S.pombe tRNASer SupS1; (117)), a kind gift of 
Dr. B. Séraphin, was transcribed in vitro and gel-puri-
fied. This 110 nt-long substrate contains a 5’-end exten-
sion of 28 nts in comparison with the mature tRNA. The 
immunoprecipitates were incubated with equal amounts 
of substrate in assay buffer (20 mM Tris-HCl pH 8.0, 
10 mM MgCl2, 1 mM DTE, 50 mM KCl, 50 mg/ml BSA, 
60 U/ml RNasin) for 10 minutes at 37ºC under constant 
agitation. RNA was subsequently isolated by phenol-
chloroform extraction and ethanol precipitation and ana-
lyzed by denaturing polyacrylamide gel electrophoresis 
and autoradiography.
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Introduction
The RNase MRP/RNase P ribonucleopro-
tein particles form one of the three families of 
small nucleolar ribonucleoprotein complexes 
that are involved in the processing of pre-
cursor-rRNA to mature 5.8S, 18S and 25/28S 
rRNA (reviewed in ref. (5)). The RNase MRP 
ribonucleoprotein particle has originally been 
identified by virtue of its capacity to cleave a 
mitochondrial RNA in vitro to generate RNA 
primers for mitochondrial DNA replication (22). 
However, most of the RNase MRP complex has 
Abstract
The RNase MRP and RNase P particles both function as endoribo-nucleases. RNase MRP has been implicated in the processing of precursor-rRNA, whereas RNase P has been shown to function in 
the processing of pre-tRNA. Both ribonucleoprotein particles have an RNA 
component that can be folded into a similar secondary structure and share 
several protein components.
We have identified human, rat, mouse, cow and Drosophila homologues of 
the Pop5p protein subunit of the yeast RNase MRP and RNase P complexes. 
The human Pop5 cDNA encodes a protein of 163 amino acids with a pre-
dicted molecular mass of 18.8 kDa. Polyclonal antibodies raised against 
recombinant hPop5 identified a 19 kDa polypeptide in HeLa cells and 
showed that hPop5 is associated with both RNase MRP and RNase P. Using 
affinity-purified anti-hPop5 antibodies we demonstrated that the endo-
genous hPop5 protein is localised in the nucleus and accumulates in the 
nucleolus, which is consistent with its association with RNase MRP and 
RNase P. Catalytically active RNase P was partially purified from HeLa cells 
and hPop5 was shown to be associated with it. Finally, the evolutionarily 
conserved acidic C-terminal tail of hPop5 appeared to be neither required 
for complex formation nor for RNase P activity.
been shown to reside in the nucleolus (26,72). 
There it functions in the formation of the short 
form of the 5.8S rRNA (5.8S(S)) by cleaving 
at site A3 in the internal transcribed spacer 1 
(ITS1) of precursor-rRNA (28-30,37). In many 
different aspects, the RNase MRP complex is 
related to the RNase P complex, a ribonucleo-
protein complex required for the removal of 
the 5’-end of the precursor tRNAs. Both func-
tion as site-specific endonucleases, contain an 
RNA component that has been proposed to 
adopt a similar cage-shaped structure, share 
several protein subunits and are predominantly 
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localised in the nucleolus (reviewed in ref. 
(118)).
The biological importance of the RNase 
MRP function is substantiated by the recent 
observations that mutations in the gene enco-
ding the RNA component of the human RNase 
MRP complex cause an autosomal recessive 
disease called cartilage-hair hypoplasia (119). 
In addition, RNase MRP and RNase P play a 
role in certain autoimmune diseases. Protein 
components of the RNase MRP and RNase P 
complexes are targeted by autoantibodies in 
systemic lupus erythematosus and scleroderma 
(61,62,64,65,104).
The first identified protein subunit of the 
human RNase MRP and RNase P complexes is 
the hPop1 protein, which is a homologue of the 
yeast Pop1p protein (77). Most of the currently 
known human protein subunits of the RNase 
MRP and RNase P complexes have been identi-
fied via purification of the RNase P complex 
from HeLa cells: Rpp14, Rpp20, Rpp29/hPop4, 
Rpp30, Rpp38 and Rpp40 (78-80,120). In yeast 
ten proteins have been found to be associated 
with either RNase MRP, RNase P or with both 
complexes (reviewed in ref. (118)). Snm1p has 
been reported to be associated specifically 
with the RNase MRP complex, whereas the 
Rpr2p protein is only bound to the RNase 
P complex (32,38). Other subunits shared by 
RNase MRP and RNase P in yeast are: Pop1p, 
Pop7p/Rpp2p, Pop4p, Rpp1p, Pop3p, Pop5p, 
Pop6p and Pop8p (33-38). Although homo-
logues for several of the yeast proteins are 
found in human cells (Pop1p, Pop4p, Pop7p/
Rpp2p, Rpp1p), until now no homologues 
have been identified for Snm1p, Pop3p, Pop5p, 
Pop6p, Pop8p and Rpr2p (reviewed in ref. 
(118)). In this report we describe the identifi-
cation, cDNA cloning and characterization of 
the human Pop5 protein, which, like all human 
protein subunits identified so far, is associated 
with both RNase MRP and RNase P RNAs.
Results
Identification of homologues of yeast 
Pop5p
Purification of the yeast RNase P holoen-
zyme has resulted in the identification of nine 
protein subunits (38). Although some of these 
were shown to have homologues in humans, 
no human homologues have been reported 
for Snm1p, Pop3p, Pop5p, Pop6p, Pop8p and 
Rpr2p. We have searched protein and ‘trans-
lated nucleic acid’ sequence databases to iden-
tify sequences that might represent human 
homologues of these yeast protein subunits.
Four virtually identical nucleic acid entries 
were found that encode a putative human 
homologue of the yeast Pop5p protein (hereaf-
ter designated yPop5). The latter polypeptide 
consists of 173 amino acids and has a predicted 
molecular mass of 19.6 kDa. The corresponding 
human sequence (database entry AF117232) 
is 785 nt long and contains an ORF encoding 
a polypeptide of 162 amino acids with a pre-
dicted molecular mass of 18.7 kDa. For reasons 
documented below this protein will be referred 
to as hPop5.
Besides the human ESTs retrieved from the 
sequence databases, two mouse ESTs, two rat 
ESTs, one cow EST and one Drosophila melano-
gaster entry that encode putative homologues 
of the yeast Pop5p protein were identified. 
These entries contain ORFs of 169, 169, 170 
and 145 amino acids, respectively.
Cloning of the human Pop5 cDNA
To obtain a cDNA encoding the putative 
human Pop5 protein, two oligonucleotides were 
designed based on the identified human EST 
sequence. These oligonucleotides were used 
as PCR primers to isolate hPop5 cDNAs from 
human teratocarcinoma and placenta cDNA 
libraries. Sequence analysis of several clones 
obtained by this procedure revealed that 
cDNAs derived from both sources were iden-
tical, thereby ruling out the introduction of 
PCR artefacts. Two minor differences were 
found in all sequenced cDNAs in comparison 
with the corresponding EST described above 
(AF117232). Nucleotides 154-162 in the cloned 
cDNA sequence (numbering according to 
database accession no. AJ306296) are 
5’-GCA·GCC·GCC-3’, whereas the EST contains 
5’-GCA·CCC-3’ at this position, resulting in the 
replacement of a Pro-codon by two Ala-codons 
in the cloned cDNA in comparison with the 
EST. Furthermore, a single nucleotide substi-
tution was detected at position 461, where a 
T residue was found rather than a C residue, 
which is observed at this position in the human 
EST.
To determine whether the first ATG pre-
sent in the human EST represents the transla-
tional start codon, we synthesised cDNA from 
several sources of mRNA. DNA sequencing of 
the resulting clones revealed that no additional 
sequence information was obtained (data not 
shown). The cloned cDNA encodes a protein 
of 163 amino acids, with a predicted molecular 
mass of 18.8 kDa and a predicted pI of 7.9.
In Figure 1 an alignment of the amino acid 
sequences derived from the human, cow, rat, 
mouse, Drosophila and yeast cDNAs/ESTs is 
shown. This illustrates the high level of homo-
logy between the mammalian Pop5 polypep-
Figure 1. Alignment of amino acid sequences derived from human, cow, rat, mouse, Drosophila and yeast (Saccharomyces cerevisiae) 
Pop5 cDNAs. Amino acids that are identical in at least four of six proteins are marked by a black box, whereas related amino acids 
are marked with a grey box. Dashes indicate the absence of amino acids.
MVRFKHRYLLCELVS DDPRCRLSLDDRVL LVRDTIARVH
MVRFKHRYLLCEVVS DDPRCRLTLEDRVL LVRDTIARVH
MVRFKHRYLLCELVS EDPRCRLSLD RVL LVRDTIARVH
MVRFKHRYLLCELVS ED RCRLSLDDRVL LVRDTIARVH
MVR K RYI QIV P L L DH L IL V K
MVR K RYIL EII V K I IR SLS
G FGAAACSIGFAVRYLNAYTGIVLLRCRKEFY LVWSALPFIT LENKGH YPCFFNTL
G FGAAACSIGFAVRYLNAYTGIVLLRCRKEFY LVWSALPFIT LENKGH YPCF NTL
G FGAAACSVGFAVRYLNAYTGVVLLRCRKDFY LVWSALPFIT LENKGH YPCFFNTL
G FGAAACSVGFAVRYLNAYTGVVLLRCRKDFY LVWSALPFIT LENKGH YPCFFNTL
G YG A GF VKYIN T M IIRC H V S LP IT I F TL
G YGSA C LKY T IIRCHRE LV AL MS I N V
HVGGTIRTCQKFLIQYNRRQLLILLQN TDEGEREAI KSVTRSCLLE E
HVGGTIRTCQKFLIQYNRRQLLILLQN TDEGEREAI KSVTKSCLLE E EE
HVGGTIRTCQKFLIQYNRRQLLVLLQN TDEGEREAI KSVSRSCLLD E EE
HVGGTIRTCQKFLIQYNRRQLLILLQN TDEGEREAI KSVSRSCLLD E EE
IGATI CNKFIV QK L M Q T ERQ L K V M
KV GTIK E F M N K L II S K E E ED
GEE AE ME
GEE AE ME
GEE AE ME
GEE AE ME
human 1 ------------------- SS
cow 1 ------------------- GT
rat 1 ------------------- Y GG
mouse 1 ------------------- A GG
drosophila 1 I N AV P-------------------YT TQS R N S TK LQN E YY
yeast 1 L S F FPPTDTNVEESVSKADILLSHHRASPAD SI S LQE R LNL
human 42 T Q Y R
cow 42 T R S R L
KI Q A RR S I N KCSQ SHLSDNDFIINDF KIGR N NEN D----
human 155 A A
cow 162 T P
rat 161 A A
mouse 161 V A
drosophila ---------
---------yeast
rat 42 A Q C S
mouse 42 A Q Y R
drosophila 42 V L VIEQ R DR K A L RGQRF S V L L G----DVRAK R
yeast 61 D K NSLLQ FSNK STG DCD IM ML K G---DVDGLIV P
human 102 C Q E EE-------S
cow 102 C Q E SAG LSDSG
rat 102 Y K R SV- LSDSA
mouse 102 C K R PV- LSDSA
drosophila 98 Y IQ KH QF DRT G I SAK D F R MEFD DR------------
yeast 118 S
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tides (88-91% identity, 93-95% similarity), 
whereas the homology between the human, 
Drosophila and yeast proteins is much lower 
(23-27% identity and 40-43% similarity). The 
conservation of the yeast and human Pop5 
amino acid sequences is most extensive in the 
N-terminus. Except for the acidic C-terminus, 
the primary sequence of hPop5 does not reveal 
established sequence motifs. The acidic nature 
of the C-terminus is conserved from human to 
yeast (in hPop5 9 out of 15 residues are acidic), 
although it it appears to be absent in the Dro-
sophila sequence.
Anti-hPop5 antibodies immunoprecipi-
tate both RNase MRP and RNase P par-
ticles
To determine whether the hPop5 protein 
is associated with the human RNase MRP and 
RNase P ribonucleoprotein particles, a poly-
clonal antibody was raised against recombi-
nant hPop5. The hPop5 protein was expressed 
as a fusion protein with GST in E. coli. The 
recombinant GST-hPop5 fusion protein was 
purified using glutathione-Sepharose 4B beads 
(Figure 2, lane 2) and used for immunisation 
of rabbits. Western blot analysis showed that 
the resulting rabbit serum is reactive with the 
GST-hPop5 protein (lane 4), whereas the pre-
immune serum is not (lanes 3). Because the 
rabbit serum failed to recognise the hPop5 pro-
tein in HeLa extracts (data not shown), anti-
hPop5 antibodies were purified by affinity 
selection with recombinant GST-hPop5 from 
the rabbit serum. Prior to the GST-hPop5 selec-
tion the rabbit serum was depleted of anti-
GST activity by performing affinity selection 
with recombinant GST. Western blot analysis 
of HeLa cell extracts with the affinity-purified 
antibodies against hPop5 revealed a single pro-
tein with an estimated size of 19 kDa (lane 6), 
whereas the affinity-purified antibodies against 
GST failed to detect any protein in HeLa 
extracts (lane 5).
To investigate whether the hPop5 protein 
is associated with the RNase MRP and RNase 
P complexes, immunoprecipitations with the 
anti-hPop5 serum using total HeLa cell extract 
were performed. The co-precipitating RNAs 
were isolated and analysed by northern blot 
hybridisation using riboprobes specific for 
RNase MRP, RNase P and U3 RNA. As depicted 
in Figure 3 (lane 6), the anti-hPop5 antiserum 
efficiently immunoprecipitated both RNase 
MRP and RNase P RNAs, whereas no detect-
able precipitation of U3 RNA was observed. 
The specificity of this assay was demonstrated 
by the observation that pre-immune serum 
did not precipitate any of the RNAs analysed 
(lane 5) and that anti-55K antibodies specifi-
cally precipitated U3 RNA (lane 3) in accor-
dance with previous observations (113). In 
addition, the RNase MRP and RNase P RNAs 
were co-immunoprecipitated by a patient anti-
Th/To antiserum and by anti-hPop4 antibodies 
(lanes 2 and 4). These results indicate that the 
19 kDa hPop5 protein is associated with both 
RNase MRP and RNase P RNAs in HeLa cells.
hPop5 accumulates in the nucleoli
To investigate the subcellular localization 
of the hPop5 protein, the affinity-purified anti-
bodies directed against GST-hPop5 and GST 
were used for immunolocalisation experiments 
in HEp-2 cells. The affinity-purified anti-
hPop5 antibodies strongly stained the nucleoli 
and showed in addition a fine-speckled cyto-
plasmic staining (Figure 4, panel A). Using 
affinity-purified anti-GST antibodies a similar 
fine-speckled cytoplasmic staining pattern, but 
no nucleolar staining was observed (panel C), 
strongly suggesting that the cytoplasmic stai-
ning is caused by anti-GST reactivity. Although 
these results do not completely rule out a cyto-
plasmic localization of the hPop5 protein, they 
clearly show that the hPop5 protein accumu-
lates in the nucleoli, consistent with its associa-
tion with RNase MRP and RNase P.
Anti-hPop5 antibodies immunoprecipi-
tate catalytically active RNase P
To obtain further evidence that the hPop5 
protein is part of the complete RNase P com-
plex, we tested whether hPop5 is associated 
with catalytically active RNase P. First, we par-
tially purified the active RNase P complex from 
a HeLa cell extract by DEAE-Sepharose chro-
matography and glycerol gradient centrifuga-
tion. The fractions of the glycerol gradient 
were tested for RNase P activity by monitoring 
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Figure 2. HeLa cells express a 19 kDa hPop5 polypeptide. A 
rabbit antiserum was raised against recombinant GST-hPop5 
fusion protein expressed in E. coli. Lane 2 shows the recombi-
nant GST-hPop5 protein preparation stained with Coomassie 
Brilliant Blue. The GST-hPop5 protein was efficiently recognized 
by the anti-hPop5 antiserum (lane 4) on western blots. As a 
control the reactivity of the corresponding pre-immune serum 
is shown in lane 3. The anti-GST and anti-hPop5 antibodies 
and their reactivity with proteins from a total HeLa cell extract 
was analysed by western blotting (lanes 5 and 6, respectively). 
Lane 1 contains molecular weight marker proteins.
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Figure 3. hPop5 is associated with the RNA components of 
RNase MRP and RNase P. RNPs were immunoprecipitated 
from a total HeLa cell extract using anti-Th/To (lane 2), anti-
55K (lane 3), anti-hPop4 (lane 4), pre-immune (lane 5) and 
anti-hPop5 (lane 6) antisera. Co-precipitating RNAs and RNAs 
from total extract (lane 1) were isolated, resolved by dena-
turing polyacrylamide gel electrophoresis and analyzed by 
northern blotting using riboprobes specific for human RNase P, 
RNase MRP and U3 RNA, as indicated on the right. The signals 
marked with an asterisk represent degradation products of the 
U3 RNA.
A B
C D
Figure 4. Subcellular localisation of the hPop5 protein. HEp-2 
cells were fixed and stained with affinity-purified anti-hPop5 
(panel A) or affinity-purified anti-GST (panel C) antibodies. 
The corresponding phase-contrast images are shown in panels 
B and D, respectively.
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immunoblotting. As shown in the lower part 
of Figure 5A, hPop5 (bottom panel), hPop4 
(middle panel) and Rpp38 (top panel) co-frac-
tionated with the RNase P activity, suggesting 
that hPop5 indeed is associated with catalyti-
cally active RNase P. To confirm this, immu-
noprecipitations were performed on RNase P 
containing glycerol gradient fractions using 
affinity-purified anti-hPop5 and anti-GST 
antibodies and the immunoprecipitates were 
assayed for RNase P activity. As shown in 
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its ability to specifically cleave an internally 
labelled precursor-tRNA substrate to tRNA and 
its 5’-leader. Products of this reaction were 
separated on a denaturing polyacrylamide gel 
and visualised by autoradiography. In agree-
ment with previous observations (63,78), the 
RNase P activity was only detected in rela-
tively fast sedimenting fractions (Figure 5A). 
To study the presence of the hPop5 protein 
in the active RNase P fractions of the glycerol 
gradient, these fractions were analysed by 
← Figure 5. hPop5 associates with catalytically active RNase P. 
The RNase P holoenzyme was purified from a total HeLa 
extract by DEAE-Sepharose column chromatography followed 
by glycerol gradient centrifugation.
A. Top panel: Fractions of the glycerol gradient (1-29) were 
assayed for RNase P activity by incubation with a 32P-labelled 
pre-tRNA substrate (input). Subsequently, the reaction pro-
ducts were analysed by denaturing polyacrylamide gel electro-
phoresis and autoradiography. On the right, the positions of 
the pre-tRNA, the mature tRNA and the 5’-leader are indi-
cated.
Bottom part: Detection of RNase MRP/RNase P proteins in 
glycerol gradient fractions. Reactivity with affinity-purified anti-
hPop5 (bottom), anti-hPop4 (middle) and anti-Rpp38 (top) 
antisera with proteins from glycerol gradient fractions was ana-
lysed by western blotting. On the left the positions of molecu-
lar weight markers are indicated and on the right the antisera 
that were used.
B. Anti-hPop4 (lanes 1 and 5), affinity-purified anti-GST (lanes 
2 and 6) and affinity-purified anti-hPop5 (lanes 3 and 7) anti-
bodies were used for immunoprecipitations using fraction 5 of 
the glycerol gradient. Immunoprecipitates (IPP) and superna-
tants were assayed for RNase P activity (lanes 1-3 and lanes 
5-7, respectively). On the right, the positions of the pre-tRNA, 
the mature tRNA and the 5’-leader are indicated.
→ Figure 6. The C-terminus of hPop5 is neither required 
for complex association nor for RNase P activity. HEp-2 cells 
were transfected with constructs encoding hPop5, hPop5 
∆(145-163) and the corresponding ‘empty’ vector as a negative 
control and extracts of these cells were subjected to immuno-
precipitation with anti-VSV antibodies.
A. Association of VSV-tagged hPop5 and the C-terminal dele-
tion mutant of hPop5 with RNase MRP and RNase P com-
plexes. Lanes 1 and 4, empty vector; lanes 2 and 5, hPop5; lanes 
3 and 6, hPop5 ∆(145-163). RNA isolated from extract (input; 
lanes 4-6) and immunoprecipitates (IPP; lanes 1-3) was ana-
lysed by northern blotting using riboprobes for RNase MRP 
and RNase P RNA, as indicated on the right.
B. RNase P activity was assayed as described in the legend 
of Figure 5. Lane 1, material from cells expressing hPop5-VSV; 
lane 2, hPop5 ∆(145-163); lane 3, empty vector; lane 4, sub-
strate pre-tRNA; lane 5 glycerol gradient fraction 5. On the 
right, the positions of the pre-tRNA, the mature RNA and the 
5’-leader are indicated.
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1 and 2), RNase MRP and RNase P RNA were 
both immunoprecipitated from a cell extract 
containing the hPop5-VSV protein, but not 
from an extract from cells transfected with the 
empty vector. This result confirms that hPop5 
associates with the RNase MRP and RNase P 
RNAs in human cells and demonstrates that 
this approach is suitable to analyse hPop5 
mutants. As depicted in lane 3, the hPop5 
∆(145-163) mutant was able to associate with 
both RNase MRP and RNase P RNA, indica-
ting that the evolutionarily conserved acidic 
C-terminus is not required for association with 
these ribonucleoproteins.
To investigate whether this element plays 
a role in the endoribonuclease activity of 
RNase P, HEp-2 cells were transfected with the 
VSV-tagged hPop5 and hPop5 ∆(145-163) con-
structs and immunoprecipitations were per-
formed on extracts prepared from these cells. 
A 32P-labeled precursor-tRNA was incubated 
at 37°C with the immunoprecipitates and the 
resulting products were analysed by dena-
turing polyacrylamide gel electrophoresis and 
autoradiography. As shown in Figure 6B, lanes 
1 and 2, complexes associated with both hPop5 
and the mutant lacking the acidic C-terminus 
displayed RNase P activity, whereas a control 
immunoprecipitate did not. Thus the most 
C-terminal 19 amino acids of hPop5 are nei-
ther required for complex association nor for 
RNase P activity.
Discussion
In this report we describe the cloning of a 
novel human RNase MRP/RNase P protein sub-
unit. Based upon its homology with the yeast 
Pop5p protein we have designated this protein 
hPop5. We showed that the human protein, 
like the yeast Pop5p protein is associated with 
both RNase MRP and RNase P ribonucleopro-
tein particles and that the latter particle is cata-
lytically active in vitro.
hPop5 is evolutionarily conserved
Besides the human homologue of Pop5p, 
our database searches identified two ESTs 
(accession no. AI751395 and AA534933) enco-
ding a putative homologue of the RNase P 
specific protein subunit: Rpr2p (118). No homo-
logues were identified for the Snm1p, Pop3p, 
Pop6p and Pop8p protein, suggesting that only 
6 of the 10 yeast RNase MRP/RNase P protein 
subunits have human counterparts. A high 
degree of sequence conservation was observed 
among the mammalian Pop5 proteins, whereas 
only a moderate level of conservation exists 
between human, yeast and Drosophila Pop5 
(23-27% identity). A similar level of sequence 
conservation has been reported for other 
RNase MRP and RNase P protein subunits: 
hPop1/Pop1p (22% identity), Rpp30/Rpp1p 
(23% identity), Rpp20/Rpp2p (14% identity) 
and hPop4/Pop4p (29% identity) (77-80,120). 
Recently, the analysis of the genomes of archae 
bacteria allowed the detection of hPop5 and 
Rpp30 counterparts also in these organisms 
(121) and in addition showed that the secon-
dary structures of Pop5 and Rpp14 are related. 
A similar conservation from humans to archaea 
has been suggested for the Rpp29/hPop4 and 
Rpp21 subunits (51). A comparison of the 
secondary structures of RNase MRP RNA and 
RNase P RNA from various organisms has led 
to the hypothesis that RNase MRP evolved 
from RNase P in an early eukaryote (122). The 
association of the four highly conserved pro-
teins with MRP RNA would be explained by 
Figure 5B (lanes 2 and 3) the immunoprecipi-
tate obtained with the affinity-purified anti-
hPop5 antibodies was able to cleave pre-tRNA 
into mature tRNA and its 5’-leader, whereas 
the immunoprecipitate of the affinity-purified 
anti-GST antibodies was not. The RNase P 
activity in the anti-hPop5 immunoprecipitate 
was indistinguishable from that obtained with 
anti-hPop4 antibodies, which functioned as a 
positive control (lane 1). These results indicate 
that the hPop5 protein is part of the catalyti-
cally active RNase P complex. Although these 
data do not show that the hPop5 protein is 
associated with catalytically active RNase MRP 
as well, the strong evolutionary relationship 
between the RNase P and RNase MRP com-
plexes suggests that hPop5 is also associated 
with RNase MRP.
The acidic C-terminus of hPop5 is not 
essential for complex association
As described above the only amino acid 
sequence element that could be detected in the 
primary structure of hPop5 is its acidic C-ter-
minus. Therefore, we investigated whether this 
sequence element is required for complex asso-
ciation. A VSV-tag sequence (106) was fused to 
the 3’-end of the hPop5 ORF and to the 3’ end of 
a truncated cDNA lacking the sequence corre-
sponding to the acidic C-terminus (designated 
hPop5-VSV and hPop5 ∆(145-163), respec-
tively). HEp-2 cells were transfected with these 
constructs or with the corresponding ‘empty’ 
vector as a negative control. After culturing 
the cells for 16 h extracts were prepared and 
used for immunoprecipitation with anti-VSV-
tag antibodies. Co-precipitating RNAs were 
isolated and analysed via northern blot hybri-
disation using riboprobes for RNase MRP and 
RNase P RNA. As is shown in Figure 6A (lanes 
the hypothesis that proteins associated with 
RNase P RNA have the capacity to bind MRP 
RNA as well.
Nucleolar accumulation of hPop5
We showed that the hPop5 protein is 
localised in the nucleus and accumulates in the 
nucleolus (Figure 4). Previously, it has been 
proposed that nucleolar entry is a two-step 
mechanism (107-109). First, a nucleolar protein 
is transported to the nucleus and subsequently 
it accumulates in the nucleolus. Recently, we 
demonstrated that clusters of basic amino acids 
are important for the localisation of protein 
subunits of RNase MRP and RNase P in the 
nucleolus (123). The absence of a nuclear locali-
sation signal as well as clusters of basic residues 
in the hPop5 amino acid sequence suggests 
that hPop5 is targeted to the nucleus/nucleolus 
in a different manner. The hPop5 protein might 
be transported to the nucleus and nucleolus 
by a piggyback mechanism. In that case hPop5 
binds in the cytoplasm to another (RNase MRP/
RNase P) protein, which carries the hPop5 pro-
tein to the nucleus and subsequently to the 
nucleolus. Transport of the hPop5 protein from 
the nucleoplasm to the nucleolus might also be 
dependent on its association with the (partially 
assembled) RNase MRP/RNase P ribonucleo-
protein complexes. A similar situation has been 
proposed for the Rpp14 protein (83).
hPop5 is the sixth protein subunit 
shared by the human RNase MRP and 
RNase P complexes
The results in Figures 3 and 6 demonstrate 
that the hPop5 protein subunit, like its yeast 
counterpart, is associated with both RNase MRP 
and RNase P. The association of protein sub-
units with both RNase MRP and RNase P has 
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Materials and Methods
Accession number
The hPop5 cDNA described in this report has been 
deposited in the EMBL database: accession number 
AJ306296.
cDNA cloning and sequence analysis
Database searches were performed using the BLASTN 
2.0.10 program (111). The accession numbers of the 
human Expressed Sequence Tags (ESTs) are AF117232, 
XM-012126, NM-015918 and AF070660. The accession 
numbers for the overlapping mouse ESTs are BF121181 
and BF583365, for rat ESTs BF567090 and AW918527, 
for cow BF075658 and for Drosophila melanogaster 
AAF49372.
The following oligonucleotides (based on the human 
EST sequence) were used to isolate the open reading frame 
of hPop5 by a PCR-based approach: pop51 [5’-GCG-GAT-
CCC-TCG-AGA-TGG-TGC-GGT-TCA-AGC-ACA-GG-3’] 
and pop52 [5’-GCG-GAT-CCC-CCG-GGT-CAT-CTA-GAC-
TCC-ATT-GCT-TCT-GCA-GCC-TCC-TC-3’]. The poly-
merase chain reaction was performed with 200 ng 
denatured DNA from λgt11 human placenta (Clontech) 
and teratocarcinoma cDNA libraries as starting material 
(112). The amplified fragments were ligated in the 
PCR-II-TOPO vector (Invitrogen) and sequenced using 
the dideoxynucleotide chain termination method.
Anti-hPop5 antiserum
To raise a polyclonal anti-hPop5 antiserum, the hPop5 
protein was expressed as a fusion protein with Gluta-
thione S-Transferase (GST) in E. coli and purified by 
glutathione affinity chromatography (114). Rabbits were 
immunised with this material following standard proce-
dures (115). For each injection 200 µg of GST-hPop5 was 
used.
Affinity purification of hPop5 antibodies
To obtain anti-hPop5 and anti-GST antibodies, two 
affinity columns were prepared by immobilising either 
1.25 mg of GST-hPop5 or 4.8 mg of GST protein to 1.5 g 
of CNBr-activated Sepharose-4B (Amersham-Pharmacia) 
according to the manufacturer’s instructions. Rabbit 
serum raised against GST-hPop5 was first depleted of 
anti-GST activity by chromatography on the GST affin-
ity column equilibrated with Buffer A (350 mM NaCl, 
0.05% NP-40, 1 x PBS). Anti-GST antibodies were eluted 
from the column using Buffer B (0.1 M Glycine-HCl 
pH 2.5, 0.5 M NaCl, 0.05% NP-40). This procedure was 
repeated until no detectable anti-GST activity could be 
measured in the flow-through using ELISA methods. 
Subsequently, the flow-through was loaded on the GST-
hPop5 column in Buffer A. After washing with Buffer A, 
the anti-hPop5 antibodies were eluted with Buffer B.
Western blot analysis
For western blot analysis the rabbit anti-hPop5 and 
pre-immune sera were used in a 500-fold dilution, 
whereas affinity-purified anti-GST and anti-hPop5 anti-
bodies were used in a 100-fold dilution. Detection 
was performed using horseradish peroxidase-conjugated 
goat-anti-rabbit IgG (Dako Immunoglobulins) as secon-
dary antibody and visualisation by chemiluminescence.
been previously reported for hPop1, Rpp30, 
Rpp38 and hPop4/Rpp29 (reviewed in ref. 
(118)) and has been observed for the Rpp20 
protein subunit as well (our unpublished obser-
vations). The sharing of protein subunits by 
these endoribonuclease complexes might be 
explained at least in part by the conservation 
of the secondary structure of their RNA com-
ponents and the suggestion that the RNase 
MRP RNA has evolved from the RNase P RNA 
in early eukaryotes (see above). In yeast two 
protein subunits have been described to be 
specifically associated with either the RNase 
MRP complex or the RNase P complex (32,38). 
Such complex-specific protein subunits have 
not been described for the human enzymes 
yet.
An alternative explanation for extensive 
subunit sharing is the possibility that RNase 
MRP and RNase P assemble into a single com-
plex in human cells. This possibility is sup-
ported by the finding that a subset of the 
cellular RNase MRP and RNase P complexes has 
been shown to exist in such a macromolecular 
complex (57). However, in yeast the majority of 
the RNase MRP and RNase P complexes can be 
physically separated and they function sepa-
rately from each other (30,38,78,80). The exact 
function and architecture of this human mac-
romolecular complex and its relation to the 
individual RNase MRP and RNase P complexes 
remain to be elucidated and provide interest-
ing topics for further research.
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Preparation of HEp-2 cell extracts
Extracts of HEp-2 cells were prepared by resuspend-
ing cell pellets in buffer A (25 mM Tris-HCl pH 7.5, 
100 mM KCl, 1 mM dithioerythritol, 2 mM EDTA, 
0.5 mM phenylmethylsulfonyl fluoride, 0.05% NP-40) 
and lysis by sonication using a Branson microtip (three 
times 20 s). Insoluble material was removed by centrifu-
gation (12,000 g, 15 min) and supernatants were used 
directly for immunoprecipitations.
Immunoprecipitation
A monoclonal anti-VSV-tag antibody (Roche), an anti-
55K (113) antiserum, a patient anti-Th/To serum, the 
rabbit anti-hPop5 antiserum, an anti-hPop4 antiserum 
(120) and pre-immune serum from the rabbit immunised 
with hPop5 protein were coupled to protein A agarose 
beads (Biozym) in IPP500 (500 mM NaCl, 10 mM Tris-
HCl pH 8.0, 0.05% NP-40) by incubation for 1 h at room 
temperature. Beads were washed twice with IPP500 
and once with IPP150 (150 mM NaCl, 10 mM Tris-HCl 
pH 8.0, 0.05% NP-40). For each immunoprecipitation a 
cell extract was incubated with the antibody-coupled 
beads for 2 h at 4°C. Subsequently, beads were washed 
three times with IPP150.
To analyse co-precipitating RNAs, the RNA was iso-
lated by phenol-chloroform extraction and ethanol 
precipitation. RNAs were resolved on a denaturing poly-
acrylamide gel and blotted to a Hybond-N membrane 
(Amersham). Northern blot hybridisations with ribo-
probes specific for human RNase P, RNase MRP and U3 
RNAs were performed as previously described (116).
Immunofluorescence
Indirect immunofluorescence assays with affinity-
purified rabbit anti-hPop5 antibodies and affinity-puri-
fied rabbit anti-GST antibodies were performed on HEp-2 
cells. Fixed cells were incubated with affinity-purified 
antibodies (diluted 1:20 in PBS) for 1 h at room tem-
perature, washed with PBS and subsequently incubated 
with Alexa Fluor 488 goat-anti-rabbit IgG conjugate 
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(Molecular Probes, diluted 1:75 in PBS) for 1 h at room 
temperature. Bound antibodies were visualised by epi-
fluorescence microscopy.
RNase P purification from HeLa cells
Purification of the human RNase P enzyme was 
performed as described before (63,78). HeLa S3 cells 
(National Cell Culture Center, Minneapolis, Minnesota) 
were pelleted, disrupted, and the cell lysate was centri-
fuged at 10,000 g followed by another centrifugation at 
100,000 g. The extract was loaded on a DEAE-Sepharose 
column and bound material was eluted with a linear 
100-500 mM KCl gradient. Fractions containing RNase P 
activity were pooled, concentrated and further fraction-
ated by centrifugation in a 15-30% glycerol gradient.
pre-tRNA processing assay
To assay for RNase P activity in the immunoprecipi-
tates and column fractions, an internally 32P-labeled 
pre-tRNA substrate (S. pombe tRNASer SupS1), was 
transcribed in vitro and gel-purified. This 110 nt-long 
substrate contains a 5’-end extension of 28 nts in com-
parison with the mature tRNA. The immunoprecipitates 
or fractions were incubated with equal amounts of sub-
strate in assay buffer (20 mM Tris-HCl pH 8.0, 10 mM 
MgCl2, 1 mM DTE, 50 mM KCl, 50 µg/ml BSA, 60 U/ml 
RNasin) for 10 minutes at 37ºC. Reaction products were 
analysed by denaturing polyacrylamide gel electropho-
resis and autoradiography.
Transfection constructs
Vesicular stomatitis virus G epitope (106) (VSV-G)-
tagged (hereafter referred to as VSV-tagged) cDNAs were 
constructed as follows. 55k-VSV cDNA constructs (113), 
containing either a XhoI or a XbaI-site between the 55k 
open reading frame (ORF) and the VSV-tag sequence 
(positioned at the N- and C-terminal sides, respectively) 
were cleaved with XhoI and XbaI releasing the 55k-cDNA 
from this plasmid. The VSV-tagged constructs of hPop5 
were constructed by isolation of the hPop5 ORF from 
the hPop5/PCR-II-TOPO construct by XhoI/XbaI diges-
tion and ligation into the XhoI/XbaI digested 55k-VSV 
constructs.
A construct expressing deletion mutant hPop5 
∆(145-163) was generated by a PCR-based approach. 
Besides the deletion introduced by the PCR strategy, 
an XhoI site was introduced at the 5’-end of the transla-
tional start codon, whereas an XbaI site was introduced 
at the 3’-end of the coding sequence. The transfection 
construct was generated by ligating the XhoI/XbaI frag-
ment into the XhoI/XbaI digested 55k-VSV constructs. 
The integrity of the resulting construct was confirmed 
by DNA sequencing. The pCI-neo vector (Promega), 
which has been used to prepare 55k-VSV previously, 
was used as a control in the transfection experiments.
Transient transfection of HEp-2 cells
HEp-2 monolayer cells were grown to 70% conflu-
ency by standard tissue culture techniques in either 
culture flasks or on coverslips. HEp-2 cells were trans-
fected with the VSV-tagged constructs (3-4 µg) using 
LipofectAmine 2000 (Gibco-BRL) according to the manu-
facturer’s instructions. After overnight growth in flasks, 
cells were harvested, washed once with PBS and used to 
prepare extracts for immunoprecipitation assays.
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Introduction
The endoribonuclease MRP (Mitochon-
drial RNA Processing) complex is a member 
of the large family of small nucleolar ribonu-
cleoprotein particles shown to be involved in 
precursor-rRNA processing. Three classes of 
snoRNPs can be distinguished based on struc-
tural elements: Box H/ACA snoRNPs, Box C/D 
snoRNPs and RNase MRP/RNase P (5).
RNase MRP and RNase P ribonucleopro-
tein particles are related in many aspects. 
Abstract
The RNase MRP and RNase P ribonucleoprotein particles both func-tion as endoribonucleases, have a similar RNA component and share several protein subunits. RNase MRP has been implicated in 
pre-rRNA processing and mitochondrial DNA replication, whereas RNase P 
functions in pre-tRNA processing. Both RNase MRP and RNase P accumulate 
in the nucleolus of eukaryotic cells.
In this report we show that for three protein subunits of the RNase MRP 
complex (hPop1, hPop4 and Rpp38) basic domains are responsible for their 
nucleolar accumulation and that they are able to accumulate in the nucleo-
lus independently of their association with the RNase MRP and RNase P 
complexes. We also show that certain mutants of hPop4 accumulate in the 
Cajal bodies, suggesting that hPop4 traverses through these bodies to the 
nucleolus. Furthermore, we characterised a deletion mutant of Rpp38 that 
preferentially associates with the RNase MRP complex, giving a first clue 
about the difference in protein composition of the human RNase MRP and 
RNase P complexes. Based upon all available data on nucleolar localisation 
sequences we hypothesise that nucleolar accumulation of proteins contain-
ing basic domains proceeds by diffusion and retention rather than by an 
active transport process. The existence of nucleolar localisation sequences 
is discussed.
Both complexes function as site-specific 
endonucleases: RNase P is involved in the 
generation of the mature 5’ end of tRNAs, 
whereas RNase MRP has been shown to be 
involved in the processing of pre-rRNA. 
The RNA components of both enzymes 
adopt a similar cage-shaped secondary 
structure. Furthermore, it became clear that 
most of the currently known human pro-
tein subunits of RNase MRP and RNase P 
are shared by both enzymes (see for review 
ref. (118)).
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Besides the reported function of RNase 
MRP in the processing of pre-rRNA, in vitro 
experiments have shown that RNase MRP is 
also involved in the processing of mitochon-
drial RNA that functions as a primer for 
mitochondrial DNA replication (22). Only a 
relatively small amount of RNase MRP has been 
reported to reside in the mitochondria, whereas 
the majority (99%) of RNase MRP is located 
in the nucleolus (110). By genetic depletion 
in yeast it has been shown that the nucleolar 
RNase MRP is involved in the formation of 
the short form of the 5.8S rRNA [5.8S(S)], by 
catalysing the cleavage at site A3 in the first 
internal transcribed spacer (ITS1) of pre-rRNA 
(28, 30,29). Although none of these functions 
have been demonstrated to apply to the human 
system as yet, they are thought to be evolu-
tionarily conserved. Recently, it was demon-
strated that mutations in the human gene 
coding for the RNase MRP RNA cause an auto-
somal recessive disease called cartilage-hair 
hypoplasia, suggesting that the RNase MRP 
complex and/or its substrates play an impor-
tant role in embryogenesis (119).
The first identified element important for 
the targeting of RNase MRP to the nucleolus is 
the 5’-terminal region of the RNase MRP RNA 
(referred to as P3 domain or Th/To binding site) 
(44). The RNase P complex has been detected 
in both nucleolus and nucleoplasm (58,60) 
and it has been determined that the evolu-
tionarily conserved P3 domain of RNase P 
RNA functions in nucleolar localisation as well 
(58). Recently, a domain in two protein sub-
units, Rpp29 (identical to hPop4) and Rpp38, 
of RNase MRP and RNase P has been reported 
to be involved in the nucleolar localisation of 
these protein subunits (83). In both cases the 
highly basic nature of these domains rather 
than a distinct amino acid sequence appeared 
to be important.
In this study we analysed several deletion 
mutants of three protein subunits associated 
with both RNase MRP and RNase P: hPop1 
(77), hPop4 (120) and Rpp38 (78,105) and exam-
ined the accumulation of these mutants in the 
nucleolus, complex association and RNase P 
enzymatic activity.
Results
To learn more about the nucleolar targeting 
of the human RNase MRP and RNase P com-
plexes, three of their protein subunits (hPop1, 
Rpp38 and hPop4) were mutated and the effects 
of the mutations on their subcellular locali-
sation was analysed by fluorescence micros-
copy. Figure 1 shows the main characteristics 
of the hPop1, Rpp38 and hPop4 protein sub-
units, including putative nuclear localisation 
signals, identified nucleolar localisation signals 
and conserved sequence elements.
Because the nucleolar accumulation of these 
protein subunits might be dependent on their 
association with the particles, the association of 
the mutants with the RNase MRP and RNase P 
RNAs was analysed by northern blot hybri-
disation and their assembly into functional par-
ticles was analysed in an in vitro pre-tRNA 
processing assay.
Basic domains of the hPop1 protein are 
required for its nucleolar targeting
DNA molecules encoding wildtype hPop1 
and deletion mutants of hPop1 were cloned 
into the mammalian expression vector pCI-neo, 
in combination with a sequence encoding a 
VSV-G tag (106) fused to the 5’-end of the 
coding sequences, and transiently expressed 
in HEp-2 cells. After overnight culturing, the 
cells were fixed and the subcellular localisa-
tion of the VSV-tagged hPop1 (mutants) was 
determined by indirect immunofluorescence 
using anti-VSV-tag antibodies.
The results in Figure 2A, panels 1 and 2, 
show that the VSV-hPop1 construct expressed 
a protein that accumulated in the nucleoli, 
in accordance with previous observations 
(77). A similar nucleolar staining pattern was 
found for VSV-tagged hPop1 deletion mutants 
∆(711-1024), ∆(558-1024) and ∆(339-1024) (see 
Table I), indicating that the N-terminal region 
plays an important role in the nucleolar accu-
mulation of the hPop1 protein. This was 
confirmed by the finding that a mutant in 
which most of these amino acids had been 
deleted, VSV-hPop1 ∆(1-318), was targeted to 
the nucleoplasm and did not accumulate in the 
nucleoli (Figure 2A, panels 3 and 4).
These results were further detailed by the 
finding that a deletion mutant containing only 
the N-terminal 128 amino acids, ∆(129-1024), 
was found uniformly distributed throughout 
the cell (Figure 2A, panels 5 and 6). Taken 
together, these results suggest that amino acids 
129-318 are important for the nucleolar accu-
mulation of the hPop1 protein.
To study whether a hPop1 fragment com-
prising amino acids 128-319 was able to accu-
mulate in the nucleolus, we fused this part of 
the hPop1 protein to EGFP and analysed its 
localisation. This fragment of hPop1 indeed 
proved to be sufficient for nucleolar targeting 
of EGFP (Figure 2B, panels 1 and 2). In this 
region one of the two putative nuclear loca-
lisation sequences, a highly conserved argi-
nine-rich motif (R-box) and a tryptophan-rich 
domain (W-box) have been identified (77). In 
the same way, three subfragments of the aa 
128-319 region were analysed. Constructs were 
made that encode only the R-box (aa 128-167), 
the NLS and W-box together (aa 168-319) 
and the R-box, NLS and W-box (aa 128-245), 
each fused to EGFP. Surprisingly, these fusion 
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Figure 1. Schematic representation of the hPop1, Rpp38 and 
hPop4 proteins. The length, putative nuclear localisation signals 
(NLS) and nucleolar localisation signals (NoLSs) as established 
by Jarrous and coworkers (83) for the hPop1 (A), Rpp38 (B) 
and hPop4 (C) protein subunits are depicted in the upper 
parts. The lower parts represent charge plots of these proteins. 
Values on the vertical axis represent positively charged and 
negatively charged regions respectively. These values were cal-
culated using a window of 9 amino acids. Light blue regions in 
the charge plots represent the regions of the proteins impor-
tant for their nucleolar localisation. For the hPop1 protein (A) 
the charge plot of only amino acids 100-400 is depicted (blue 
area in upper part). The R-, W- and G-box refer to conserved 
sequence elements observed in the hPop1 protein (77).
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proteins all localised to the nucleolus (see 
Figure 2B, panels 3-6 for 128-167 and 128-245 
and Table I for 168-319), although the efficiency 
of nucleolar accumulation for the 168-319 and 
128-245 fusion proteins was much higher than 
that for the 128-167 fragment. The latter was 
also detected in the cytoplasm and nucleoplasm 
(panel 3).
Rpp38 harbours two regions important 
for nucleolar accumulation
Recently, Jarrous and collaborators have 
identified a so-called nucleolar localisation 
sequence (referred to as NoLS) near the C-ter-
minus of the Rpp38 protein subunit of the 
RNase MRP and RNase P complexes (83). To 
investigate whether this NoLS was sufficient 
for the nucleolar localisation of the Rpp38 pro-
tein we made several deletion mutants of the 
Rpp38, fused them to ECFP and expressed 
them transiently in HEp-2 cells. As is depicted 
in Figure 3, panel 1, the wild type Rpp38-ECFP 
fusion protein was localised in both nucleoli 
and nucleoplasm. This distribution is very 
similar to that reported before for a GFP-Rpp38 
fusion protein (83). Although this distribution 
deviates from what has been described for the 
endogenous Rpp38 protein (localisation to the 
nucleolus and Cajal bodies (83)), cells with 
a lower level of expression of this construct 
showed more prominent nucleolar staining, 
suggesting that the strong nucleoplasmic stai-
ning is caused by overexpression.
A construct that encodes Rpp38 lacking 
the N-terminal 40 amino acids showed an iden-
tical subcellular localisation (Table I). Surpri-
singly, deletion of the N-terminal 98 amino 
acids resulted in staining of only the nucleo-
plasm (Figure 3, panel 3), which suggests that 
in spite of the presence of the complete NoLS 
(amino acids 246-283), this mutant is not able 
to enter the nucleoli. Further truncation of 
the N-terminus of the Rpp38 protein (Rpp38 
∆(1-141)) resulted in a cytoplasmic accumula-
tion and a weak nuclear staining (see Figure 3, 
panel 5). Finally, we showed that deletion of 
the C-terminus (Rpp38 ∆(246-283) and Rpp38 
∆(181-283)) results in nucleoplasmic staining, 
loss of nucleolar accumulation and staining of 
the cytoplasm (Figure 3, panel 7 and Table I).
Taken together, these results indicate that 
two domains appear to be necessary for the 
nucleolar accumulation of the Rpp38 protein 
subunit and that each of these domains (amino 
acids 40-98 and 246-283) alone is not sufficient 
for nucleolar targeting.
The amino-terminus of Rpp38 differenti-
ates between RNase MRP and RNase P 
complexes
Because differences in the subcellular loca-
lisation of various Rpp38 deletion mutants 
might be dependent on its ability to associate 
with the RNase MRP and/or RNase P particle, 
complex association was studied by immuno-
precipitation using anti-ECFP antibodies and 
extracts of transiently transfected cells. Com-
plex association was monitored by the isola-
Table I. Summary of subcellular 
localisation, complex association 
with RNase MRP and RNase P 
and RNase P activity of deletion 
mutants of hPop1, Rpp38 and 
hPop4 protein subunits.
Abbreviations:
No = Nucleolus;
Np = Nucleoplasm;
Cy = Cytoplasm;
CB = Cajal Bodies;
– = no association with RNase 
MRP and RNase P/no association 
with RNase P activity;
+ = association with RNase MRP 
and RNase P/association with 
active RNase P; 
nd = not determined
Construct Subcellular Complex Association
 localisation association with with RNase P
  RNase MRP/P activity
hPop1 protein 
wild type No – –
∆(711-1024) No nd nd
∆(558-1024) No nd nd
∆(339-1024) No nd nd
∆(1-318) Np nd nd
∆(129-1024) No + Np + Cy nd nd
128-319 No nd nd
128-167 No + Np + Cy nd nd
168-319 No nd nd
128-245 No nd nd
   
Rpp38 protein 
wild type No + Np + +
∆(1-40) No + Np only MRP –
∆(1-98) Np – –
∆(1-141) No + Np + Cy – –
∆(181-283) Np + Cy – –
∆(246-283) Np  + +
   
hPop4 protein 
wild type No + +
∆(1-10) No + +
∆(1-47) No + +
∆(61-109) No + CB – –
∆(162-220) No + CB – –
∆(181-220) No – –
∆(210-220) No + +
Figure 2. Subcellular localisation of deletion mutants of hPop1. A. VSV-hPop1 constructs were transiently transfected into HEp-2 
cells. Cells were fixed with paraformaldehyde and the expressed proteins were visualised using anti-VSV antibodies (panels 1,3 and 
5). A phase-contrast image of the same cells is shown in panels 2, 4 and 6. Panels 1 and 2: VSV-hPop1 construct, panels 3 and 4: VSV-
hPop1 ∆(1-318), panels 5 and 6: VSV-hPop1 ∆(129-1024). B. EGFP-hPop1 constructs were transiently transfected into HEp-2 cells. 
Cells were fixed with methanol/aceton and the fluorescent proteins were visualised by direct fluorescence microscopy (panels 1, 
3 and 5). Phase-contrast images of the same cells are shown in panels 2, 4 and 6. Panels 1 and 2: EGFP-hPop1 128-319, panels 3 
and 4: EGFP-hPop1 128-167, panels 5 and 6: EGFP-hPop1 128-245.
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tion of RNA from the immunoprecipitates and 
visualisation of RNase MRP and RNase P RNA 
by northern blot hybridisation. As indicated in 
Figure 4A, lane 9, the wild type Rpp38-ECFP 
fusion protein effectively associated with both 
RNase P and RNase MRP, in accordance with 
previously published data (105). Surprisingly, 
the Rpp38 ∆(246-283) mutant also associated 
with both the RNase MRP and the RNase P 
complex (Figure 4A, lane 14), despite the loss 
of its ability to enter the nucleolus. Moreover, 
an N-terminal deletion mutant, which dis-
played a wild type subcellular distribution, 
Rpp38 ∆(1-40), appeared to associate preferen-
tially with the RNase MRP particle (Figure 4A, 
lane 10). With this mutant only a very inef-
ficient co-precipitation of RNase P RNA was 
reproducibly observed, which suggests that 
the N-terminus of the Rpp38 is involved in its 
stable association with the RNase P complex 
but not with the RNase MRP complex.
In contrast, no complex association was 
observed for the remaining deletion mutants of 
Rpp38, Rpp38 ∆(1-98), ∆(1-141) and ∆(181-283), 
which was not due to lack of expression as 
demonstrated by western blotting (our unpub-
lished results).
The carboxy-terminus of Rpp38 is dis-
pensable for RNase P function
To investigate whether the complexes 
bound by the Rpp38 deletion mutants were 
functionally active, we analysed the immu-
noprecipitated complexes in an in vitro pre-
cursor-tRNA processing assay. A 32P-labeled 
precursor-tRNA was incubated at 37°C with 
the anti-ECFP immunoprecipitates and the 
resulting products were analysed by dena-
turing polyacrylamide gel electrophoresis and 
autoradiography.
Particles associated with either the wild 
type ECFP-Rpp38 fusion protein or the C-ter-
minal deletion mutant ∆(246-283) displayed 
RNase P enzymatic activity (Figure 4B, lanes 2 
and 7, respectively), whereas control material 
obtained from extracts of cells expressing ECFP 
alone did not (lane 1). As expected, no RNase P 
activity was detected with the remaining dele-
tion mutants of Rpp38, including ∆(1-40), in 
agreement with the lack of stable association 
with the RNase P complex (Figure 4B, lanes 
3-6).
hPop4 contains two regions important 
for nucleolar localisation
Next, the subcellular localisation and the 
association with the RNase MRP and (catalyti-
cally active) RNase P complexes were studied 
for six deletion mutants of the hPop4 protein 
subunit, following the procedures described 
above.
Indirect immunofluorescence showed that 
the VSV-tagged hPop4 protein subunit is 
localised in the nucleoli as has been established 
previously (120), (Figure 5, panel 1). The sub-
cellular localisation of the ∆(1-10), ∆(1-47), 
∆(181-220) and ∆(210-220) deletion mutants 
(all VSV-tagged) showed that deletion of either 
the N- or the C-terminal regions of the hPop4 
does not affect the localisation of this protein 
as they all accumulated in the nucleoli (see 
Table I).
Two different subcellular localisation pat-
terns were observed for two other deletion 
mutants, one lacking an internal region 
(∆(61-109)) and another in which a relatively 
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Figure 4. Association of ECFP-Rpp38 (mutants) with RNase 
MRP and RNase P ribonucleoprotein particles and RNase P 
activity associated with ECFP-Rpp38 deletion mutants.
A. Constructs encoding (deletion mutants of) ECFP-Rpp38 
were transiently transfected in HEp-2 cells. Extracts from these 
cells used for immunoprecipitations with anti-ECFP antibodies. 
RNA isolated from total cell extracts (lanes 1-7) and immuno-
precipitates (lanes 8-14) was analysed by northern blot hybri-
disation using riboprobes specific for RNase MRP and RNase P 
RNA. Lanes 1 and 8, material from control cells expressing 
ECFP alone; lanes 2 and 9, ECFP-Rpp38; lanes 3 and 10, ECFP-
Rpp38 ∆(1-40); lanes 4 and 11, ECFP-Rpp38 ∆(1-98); lanes 5 
and 12, ECFP-Rpp38 ∆(1-141); lanes 6 and 13, ECFP-Rpp38 
∆(181-283) and lanes 7 and 14, ECFP-Rpp38 ∆(246-283). The 
positions of RNase P and RNase MRP RNA are indicated.
B. RNase P activity assay associated with anti-ECFP immuno-
precipitates from extracts of cells transiently transfected with 
ECFP-Rpp38 (deletion mutants). Lane 1, material from control 
cells expressing ECFP alone; lane 2, ECFP-Rpp38; lane 3, ECFP-
Rpp38 ∆(1-40); lane 4, ECFP-Rpp38 ∆(1-98); lane 5, ECFP-
Rpp38 ∆(1-141); lane 6, ECFP-Rpp38 ∆(181-283); lane 7, 
ECFP-Rpp38 ∆(246-283); lane 8, beads alone and lane 9, sub-
strate RNA. On the right, the positions of the pre-tRNA, the 
mature tRNA and the 5’-leader are indicated.
A
B
Figure 3. Subcellular localisation of deletion mutants of Rpp38. 
ECFP-Rpp38 constructs were transiently transfected into 
HEp-2 cells. Cells were fixed with methanol/aceton and the 
fluorescent proteins were visualised by direct fluorescence 
microscopy (panels 1, 3, 5 and 7). Phase-contrast images of the 
same cells are shown in panels 2, 4, 6 and 8. Panels 1 and 2: 
ECFP-Rpp38, panels 3 and 4: ECFP-Rpp38 ∆(1-98), panels 5 
and 6: ECFP-Rpp38 ∆(1-141) and panels 7 and 8: ECFP-Rpp38 
∆(181-283).
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large part of the C-terminus had been deleted 
(∆(162-220)). As shown in Figure 5, panels 3 
and 7, both mutants do have the ability to 
accumulate in the nucleolus. However, in addi-
tion to strong nucleolar staining observed in 
a subset of cells, for both mutants cells with 
weaker or no nucleolar staining were present 
as well. In many of these cells the fluorescent 
staining was concentrated in nucleoplasmic 
foci, as is depicted in Figure 5, panel 5, for 
∆(61-109). These foci appeared to be Cajal 
bodies (formerly designated coiled bodies), 
which was established by co-localisation expe-
riments using anti-p80 coilin antibodies (our 
unpublished results).
To investigate whether the subcellular 
distribution of these deletion mutants was 
somehow correlated with the ability to asso-
ciate with RNase MRP and RNase P ribonu-
cleoprotein particles, co-immunoprecipitation 
experiments were performed with anti-VSV-
tag antibodies using extracts from transiently 
transfected cells. As described previously (120), 
the wild type hPop4 protein was found to be 
associated with both RNase MRP and RNase P 
complexes (Figure 6A, lane 10), whereas con-
trol precipitations did not display RNase MRP 
and RNase P RNA (lane 9). Deletion of the 
N-terminus of the hPop4 protein subunit did 
not abolish the association with both com-
plexes, because deletion mutants ∆(1-10) and 
∆(1-47) coprecipitated wild type levels of both 
RNAs (lanes 11-12). Also deletion of 11 amino 
acids from the C-terminus did not affect the 
association with both particles (lane 14). In 
contrast, the internal deletion mutant and the 
mutants having more than 10 amino acids 
deleted from the C-terminus of the hPop4 pro-
tein did not detectably associate with RNase 
MRP and RNase P RNA, as demonstrated by 
the results in lanes 13 and 15-16 (Figure 6A). 
Control experiments (western blotting) showed 
that this was not due to lack of expression (our 
unpublished results).
Finally, to investigate the association of 
the hPop4 deletion mutants with catalytically 
active RNase P complexes the immunoprecipi-
tates were analysed in the pre-tRNA process-
ing assay. As demonstrated in Figure 6B, lanes 
1 and 2, particles containing the wild type 
VSV-tagged hPop4 protein displayed enzymatic 
activity. The analysis of the deletion mutants 
showed a complete correlation between the 
capacity to associate with the RNase P particle 
and the enzymatic activity (lanes 3-8). This 
result implies that neither the N-terminal 47 
nor the C-terminal 11 amino acids of hPop4 are 
required for RNase P activity.
Discussion
We have analysed the effects of deletions in 
the hPop1, hPop4 and Rpp38 protein subunits 
of RNase MRP and RNase P on their subcellu-
lar localisation, on their association with RNase 
MRP and RNase P and on the enzymatic acti-
vity of RNase P (see Table I for a summary). 
The results identified regions in each of these 
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Figure 6. Association of VSV-hPop4 (mutants) with RNase 
MRP and RNase P ribonucleoprotein particles and RNase P 
activity associated with VSV-hPop4 deletion mutants.
A. Constructs encoding (deletion mutants) of VSV-hPop4 were 
transiently transfected into HEp-2 cells. Extracts from these 
cells were used for immunoprecipitation with anti-ECFP anti-
bodies. RNA isolated from total cell extracts (lanes 1-8) and 
immunoprecipitates (lanes 9-16) was analysed by northern 
blot hybridisations using riboprobes specific for RNase MRP 
and RNase P RNA. Lanes 1 and 9, material from cells trans-
fected with empty vector alone; lanes 2 and 10, VSV-hPop4; 
lanes 3 and 11, VSV-hPop4 ∆(1-10); lanes 4 and 12, VSV-
hPop4 ∆(1-47); lanes 5 and 13, VSV-hPop4 ∆(61-109); lanes 
6 and 14, VSV-hPop4 ∆(210-220); lanes 7 and 15, VSV-hPop4 
∆(181-220) and lanes 8 and 16, VSV-hPpop4 ∆(162-220). The 
positions of RNase MRP and RNase P RNA are indicated on 
the right.
B. RNase P activity assay associated with immunoprecipitates 
from extracts of cells transiently transfected with VSV-hPop4 
(deletion mutants). Lane 1, material from cells transfected with 
empty vector alone; lane 2, material from cells expressing VSV-
hPop4; lane 3 VSV-hPop4 ∆(1-10); lane 4, VSV-hPop4 ∆(1-47); 
lane 5, VSV-hPop4 ∆(61-109); lane 6, VSV-hPop4 ∆(162-220); 
lane 7, VSV-hPop4 ∆(181-220); lane 8, VSV-hPop4 ∆(210-220); 
lane 9, input. On the right, the positions of the pre-tRNA, the 
mature tRNA and the 5’-leader are indicated.
A
B
Figure 5. Subcellular localisation of deletion mutants of hPop4.
VSV-hPop4 constructs were transiently transfected into HEp-2 
cells. Cells were fixed with methanol/aceton and the expressed 
proteins were visualised by indirect fluorescence microscopy 
using anti-VSV antibodies (panels 1, 3, 5 and 7). Phase-con-
trast images of the same cells are shown in panels 2, 4, 6 
and 8. Panels 1 and 2: VSV-hPop4, panels 3 and 4: VSV-hPop4 
∆(61-109), nucleolar accumulation, panels 5 and 6: VSV-hPop4 
∆(61-109), accumulation in the Cajal bodies and panels 7 and 
8: VSV-hPop4 ∆(162-220), nucleolar pattern.
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proteins important for their nucleolar accu-
mulation. The nucleolar localisation of hPop1 
appeared to be dependent on a region near the 
N-terminus of this protein. The Rpp38 protein 
subunit needs two distinct regions to accumu-
late in the nucleolus. Although none of the 
hPop4 deletion mutants analysed failed to enter 
the nucleolus two mutants of this protein accu-
mulated in the Cajal bodies in a subset of the 
cells. Importantly, complex association did 
not appear to be a requirement for nucleolar 
accumulation. All deletion mutants of Rpp38 
and hPop4 that retained the capacity to asso-
ciate with the RNase MRP and P complexes 
were bound to enzymatically active RNase P, 
suggesting that the deleted amino acids are dis-
pensable for this activity. Finally, the N-ter-
minus of Rpp38 appeared to be required for a 
stable association with RNase P but not with 
RNase MRP.
 The N-terminus of Rpp38 discriminates 
between RNase P and RNase MRP
The RNase MRP and RNase P ribonucleo-
protein complexes show a high degree of simi-
larity. Their RNA components can be folded in 
similar cage-shaped structures, and most of the 
currently known protein subunits have been 
shown to be associated with both complexes 
(for review see ref. (118)). In yeast only a single 
protein subunit has been reported to be speci-
fically associated with either RNase MRP (98) 
or RNase P (38), whereas the other seven pro-
teins are common to both particles. So far 
no human orthologues of the particle-specific 
yeast proteins have been found.
The N-terminal deletion mutant ∆(1-40) of 
Rpp38 appeared to associate preferentially with 
the RNase MRP complex. This implicates that 
the N-terminus of this protein plays an impor-
tant role in the association with the RNase P 
complex. Whether the lack of binding of this 
mutant to RNase P is due to the loss of interac-
tions with the RNA component (105) or with 
another, most likely particle-specific protein 
subunit is presently not known.
The selective interaction of Rpp38 ∆(1-40) 
with the RNase MRP complex in combination 
with the lack of RNase P activity associated 
with this complex implies that the RNase MRP 
particle is unable to cleave the precursor-tRNA 
(substrate for RNase P), unless the N-terminus 
of Rpp38 is required for this activity.
Basic domains in the protein subunits of 
RNase MRP and P are involved in their 
nucleolar accumulation
A comparison of the regions in the three 
proteins that affect their nucleolar accumula-
tion showed that all were highly enriched in 
basic amino acids (see Figure 1), suggesting 
that basic regions are important for nucleolar 
localisation. Basic sequence elements have 
been implicated in nucleolar localisation of 
the Rpp38 and Rpp29/hPop4 protein subunits 
before (83). Jarrous and co-workers proposed 
that nucleolar localisation sequences (referred 
to as NoLS) are present at positions 260-283 in 
Rpp38 and 63-85 in hPop4, respectively (83). 
They showed that these elements are able to 
direct a reporter protein to the nucleolus. Our 
data confirm that these elements are required 
for nucleolar targeting of these proteins but 
also show that in the case of Rpp38 an addi-
tional element (aa 40-98) is required, whereas 
in the case of hPop4 a deletion of the pre-
viously identified NoLS (∆(61-109)) does not 
abrogate its transport to the nucleolus. Appa-
rently, the NoLS of Rpp38 identified previously 
is required but not sufficient for nucleolar 
accumulation, and hPop4 contains more than 
one functional NoLS.
The wild type Rpp29/hPop4 has been 
reported to be present in the Cajal bodies previ-
ously (83). Surprisingly, two deletion mutants 
of hPop4 appeared to be retained in the Cajal 
bodies in a subset of the transfected cells. 
Transport of the Rpp29/hPop4 protein sub-
unit through the Cajal bodies on its way to the 
nucleolus fits very well in the model proposing 
that snoRNPs assemble into larger complexes 
in the Cajal bodies and are subsequently trans-
ported to the nucleolus (124). A defect in this 
assembly process caused by the deletions in 
our mutants might lead to their retention in the 
Cajal bodies. However, in addition to the reten-
tion in the Cajal bodies both mutants did enter 
the nucleoli in some cells. More importantly, 
all three proteins studied in this report have 
the capacity to enter the nucleus and nucleolus 
independent of an association with the cognate 
RNAs strongly suggesting that the association 
with the cognate particles is not an absolute 
requirement for transport of these proteins to 
the nucleoli.
Does a NoLS exist?
The involvement of regions rich in basic 
amino acids in nucleolar localisation has been 
found by others as well. For the poly(A)-bind-
ing protein II (PABP2) it has been shown that 
the basic C-terminal region of this nucleoplas-
mic protein directs a reporter protein to the 
nucleolus (125) and more recently it was shown 
that a basic element in p80-coilin, a marker 
protein for Cajal bodies, when uncovered by 
the deletion of an acidic region, also leads to 
a nucleolar localisation (126). In addition, two 
viral proteins, herpesvirus MEQ protein and 
PRRSV nucleocapsid protein (127,128), and 
two cellular proteins, rat spermatidal protein 
TP2 and human I-mfa domain containing pro-
tein HICp40 (129,130) have been reported to 
contain NoLSs consisting of stretches of basic 
residues as well. Comparison of these various 
basic sequence elements does not reveal a con-
sensus sequence. Taken together, our results 
and the work of others indicate that stretches 
of basic residues, even when these are derived 
from proteins that normally do not reside in 
the nucleoli, may target proteins to the nucleo-
lus independently of functionality (e.g. com-
plex association).
A prerequisite for nucleolar accumulation 
is translocation of a protein from the cyto-
plasm to the nucleoplasm. In the nucleoplasm 
proteins may bind to their functional entities. 
Nucleolar accumulation can subsequently pro-
ceed by two mechanisms: one in which the 
translocation to the nucleolus is an active pro-
cess (either mediated by a signal in the protein 
which directs it to the nucleolus or mediated by 
its association with other molecules/complexes 
which are actively transported to the nucleo-
lus); another in which nucleolar entry is a 
passive process mediated by diffusion. In the 
latter case accumulation in the nucleolus may 
be due to retention by binding to nucleolar 
components.
The existence of a specific signal that 
directs proteins to the nucleolus is not sup-
ported by the data discussed above. The dele-
tion of the previously described NoLS in hPop4 
does not block nucleolar localisation (hPop4 
∆(61-109)) and a mutant that does contain the 
NoLS identified in Rpp38 is not localised to the 
nucleolus (Rpp38 ∆(1-98)). Moreover, the NoLS 
identified in PABP2 is not able to direct this 
protein to the nucleolus (125). In conclusion, 
these data strongly suggest that the identified 
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basic domains are not functioning in an active 
nucleolar transport pathway. Transport to the 
nucleolus via assembly into functional com-
plexes is also not supported by our data. 
Mutants of all three proteins studied (hPop1, 
hPop4 and Rpp38) are able to localise to the 
nucleolus independently of complex associa-
tion. This is substantiated by the finding that 
different proteins composed of 10-20 basic 
amino acids fused to EGFP are able to localise 
to the nucleolus as well (83,125,130). Nucleo-
lar accumulation by diffusion and retention 
is consistent with all available data. Whether 
nucleolar retention is caused by the specific 
binding to nucleolar components, is not clear 
at present. Most likely the RNase MRP com-
plex is bound in the nucleolus because it is 
involved in the processing of the precursor-
rRNA and it associates with either pre-rRNA 
or the processing-machinery. However, such 
a mechanism does not explain the nucleolar 
localisation mediated by small stretches of basic 
amino acids. This type of nucleolar accumula-
tion might be explained by the high concen-
tration of negatively charged molecules in the 
nucleolar compartment (e.g. precursor-rRNA, 
rDNA) to which these basic elements may non-
specifically bind. Thus, in our opinion data 
obtained by these kind of experiments should 
be interpreted with great care.
In conclusion, we suggest that nucleolar 
localisation signals that mediate active trans-
port to the nucleolus may not exist and that the 
previously identified basic elements localise 
proteins to the nucleolus by virtue of their 
nucleolar retention capacity after diffusion into 
the nucleolus.
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Materials and Methods
hPop1 deletion mutant constructs
hPop1 cDNA (77) was mutated by PCR to introduce a 
XhoI site before the translational start codon. The PCR 
product was digested with XhoI/EcoRI and ligated into 
an XhoI/EcoRI digested pCI-neo vector (Promega) that 
contains a 5’ VSV-G tag encoding sequence inserted 
between the original NheI-XhoI sites of pCI-neo (113), 
resulting in a construct referred to as VSV-hPop1.
Partial digestion of VSV-hPop1 with HpaI and 
XbaI results in the release of a DNA fragment of 
900 bp. The vector with the remaining hPop1 cDNA 
sequence was treated with Klenow polymerase and reli-
gated, generating a construct encoding the VSV-hPop1 
∆(711-1024) deletion mutant. Constructs encoding VSV-
hPop1 ∆(558-1024) and VSV-hPop1 ∆(339-1024) were 
obtained by partial EcoRV digestion of VSV-hPop1, fol-
lowed by religation to the filled-in SalI-site of pCI-neo. 
The later constructs contain a vector-encoded transla-
tional stop codon, thus encoding 8 additional amino 
acids at the C-terminus.
Digestion with SmaI of VSV-hPop1 releases a DNA 
fragment with a length of 2100 bp, which was ligated 
in filled-in XhoI/SmaI digested VSV-pCI-neo, resulting 
in a construct designated VSV-hPop1 ∆(1-318). VSV-
hPop1 ∆(129-1024) was obtained by cleavage of VSV-
hPop1 with EcoRI/SmaI and subsequent religation of 
the vector-containing fragment. Synthesis of the mutant 
encoded by this construct is terminated by a vector-
encoded translational stop codon, leading to 6 additional 
C-terminal amino acids.
A construct encoding hPop1 (128-319) was obtained 
by ligation of the EcoRI/SmaI DNA fragment of VSV-
hPop1 in EcoRI/SmaI digested pEGFP-C1 (Clontech). 
Ligation of the EcoRI/RsaI fragment of VSV-hPop1 in 
EcoRI/SmaI digested pEGFP-C1 results in a construct 
designated hPop1 (128-167). Digestion of VSV-hPop1 
with RsaI/SmaI and subsequent ligation of the result-
ing fragment in SmaI digested pEGFP-C1 generates the 
hPop1 (168-319) construct. The EcoRI/PstI digested frag-
ment of VSV-hPop1 was ligated in EcoRI/PstI digested 
pEGFP-C1 resulting in hPop1 (128-245).
The integrity of all DNA constructs described above 
was confirmed by DNA sequencing.
hPop4 deletion mutant constructs
Wildtype hPop4 cDNA was subcloned in pCI-neo con-
taining a DNA sequence coding for either an N-terminal 
or a C-terminal VSV-G tag as described (120); the result-
ing constructs were designated VSV-hPop4 and hPop4-
VSV, respectively.
A DNA fragment of hPop4/pCR-II-Topo obtained by 
digestion with DdeI/SmaI (120) was treated with Klenow 
polymerase to fill in the overhangs and was ligated in 
VSV-hPop4 digested with XhoI/SmaI and treated with 
Klenow polymerase, resulting in the VSV-hPop4 ∆(1-10) 
construct. Ligation of a Klenow polymerase treated DNA 
fragment resulting from digestion of hPop4/pCR-II-Topo 
with NcoI/XbaI in hPop4-VSV treated with Klenow poly-
merase after XhoI/XbaI digestion, generated a construct 
encoding hPop4-VSV ∆(1-47).
Two DNA fragments generated by XhoI/RsaI and 
RsaI/XbaI digestion of hPop4/PCR-II-Topo were ligated 
in XhoI/XbaI digested VSV-hPop4, resulting in the VSV-
hPop4 ∆(61-109) construct.
Three C-terminal deletion mutants were generated 
using PCR-based approaches. Besides the mutations 
introduced by PCR, a XbaI-site was introduced after 
the most 3’ codon, followed by an in-frame stop-codon 
and a SmaI-site in the oligonucleotides used. Using this 
strategy DNA fragments were produced and digested 
with XhoI/SmaI and ligated in XhoI/SmaI digested VSV-
hPop4, generating VSV-hPop4 ∆(162-220), ∆(181-220) 
and ∆(210-220), respectively.
The integrity of these constructs was confirmed by 
DNA sequencing.
Rpp38 deletion mutant constructs
Wildtype Rpp38 cDNA was subcloned in the pECFP-C3 
vector (Clontech) containing a DNA sequence encoding 
an N-terminal ECFP tag.
Constructs encoding deletion mutants of Rpp38 were 
generated by PCR-based approaches. Besides the dele-
tions introduced by the PCR strategy, an XhoI site was 
introduced in-frame at the 5’-end of the translational 
start codon, whereas an XbaI site was introduced at the 
3’-end of the coding sequence. Digestion with XhoI/XbaI 
of the PCR products and ligation in XhoI/XbaI digested 
pECFP-C3, generated the following constructs; Rpp38 
∆(1-40), ∆(1-98), ∆(1-141), ∆(181-283) and ∆(246-283).
The integrity of the constructs described above was 
confirmed by DNA sequencing.
Transient transfection of HEp-2 cells
HEp-2 monolayer cells were grown to 70% conflu-
ency by standard tissue culture techniques in either 
culture flasks or on coverslips. pCI-neo derived con-
structs (3-4 µg) were transfected in HEp-2 cells using 
LipofectAmine 2000 reagent (Gibco-BRL) according to 
the manufacturer’s instructions. pEGFP/pECFP derived 
constructs (10 µg) were transfected into 3x106 HEp-2 
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cells by electroporation in a total volume of 400 µl of Dul-
becco’s modified Eagle’s medium containing 10% fetal 
calf serum. Electroporation was performed at 276 V and 
a capacity of 950 mFa with a Gene Pulser II (BioRad).
Transfected cells were grown overnight in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal 
calf serum.
Cells grown on coverslips were washed twice with 
phosphate buffered saline (PBS), fixed with either metha-
nol (5 min at -20ºC) or with 4% paraformaldehyde 
(20 min at room temperature) and permeabilised using 
0.2% Triton-X-100 (5 min at room temperature).
Cells grown in flasks were harvested, washed once 
with PBS and used to prepare extracts for immunopre-
cipitation assays (see below).
Immunofluorescence
Indirect immunofluorescence assays were performed 
on transfected HEp-2 cells. Fixed cells were incubated 
with affinity-purified mouse anti-VSV tag antibodies 
(Roche, diluted 1:50 in PBS) for 1 h at room tempera-
ture, washed with PBS and subsequently incubated with 
rabbit-anti-mouse immunoglobulins coupled to FITC for 
1 h at room temperature. Cells were mounted with 
PBS/glycerol and bound antibodies were visualised by 
fluorescence microscopy.
Preparation of HEp-2 cell extracts
Extracts of HEp-2 cells were prepared by resuspen-
ding cell pellets in buffer A (25 mM Tris-HCl pH 7.5, 
100 mM KCl, 1 mM dithioerythritol, 2 mM EDTA, 
0.5 mM phenylmethylsulfonyl fluoride, 0.05% NP-40) 
and lysis by sonication using a Branson microtip (three 
times 20 s). Insoluble material was removed by centrifu-
gation (12,000 g, 15 min) and supernatants were used 
directly for immunoprecipitation.
Immunoprecipitation and pre-tRNA processing assay
Monoclonal anti-VSV-tag (Roche) or anti-EGFP anti-
bodies were coupled to protein A-agarose beads (Biozym) 
in IPP500 (500 mM NaCl, 10 mM Tris-HCl pH 8.0, 0.05% 
NP-40) by incubation for 1 h at room temperature. 
Beads were washed twice with IPP500 and once with 
IPP150 (150 mM NaCl, 10 mM Tris-HCl pH 8.0, 0.05% 
NP-40). For each immunoprecipitation the cell extract 
was incubated with the antibody-coupled beads for 2 h 
at 4°C. Subsequently, beads were washed three times 
with IPP150.
To analyse co-precipitating RNAs, the RNA was 
isolated from the beads by phenol-chloroform extrac-
tion and ethanol precipitation. RNAs were resolved 
on a denaturing polyacrylamide gel and blotted to a 
Hybond-N membrane (Amersham). Northern blot hybri-
disations with riboprobes specific for human RNase P 
and RNase MRP RNAs were performed as previously 
described (116).
To assay for RNase P enzymatic activity in the immu-
noprecipitates (i.e. the beads), an internally 32P-labeled 
pre-tRNA substrate (S. pombe tRNASer SupS1 (117)) was 
transcribed in vitro and gel-purified. This 110 nt-long 
substrate contains a 5’-extension of 28 nts in comparison 
with the mature tRNA. The immunoprecipitates were 
incubated with substrate RNA in assay buffer (20 mM 
Tris-HCl pH 8.0, 10 mM MgCl2, 1 mM DTE, 50 mM KCl, 
50 µg/ml BSA, 60 U/ml RNasin) for 10 min at 37ºC. The 
products were analysed by denaturing polyacrylamide 
gel electrophoresis and autoradiography.
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Introduction
Eukaryotic cells contain a large number 
of small nucleolar RNAs (snoRNAs) which, in 
the form of small nucleolar ribonucleoprotein 
complexes (snoRNPs), are involved in the 
various steps of ribosome synthesis. Several 
snoRNPs have been shown to be required 
for pre-rRNA processing, and a large set 
Abstract
The eukaryotic nucleolus contains a large number of small RNA molecules which, in the form of small nucleolar ribonucleoprotein complexes (snoRNPs), are involved in the processing and modifica-
tion of pre-rRNA. One of the snoRNPs which has been shown to possess 
enzymatic activity is the RNase MRP. RNase MRP is an endoribonuclease 
involved in the processing of the 5’ end of 5.8S rRNA.
In this study the association of the hPop1 protein with the RNase MRP com-
plex was investigated. The hPop1 protein seems not to be directly bound to 
the RNA component, but requires nucleotides 1-86 and 116-176 of the MRP 
RNA to associate with the RNase MRP complex via protein-protein interac-
tions. UV crosslinking followed by ribonuclease treatment and immunopre-
cipitation with anti-Th/To antibodies revealed that in addition to hPop1, 
three human proteins of about 20, 25 and 40 kDa can associate with the 
RNase MRP complex. The 20 and 25 kDa proteins appear to bind to stem-
loop I of the MRP RNA while the 40 kDa protein requires the central part 
of the MRP RNA (nt 86-176) for association with the RNase MRP complex. 
In addition, we show that the human RNase P proteins Rpp30 and Rpp38 
are also associated with the RNase MRP complex. Expression of VSV-tagged 
versions of these proteins in HeLa cells followed by anti-VSV immunopre-
cipitation resulted in co-precipitation of both RNase P and RNase MRP 
complexes. Furthermore, UV-crosslinking followed by anti-Th/To and anti-
Rpp38 immunoprecipitation revealed that the 40 kDa protein we detected 
in UV crosslinking is probably identical to Rpp38.
of snoRNPs is involved in ribose methy-
lation and pseudouridinylation of rRNA 
(reviewed in ref. (5,12,93,131)). Although 
many snoRNPs might be part of catalytic 
complexes involved in the cleavage and modi-
fication reactions, sofar only one snoRNP has 
been shown to possess enzymatic activity on 
a pre-rRNA substrate in vitro: RNase MRP 
(30).
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RNase MRP was originally identified as 
an endoribonuclease able to cleave in vitro 
an RNA substrate derived from the mitochon-
drial origin of DNA replication (22,26). The 
vast majority of RNase MRP is, however, loca-
lized in the nucleolus (42,44,72,99), where it is 
involved in the processing of the 5’ end of 5.8S 
rRNA (reviewed in ref. (94,132)). RNase MRP 
cleaves the yeast pre-rRNA at site A3 within 
ITS1 in vivo (28,29,37) and in vitro (30), giving 
rise to the 5.8S(S) rRNA. RNase MRP is related 
to the RNase P endoribonuclease since both 
RNPs contain several identical protein sub-
units (see below) and their RNA subunits, 
referred to as MRP (or Th) and P (or H1) RNA, 
respectively, have common structural features 
(76,103). Although the nucleotide sequences 
of the RNase MRP RNA and the RNase P RNA 
are not highly homologous, they can be folded 
into very similar cage-shaped secondary struc-
tures (29,69). RNase P cleaves precursor tRNA 
molecules to remove the 5’ leader sequence 
and to generate the correct 5’ end of mature 
tRNA (reviewed in ref. (100,101,133)). Recently, 
RNase P has also been implicated in the pro-
cessing of the ITS2 region of pre-rRNA; its 
exact role in pre-rRNA processing is, however, 
unclear (5,101). Human RNase P RNA was 
shown to be localized in the nucleoplasm of 
cells, but in addition transiently localizes to the 
nucleolus (58). Recently, yeast RNase P RNA as 
well as early pre-tRNA processing events were 
localized primarily to the nucleolus (60). These 
findings suggest that, in contrast to what gene-
rally has been assumed, both RNase MRP and 
RNase P may primarily function in the nucleo-
lus of cells.
Several protein subunits of the Saccha-
romyces cerevisiae RNase MRP complex have 
been characterized: Pop1p, Pop3p, Pop4p, 
Pop5p, Pop6p, Pop7p/Rpp2p, Pop8p and Rpp1p 
(33-38). These proteins are not only compo-
nents of the RNase MRP particle but are 
also associated with the RNase P ribonucleo-
protein complex. In addition, one RNase MRP 
specific protein has been identified in S. cere-
visiae: Snm1p (32). One human RNase MRP 
and RNase P associated protein, i.e. hPop1, 
has been characterized (77). hPop1, which was 
identified via its homology to the yeast Pop1p 
protein, is a 115 kDa autoantigenic protein 
that is predominantly localized in the nucleo-
lus. Recently, four human RNase P associated 
proteins were characterized: Rpp20, Rpp30, 
Rpp38 and Rpp40 (78,80). It is likely that (some 
of) these proteins, as in yeast, are associated 
with the human RNase MRP complex as well.
Sera from patients suffering from systemic 
autoimmune diseases, such as scleroderma and 
systemic lupus erythematosus (SLE), often con-
tain autoantibodies directed to a variety of 
cytoplasmic, nuclear and nucleolar proteins. A 
group of patient sera, referred to as anti-
Th/To, contain antibodies directed to the 
RNase MRP and RNase P ribonucleoprotein 
complexes. Antibodies in these sera were 
shown to immunoprecipitate the RNase MRP 
and RNase P RNPs from a HeLa cell extract 
(61,62,64,65,104). The RNA components of 
these complexes were not precipitated by these 
antibodies (65), indicating that anti-Th/To anti-
bodies recognize at least one common or anti-
genically related protein that is associated with 
both the RNase MRP and RNase P ribonucleo-
protein complexes.
Anti-Th/To sera immunoprecipitate a 
number of proteins ranging in molecular mass 
from 18 to 120 kDa from a HeLa cell extract, 
the most commonly observed one being a pro-
tein of 40 kDa, mostly referred to as the Th40 
antigen (68,72,75,134-136). It has been sug-
gested that the RNase P associated Rpp38 pro-
tein, which is recognized by at least some 
anti-Th/To sera (80), might be identical to the 
Th40 autoantigen. In addition to Th40, also 
hPop1 is a frequent target of anti-Th/To serum 
antibodies (77).
In this study we investigated the associa-
tion of the hPop1 protein with the RNase MRP 
complex. Via in vitro reconstitution and immu-
noprecipitation it was shown that the hPop1 
protein requires nucleotides 1-86 and 116-176 
of MRP RNA to associate with the MRP com-
plex. UV-crosslinking followed by immunopre-
cipitation with anti-Th/To antibodies identified 
three proteins of about 20, 25 and 40 kDa 
which are able to bind to the RNase MRP RNA. 
Furthermore, we show that the human RNase P 
proteins Rpp30 and Rpp38 are also associated 
with the RNase MRP complex. The 40 kDa pro-
tein observed by UV-crosslinking is probably 
identical to Rpp38. The binding sites of the 
crosslinked proteins on the RNase MRP RNA 
were studied and a model in which the hPop1 
protein is bound indirectly via these MRP pro-
teins to the RNase MRP complex is proposed.
Results
MRP RNA domains required for associa-
tion of hPop1 to the RNase MRP complex
To investigate the association of the hPop1 
protein with the RNase MRP complex we incu-
bated in vitro transcribed 32P-labeled MRP 
RNA with HeLa cell extract and analyzed 
reconstituted complexes by immunoprecipita-
tion using anti-hPop1 antibodies. As shown 
in Figure 1 (lane 1), rabbit antibodies raised 
against bacterially expressed hPop1 protein 
(77) were able to immunoprecipitate reconsti-
tuted MRP RNA-protein complexes. In con-
trast, reconstituted U1 and U3 RNP complexes 
were not immunoprecipitated by anti-hPop1 
antibodies, and control antibodies (rabbit 
anti-Ro52; Figure 1, lane 2) were not able to 
precipitate the MRP RNA. No MRP RNA was 
precipitated by anti-hPop1 antibodies when 
HeLa cell extract was omitted from the incu-
bation (data not shown), confirming that the 
precipitation of the MRP RNA is due to asso-
ciation of hPop1 and possibly other MRP pro-
teins with the in vitro transcribed MRP RNA. 
In addition, a patient serum containing anti-
Th/To antibodies was also able to specifically 
immunoprecipitate the reconstituted MRP com-
plex (Figure 1, lane 3). These results show that 
an in vitro reconstituted MRP complex can be 
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Figure 1. In vitro reconstitution of MRP RNA complexes. 
32P-labeled MRP, U3 and U1 RNAs were incubated in HeLa cell 
extract and reconstituted complexes were immunoprecipitated 
with rabbit anti-hPop1 antibodies (lane 1), rabbit anti-Ro52 
antibodies (lane 2) and human anti-Th/To serum antibodies 
(lane 3). RNAs were extracted from immunoprecipitates, 
immune supernatants and the input RNA mixture, resolved 
by denaturing polyacrylamide gel electrophoresis and visual-
ized by autoradiography. Lanes 1-3, RNA isolated from the 
immunoprecipitates; lane 4, RNA isolated from 2% of the input 
RNA mixture; lane 5, RNA isolated from 10% of the immune 
supernatant of the anti-hPop1 immunoprecipitation.
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immunoprecipitated by anti-hPop1 and anti-
Th/To antibodies.
To study the domain(s) of MRP RNA 
required for association of the hPop1 protein 
with the RNase MRP complex, we incubated in 
vitro transcribed 32P-labeled MRP RNA dele-
tion mutants with HeLa cell extract and immu-
noprecipitated reconstituted complexes with 
anti-hPop1 antibodies. The results of these 
experiments are shown in Figures 2A-D, and 
are summarized in Figure 2E. Deletion of the 
3’ terminal 70 or 91 nucleotides of MRP RNA 
(MRP1-197 (Figure 2A) and MRP1-176 (Figure 2B), 
respectively) has a minor effect on the associa-
tion of the hPop1 protein with the MRP com-
plex, since these mutant MRP RNAs were still, 
although somewhat less efficiently than full-
length MRP RNA, precipitated by anti-hPop1 
antibodies (Figure 2A-B, lane 2). Further dele-
tion of the 3’ end of MRP RNA to nucleotide 
117, resulting in mutant MRP1-117, resulted 
in loss of precipitation by anti-hPop1 anti-
bodies, indicating that the hPop1 protein is 
unable to associate with the MRP1-117 RNA 
(Figure 2A, lane 2). In addition, MRP RNA 
deletion mutants in which 5’ terminal nucleo-
tides are deleted, e.g. MRP67-267 (Figure 2C, 
lane 2) or MRP86-267 and MRP127-267 (data not 
shown), were not immunoprecipitated by anti-
hPop1 antibodies after incubation with HeLa 
cell extract. These results suggest that the 
hPop1 protein needs nucleotides 1 to 176 
of MRP RNA for association with the MRP 
complex. To define this region in more 
detail we constructed deletion mutants in 
which stemloops II and/or III of MRP RNA 
(Figure 3) are deleted: MRP∆87-115, MRP∆87-99 
and MRP∆100-115, respectively. After recon-
stitution in HeLa cell extract, these internal 
deletion mutants were all three efficiently pre-
cipitated by anti-hPop1 antibodies (Figure 2D, 
lanes 3, 5 and 7).
Reconstituted mutant MRP RNA complexes 
were also immunoprecipitated using an anti-
Th/To patient serum containing anti-hPop1 
antibodies. The precipitation results obtained 
with the serum were similar to the results 
obtained using rabbit anti-hPop1 antibodies; 
full-length MRP, MRP1-197, MRP1-176 and MRP 
RNA lacking stemloop II and/or III were 
efficiently precipitated (Figure 2A-B, lanes 4 
and data not shown). In addition MRP1-117, 
MRP1-82, MRP67-267 and MRP67-197, which 
could not be precipitated by anti-hPop1 anti-
bodies, were weakly precipitated by the anti-
Th/To serum (Figure 2A, lane 4 and Figure 2C, 
lane 4, respectively), suggesting that this serum 
in addition to anti-hPop1 antibodies contains 
antibodies directed to other MRP protein(s) 
which are able to associate with these mutant 
MRP RNAs.
Taken together, these results indicate that 
the hPop1 protein requires nucleotides 1-86 
and 116-176 of MRP RNA to associate with the 
2%
 in
pu
t
an
ti-
hP
op
1
an
ti-
R
o5
2
an
ti-
T
h/
T o
10
%
 s
up
2%
 in
pu
t
an
ti-
hP
op
1
an
ti-
R
o5
2
an
ti-
T
h/
T o
10
%
 s
up
2%
 in
pu
t
an
ti-
hP
op
1
an
ti-
R
o5
2
an
ti-
T
h/
T o
10
%
 s
up
MRP-
MRP -1-197
U1-
MRP -1-117
MRP -1-82
MRP-
MRP -67-267
MRP -67-197
MRP -67-167
MRP -67-117
MRP-
MRP -1-176
U1
an
ti-
hP
op
1
an
ti-
hP
op
1
an
ti-
hP
op
1
an
ti-
hP
op
1
an
ti-
R
o5
2
an
ti-
R
o5
2
an
ti-
R
o5
2
an
ti-
R
o5
2
MRP MRP
87-115
MRP
87-99
MRP
100-115
M
R
P
M
R
P 
87
-1
15
M
R
P 
87
-9
9
M
R
P 
10
0-
11
5
2% input
A B C
D
1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
1 2 3 4 5 6 7 8 9 10 11 12
Figure 2. MRP domains required for hPop1 association. 32P-labeled MRP RNAs, full-length as well as deletion mutants, were 
incubated in HeLa cell extract and reconstituted complexes were immunoprecipitated with rabbit anti-hPop1 antibodies, rabbit 
anti-Ro52 antibodies and anti-Th/To serum antibodies. RNAs were extracted from immunoprecipitates, immune supernatants 
and the input RNA mixture, resolved by denaturing polyacrylamide gel electrophoresis and visualized by autoradiography. 
A. Reconstitution using 32P-labeled MRP, MRP
1-197
, MRP
1-117
, MRP
1-82
 and U1 RNAs. Lane 1: RNA isolated from 2% of the input RNA 
mixture; lane 2: RNA isolated from the anti-hPop1 immunoprecipitate; lane 3: RNA isolated from the anti-Ro52 immunoprecipitate; 
lane 4: RNA isolated from the anti-Th/To serum immunoprecipitate; lane 5: RNA isolated from 10% of the immune supernatant 
of the anti-hPop1 immunoprecipitation. B. Reconstitution using 32P-labeled MRP, MRP
1-176
 and U1 RNAs. C. Reconstitution using 
32P-labeled MRP, MRP
67-267
, MRP
67-197
, MRP
67-167
 and MRP
67-117
 RNAs. D. Reconstitution using 32P-labeled MRP, MRP∆87-115, MRPD87-99 
and MRP∆100-115 RNAs. Lanes 1, 3, 5, 7: RNA isolated from the anti-hPop1 immunoprecipitates; lanes 2, 4, 6, 8: RNA isolated from 
the anti-Ro52 immunoprecipitates; lanes 9-12: RNA isolated from 2% of the input RNA mixture. E → top of next page.  Schematic 
representation of the MRP RNA deletion mutants and a summary of their ability to be immunoprecipitated by anti-hPop1 antibo-
dies after incubation in HeLa cell extract. Nucleotide numbers are indicated, and the domains of MRP required for association of 
hPop1 are shaded in dark blue.
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RNase MRP complex (Figure 2E). These parts 
of the MRP RNA include the predicted stem-
loop structures I and IV, but lack stemloops 
II and III. Furthermore, the predicted pseudo-
knot structure which involves the 5’ and 3’ 
regions of MRP RNA is not required for bin-
ding of hPop1 to the MRP complex since 3’ 
deletion mutants of MRP RNA lacking the abi-
lity to form this structure could be immuno-
precipitated by anti-hPop1 antibodies.
Identification of MRP RNA binding pro-
teins by UV crosslinking
To investigate if the hPop1 protein is asso-
ciated directly or indirectly with the MRP 
RNA, we performed reconstitution experiments 
with in vitro translated 35S-labeled hPop1 pro-
tein and in vitro transcribed biotinylated MRP 
RNA, followed by precipitation using strepta-
vidin agarose beads. The results of these expe-
riments strongly suggested that hPop1 is unable 
to bind to the MRP RNA directly, since no 
hPop1 protein could be detected in the pre-
cipitate (data not shown). In addition, we were 
unable to detect a mobility shift of MRP RNA 
after incubation of 32P-labeled MRP RNA with 
purified bacterially expressed hPop1 protein 
and analysis by native gel electrophoresis (data 
not shown). Next, the binding of hPop1 to the 
RNase MRP complex was studied using UV-
crosslinking. 32P-labeled MRP RNA and control 
RNAs (U3 and U1 RNA) were incubated with 
HeLa cell extract, UV irradiated and RNase A 
treated. The ribonuclease treatment is essen-
tial because it removes most of the labeled 
RNA resulting in a complex of protein cross-
linked to a short labeled oligonucleotide that 
can be immunoprecipitated by antibodies and 
analyzed by SDS-PAGE.
As shown in Figure 4A (lane 5), rabbit anti-
hPop1 antibodies were unable to precipitate a 
32P-labeled protein, suggesting that the hPop1 
protein was not in close contact with the MRP 
RNA during UV-crosslinking and thus proba-
bly not directly bound to the MRP RNA. Also 
anti-Th/To patient sera containing anti-hPop1 
antibodies were unable to immunoprecipitate 
a 32P-labeled protein of approximately 115 
kDa, i.e. hPop1 (Figure 4A, lanes 3-4). How-
ever, these sera were able to immunoprecipitate 
32P-labeled polypeptides of approximately 20, 
25 and 40 kDa, hereafter referred to as MRP20, 
MRP25 and MRP40, respectively (Figure 4A, 
lanes 3-4). These three proteins were precipi-
tated by several anti-Th/To sera, although the 
efficiency of precipitation varied depending on 
the patient serum used. The specificity of UV 
crosslinking and precipitation was confirmed 
by the observation that MRP20, MRP25 and 
MRP40 were only detected if MRP RNA was 
used for UV-crosslinking. UV-crosslinking of 
control RNAs such as U3 and U1 RNA fol-
lowed by anti-Th/To immunoprecipitation did 
not result in the detection of radiolabeled poly-
peptides (Figure 4A, lanes 9-10 and 15-16). In 
addition normal human serum did not precipi-
tate the MRP20, MRP25 and MRP40 proteins 
(Figure 4A, lane 2). As shown in Figure 4A 
(lane 6), not only MRP20, MRP25 and MRP40 
were UV-crosslinked to MRP RNA, a large 
number of 32P-labeled proteins was detectable 
after UV-crosslinking of MRP RNA and RNase A 
treatment followed by SDS-PAGE. However, 
the use of U3 and U1 RNAs also resulted in 
a large number of 32P-labeled proteins after 
UV-crosslinking (Figure 4A, lanes 12 and 18), 
which makes it rather difficult to distinguish 
between MRP specific and non-specific pro-
teins and thus stresses the need for immuno-
precipitation after UV-crosslinking.
The specificity of the MRP20, MRP25 and 
MRP40 crosslinking was further established by 
competition experiments in which an excess of 
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Figure 3. Human RNase MRP RNA. Secondary structure 
model of human MRP RNA adapted from Schmitt et al. 
(1993). Stemloop structures mentioned in the text are num-
bered (I-IV) and the proposed long range interaction (‘pseu-
doknot’) responsible for the ‘cage’ structure of MRP RNA is 
indicated (LRI-I).
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Figure 4. UV crosslinking analysis of MRP RNA. A. 32P-labeled MRP RNA (lanes 1-6), U3 RNA 
(lanes 7-12) and U1 RNA (lanes 13-18) were incubated in HeLa cell extract and exposed to 
UV light to achieve crosslinking of RNA-protein complexes. Crosslinked complexes were treated 
with RNase A and subsequently immunoprecipitated by rabbit anti-hPop1 antibodies (lanes 5, 11 
and 17), normal rabbit serum (lanes 1,7 and 13), anti-Th/To serum antibodies (lanes 3-4, 9-10 and 
15-16) and normal human serum (lanes 2, 8 and 14). Precipitated proteins were analyzed by 13% 
SDS polyacrylamide gel electrophoresis and visualized by autoradiography. Lanes 6, 12 and 18 
represent 3% of the crosslinked proteins used for immunoprecipitation. The MRP20, MRP25 and 
MRP40 proteins are indicated by arrows. Protein molecular weight markers are shown at the left. 
B. 32P-labeled MRP RNA and nonradioactive competitor RNA (10-fold excess) were incubated 
in HeLa cell extract and exposed to UV light to achieve crosslinking of RNA-protein complexes. 
Crosslinked complexes were treated with RNase A and subsequently immunoprecipitated by 
anti-Th/To serum antibodies. Precipitated proteins were analyzed by 13% SDS polyacrylamide 
gel electrophoresis and visualized by autoradiography. Lane 1: no competitor RNA present; lane 
2: cold MRP RNA as competitor ; lane 3: cold U1 RNA as competitor ; lane 4: cold U3 RNA as 
competitor.
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nonradioactive competitor MRP, U3 or U1 RNA 
was co-incubated with 32P-labeled MRP RNA 
in HeLa cell extract. Following UV-crosslinking 
and anti-Th/To serum immunoprecipitation, 
only competitor MRP RNA was able to compete 
for the crosslinking of the MRP20, MRP25 and 
MRP40 proteins (Figure 4B, lane 2). Incubation 
with competitor U1 or U3 RNA had no influ-
ence on the crosslinking of these proteins to 
the MRP RNA.
The MRP25 protein was reproducibly the 
most strongly labeled protein after UV-cross-
linking and anti-Th/To immunoprecipitation. 
However, methylene-blue mediated photo-
crosslinking (137) decreased the MRP25 signal 
and increased the MRP20 signal, thus rever-
sing the intensity of the protein bands (data 
not shown). Also, the use of [α-32P]CTP instead 
of [α-32P]UTP for the in vitro transcription of 
labeled RNAs had some influence on the rela-
tive intensities of the observed protein bands 
after crosslinking. MRP40 was more efficiently 
labeled when [α-32P]CTP was used (data not 
shown), possibly due to the presence of more C 
residues at the MRP40 crosslinking site.
Taken together our results suggest that the 
hPop1 protein is unable to bind directly to the 
MRP RNA, but associates with the complex via 
other MRP associated proteins. In addition, the 
UV-crosslinking data indicate that at least three 
proteins, MRP20, MRP25 and MRP40, are able 
to bind directly to the MRP RNA.
Identification of crosslinked MRP proteins
Recently, two human RNase P RNA asso-
ciated proteins which are recognized by 
anti-Th/To serum antibodies, have been cha-
racterized: Rpp30 and Rpp38 (78,80). It is likely 
that, similar to the situation in yeast where 
most of the RNase P associated proteins are 
also associated with the RNase MRP complex 
(38), Rpp30 and Rpp38 are also components 
of the human RNase MRP complex. Therefore, 
the MRP20, MRP25 and/or MRP40 proteins 
identified by UV-crosslinking followed by anti-
Th/To immunoprecipitation might correspond 
to the Rpp30 and/or Rpp38 proteins.
Since it had not been fully established 
whether Rpp30 and Rpp38 are associated with 
both the human RNase P and RNase MRP 
complexes, we performed immunoprecipitation 
experiments with VSV-G (Vesicular Stomatitis 
Virus; (106)) tagged Rpp30 and Rpp38 pro-
teins. Rpp30 and Rpp38 cDNAs (78) were sub-
cloned in the mammalian expression vector 
pCI-neo containing a VSV-G tag sequence fol-
lowed by a stop codon in the multiple cloning 
site (see Material and Methods). The resulting 
VSV tagged Rpp30 and Rpp38 encoding cDNAs 
(Rpp30-VSV and Rpp38-VSV, respectively) 
were transfected into HeLa cells. Two days after 
transfection, cells were lysed and the resulting 
total cell extracts were used for immunopre-
cipitation with anti-VSV and anti-fibrillarin 
monoclonal antibodies, and anti-Th/To serum 
antibodies. As a control the pCI-neo vector 
without insert (pCI-neo) was also used for 
transfection and the resulting cell extracts for 
immunoprecipitation experiments. RNAs were 
extracted from both immunoprecipitates and 
total cell extracts, fractionated by gel electro-
phoresis and analyzed by northern blot hybri-
dization with probes specific for RNase P RNA, 
RNase MRP RNA, U3 RNA and U1 RNA.
As shown in Figure 5, RNase P RNA as well 
as RNase MRP RNA were co-precipitated by 
anti-VSV antibodies from cell extracts contai-
ning VSV-tagged Rpp30 (Rpp30-VSV (lane 3)) 
or VSV-tagged Rpp38 (Rpp38-VSV (lane 7)) pro-
tein, showing that Rpp30 and Rpp38 are indeed 
associated with both the human RNase MRP 
and RNase P complexes. The specificity of 
this result was established by the lack of 
RNase MRP and RNase P RNA co-precipitation 
with (i) anti-VSV antibodies from a control cell 
extract (pCI-neo) (Figure 5, lane 11) and (ii) 
anti-fibrillarin antibodies (Figure 5, lanes 4, 8 
and 12). RNase P and MRP RNAs were immuno-
precipitated from all extracts using anti-Th/To 
serum antibodies (Figure 5, lanes 2, 6 and 10). 
No U3 or U1 RNA could be detected in the 
anti-VSV and anti-Th/To serum immunopre-
cipitates.
To investigate whether some of the cross-
linked MRP proteins are identical to the 
Rpp30 or Rpp38 proteins, UV-crosslinked com-
plexes reconstituted with 32P-labeled MRP 
RNA as described above were immunopre-
cipitated (after RNase A treatment) with 
rabbit anti-Rpp30 and rabbit anti-Rpp38 anti-
bodies (80). As shown in Figure 6 (lane 3), anti-
Rpp38 specific antibodies immunoprecipitated 
a 32P-labeled polypeptide with an electropho-
retic mobility indistinguishable from that of 
MRP40 (Figure 6, lane 1). This strongly sug-
gests that MRP40 is identical to the Rpp38 
protein. In contrast anti-Rpp30 antibodies did 
not detectably immunoprecipitate a 32P-labeled 
protein, suggesting that Rpp30 is not identical 
to any of the crosslinked MRP proteins.
Taken together, these results show that 
both Rpp30 and Rpp38 are associated with the 
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Figure 5. Rpp30 and Rpp38 are RNase P and RNase MRP 
complex associated proteins. Rpp30-VSV, Rpp38-VSV and 
pCI-neo were transiently expressed in HeLa cells. Two days 
after transfection, cells were lysed and used for immunopreci-
pitation with anti-VSV, anti-fibrillarin and anti-Th/To serum anti-
bodies. RNAs were extracted from immunoprecipitates (lanes 
2-4, 6-8 and 10-12) and total cell extracts (lanes 1, 5 and 9), 
resolved by denaturing polyacrylamide gel electrophoresis and 
transferred to a northern blot. Specific antisense RNA probes 
were used to detect human RNase P, RNase MRP, U3 and 
U1 RNAs, as indicated on the right. Lanes 1-4: cells expressing 
Rpp30-VSV; lanes 5-8: cells expressing Rpp38-VSV; lanes 9-12: 
control cells transfected with pCI-neo vector. Lanes 2, 6 and 
10: anti-Th/To serum immunoprecipitation; lanes 3, 7 and 11: 
anti-VSV immunoprecipitation; lanes 4, 8 and 12: anti-fibrillarin 
immunoprecipitation; lanes 1, 5 and 9: RNA isolated from 10% 
of total cell extract used for immunoprecipitations.
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Figure 6. Identification of crosslinked MRP proteins as Rpp30/
Rpp38. 32P-labeled MRP RNA was incubated in HeLa cell 
extract and exposed to UV light to achieve crosslinking of 
RNA-protein complexes. Crosslinked complexes were treated 
with RNase A and subsequently immunoprecipitated by anti-
Th/To serum antibodies (lane 1), rabbit anti-Rpp30 antibodies 
(lane 2), rabbit anti-Rpp38 antibodies (lane 3), normal human 
serum (lane 4) and rabbit pre-immune serum (pre-Rpp30 
(lane 5) and pre-Rpp38 (lane 6)). Precipitated proteins were 
analyzed by 13% SDS polyacrylamide gel electrophoresis and 
visualized by autoradiography.
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human RNase P as well as the human RNase 
MRP complexes. In contrast to Rpp30, Rpp38 
appears to be in close contact with MRP RNA 
in the complex. These results are in agreement 
with the observation that in vitro translated 
Rpp38 protein but not in vitro translated 
Rpp30 protein can be specifically precipitated 
by streptavidin beads after incubation with 
biotinylated MRP RNA (data not shown). Fur-
thermore, the MRP40 protein we detected via 
UV-crosslinking and anti-Th/To immunopre-
cipitation is probably identical to the Rpp38 
protein.
MRP20, MRP25 and MRP40 bind to dif-
ferent domains of the MRP RNA
To study the regions of MRP RNA which 
are required for binding of the MRP20, MRP25 
and MRP40 proteins to the RNase MRP com-
plex, we performed UV-crosslinking experi-
ments with MRP RNA deletion mutants. After 
incubation of in vitro transcribed 32P-labeled 
MRP RNA deletion mutants in a HeLa cell 
extract, UV irradiation and RNase A treat-
ment, proteins were immunoprecipitated with 
anti-Th/To patient serum and analyzed by 
SDS-PAGE followed by autoradiography. The 
results of these UV crosslinking experiments 
are shown in Figures 7A-B. Deletion of the 5’ 
terminal 66 nucleotides, thus removing the 
first stemloop structure of MRP RNA, abo-
lished the binding of MRP20 and MRP25, 
while MRP40 was still able to bind to this 
MRP RNA fragment (MRP67-267) (Figure 7A, 
lane 3). Strikingly, when MRP67-267 was used, 
MRP40 appeared to be much more efficiently 
crosslinked than when full-length MRP RNA 
was used. Further deletion of the 5’ end up to 
nucleotide 86 (MRP86-267) gave similar results 
(Figure 7A, lane 8). However, a deletion up 
to nucleotide 127 (MRP127-267) resulted in loss 
of MRP40 crosslinking (Figure 7A, lane 12). 
3’ end deletions of MRP86-267, resulting in 
mutants MRP86-176 and MRP86-167 (Figure 7A, 
lanes 10 and 11, respectively), showed that 
MRP40 requires nucleotides 86 to 176 in order 
to be efficiently crosslinked to the MRP RNA. 
In addition, MRP40 might have a weak affin-
ity for other parts of the MRP RNA since 
MRP1-82 and MRP67-117 produced a weak signal 
of MRP40 after UV-crosslinking (Figure 7A, 
lanes 2 and 6). Similar results were obtained 
when the crosslinked complexes were precipi-
tated with anti-Rpp38 antibodies, again sug-
gesting that MRP40 is identical to Rpp38 (data 
not shown).
Deletion of the 5’ end of MRP RNA to 
nucleotide 67 (MRP67-267) abolished the bind-
ing of MRP20 and MRP25 (Figure 7A, lane 3). 
However, deletion of most of the 3’ end of 
MRP RNA, resulting in MRP1-82, did not have 
any effect on MRP20 and MRP25 crosslinking 
(Figure 7A, lane 2). In addition, MRP20 and 
MRP25 were still efficiently crosslinked to an 
MRP RNA deletion mutant containing only the 
first stemloop structure, MRP22-67 (Figure 7A, 
lane 13). These results indicate that both the 
MRP20 and MRP25 proteins bind to the same 
domain of MRP RNA, that is stemloop I.
Discussion
Association of hPop1 with the RNase 
MRP complex
Via incubation of 32P-labeled MRP RNA, 
full-length as well as deletion mutants, in 
a HeLa cell extract followed by immuno-
precipitation with anti-hPop1 antibodies, the 
hPop1 protein was shown to be dependent 
on nucleotides 1-86 and 116-176 for binding 
to the RNase MRP complex. However, hPop1 
appeared not to bind directly to the MRP 
RNA since a stable interaction between in vitro 
translated or recombinant hPop1 protein and 
in vitro transcribed MRP RNA could not be 
detected, and UV-crosslinking of 32P-labeled 
MRP RNA in a HeLa cell extract, followed by 
RNase A treatment and immunoprecipitation 
with anti-hPop1 antibodies did not result in 
detection of a crosslinked 115 kDa protein. 
These observations indicate that the hPop1 
protein most likely associates with the MRP 
complex via protein-protein interactions and 
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Figure 7. Domains of MRP RNA required for binding of MRP20, MRP25 and MRP40. A. 32P-labeled MRP RNA, full-length (lane 1) 
and deletion mutants (lanes 2-13), U1 RNA (lane 14) and U3 RNA (lane 15) were incubated in HeLa cell extract and exposed to 
UV light to achieve crosslinking of RNA-protein complexes. Crosslinked complexes were treated with RNase A and subsequently 
immunoprecipitated by anti-Th/To serum antibodies. Precipitated proteins were analyzed by 13% SDS polyacrylamide gel electro-
phoresis and visualized by autoradiography. Protein molecular weight markers are shown at the left. B. Schematic representation 
of the MRP RNA deletion mutants and a summary of the ability of the MRP20, MRP25 and MRP40 proteins to be crosslinked 
to these RNAs (indicated on the right). Nucleotide numbers are indicated, and the domains of MRP required for association of 
MRP20, MRP25 and MRP40 are shaded in dark blue.
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the RNase MRP associated protein(s) necessary 
for hPop1 association require nucleotides 1-86 
and 116-176 of the MRP RNA for efficient com-
plex formation.
Three proteins of 20, 25 and 40 kDa can 
be crosslinked to the MRP RNA
UV-crosslinking experiments led to the 
identification of three proteins of about 20, 25 
and 40 kDa, respectively, which can directly 
bind to the MRP RNA. Thus, in addition to 
hPop1, at least three other proteins, MRP20, 
MRP25 and MRP40, are presumably associated 
with the human RNase MRP complex. These 
results are in agreement with previous data, 
showing that proteins with similar molecular 
weights can be immunoprecipitated by anti-
Th/To serum antibodies and thus were thought 
to be associated with the RNase MRP complex 
(68,136). Yuan et al. identified a protein of 
about 40 kDa by UV-crosslinking using RNase 
MRP RNA which was immunoprecipitable by 
anti-Th/To serum antibodies (75). However, in 
contrast to our results, the 20 and 25 kDa pro-
teins were not detected in the latter study. 
This difference might be due to variations in 
the crosslinking conditions, HeLa cell extract 
preparation or MRP RNA transcripts used. 
For example, the use of [α-32P]CTP instead of 
[α-32P]UTP for in vitro transcription did have 
a positive effect on the MRP40 signal in UV-
crosslinking, possibly due to the presence of 
more C residues at the MRP40 crosslinking 
site.
Rpp30 and Rpp38 are associated with 
the human RNase MRP complex
Recently, four human RNase P associated 
proteins have been characterized: Rpp20, 
Rpp30, Rpp38 and Rpp40 (78,80). Two of these 
human RNase P protein subunits, Rpp30 and 
Rpp38, were shown to be recognized by anti-
Th/To serum antibodies and may, as has been 
found in the yeast system (38), be part of the 
human RNase MRP complex as well (78,80). 
Expression of VSV-tagged Rpp30 and Rpp38 
proteins in HeLa cells followed by anti-VSV 
immunoprecipitation and northern blot ana-
lysis of co-precipitating RNAs showed that 
Rpp30 and Rpp38 are indeed associated with 
both the human RNase MRP and RNase P com-
plexes. UV-crosslinking of 32P-labeled MRP 
RNA in a HeLa cell extract followed by immu-
noprecipitation with anti-Rpp30, anti-Rpp38 
and anti-Th/To antibodies indicated that the 
MRP40 protein, observed after UV-crosslink-
ing, most probably is identical to the Rpp38 
protein. Although anti-Th/To and anti-Rpp38 
antibodies immunoprecipitated a crosslinked 
protein of the same molecular mass using both 
wild-type and deletion mutants of MRP RNA, 
we cannot exclude the unlikely possibility that 
MRP40 and Rpp38 are different proteins with 
similar molecular masses which both can bind 
directly to the same region of the MRP RNA 
and are recognized by different antibody popu-
lations in the anti-Th/To serum. Rpp30 appears 
not to be identical to any of the crosslinked 
MRP proteins since this protein seems unable to 
associate directly with the MRP RNA. Sequence 
analysis of the crosslinked MRP proteins will 
give definitive information about their precise 
identity.
The MRP20 and MRP25 proteins bind to 
stemloop I of MRP RNA
Using MRP RNA deletion mutants as the 
substrate in the UV-crosslinking experiments 
it could be shown that the MRP20 and MRP25 
proteins require nucleotides 22-67 of MRP 
RNA for efficient binding. Both proteins thus 
appear to bind to stemloop I of the MRP 
RNA. Although we cannot rigorously exclude 
the possibility that MRP20 is a degradation 
product of MRP25, several observations argue 
against this possibility. First, the use of differ-
ent HeLa cell extracts, which probably contain 
different levels of protease activities, did not 
have any effect on the relative intensities of 
the crosslinked MRP20 and MRP25 protein 
bands. Secondly, methylene blue mediated 
photo-crosslinking, which has been reported 
to favour crosslinking to dsRNA regions (137), 
increased the MRP20 signal concomitant with 
a decrease of the MRP25 signal. This result of 
the methylene bleu mediated crosslinking may 
even indicate that the MRP20 and MRP25 pro-
teins bind to different regions of the stemloop I 
structure, i.e. that MRP20 possibly binds to 
one of the stem structures of stemloop I while 
MRP25 might prefer a single stranded region. 
Further experiments with detailed stemloop I 
mutants have to be performed to reveal the pre-
cise binding sites of MRP20 and MRP25.
The MRP40 protein: the Th40 autoantigen?
Our analyses showed that MRP40 requires 
nucleotides 86-176 of MRP RNA for efficient 
binding. This region encompasses stemloops 
II, III and IV, but lacks the proposed pseudo-
knot structure of MRP RNA. Interestingly, 
the MRP40 protein was much stronger labeled 
when mutants in which the 5’ end was deleted 
(e.g. MRP67-267) were used compared to full-
length MRP RNA, suggesting that the MRP40 
binding site may be more readily accessible in 
these mutant RNAs. As mentioned above, the 
MRP40 protein is probably identical to the pre-
viously described Rpp38 protein (78) because 
they exhibit similar molecular masses and bind 
directly to the same region of the MRP RNA.
Previously, a 40 kDa autoantigenic pro-
tein, mostly referred to as the 40 kDa Th/To 
autoantigen (Th40) has been UV-crosslinked 
to human MRP RNA. It was shown that this 
protein required nucleotides 21-64, i.e. stem-
loop I of MRP RNA for binding to the RNase 
MRP complex (75). In addition, this protein 
was reported to bind to a similar stemloop 
structure in human RNase P RNA (134). It 
seems unlikely that the autoantigenic MRP40 
protein described by us is the Th40 autoanti-
gen since the binding site of MRP40 appears 
to be located in a different part of the MRP 
RNA. In contrast to a 40 kDa protein binding 
to stemloop I of MRP RNA, we found 20 and 
25 kDa autoantigenic proteins crosslinked with 
stemloop I of MRP RNA. At present we have no 
satisfying explanation for these contradictory 
results.
A model for the RNase MRP complex
Our results strongly suggest that the asso-
ciation of the hPop1 protein with the RNase 
MRP complex is mainly mediated by protein-
protein interactions, and that the RNase MRP 
associated protein(s) necessary for hPop1 bind-
ing require nucleotides 1-86 and 116-176 of 
MRP RNA for binding. Most interestingly, simi-
lar regions of the MRP RNA were found to be 
required for binding of the MRP20, MRP25 and 
MRP40 proteins. Therefore, it is not unlikely 
that the proteins involved in hPop1 association 
are the MRP20 and/or MRP25 proteins medi-
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ating the interaction with stemloop I of MRP 
RNA and the MRP40 protein, mediating the 
interaction with the central part of the MRP 
RNA. A model of the RNase MRP complex that 
results from these presumptive protein-pro-
tein interactions is depicted in Figure 8. In 
addition to the depicted proteins, also Rpp30 
which could not be crosslinked to the MRP 
RNA appears to associate via protein-protein 
interactions to the RNase MRP complex. Fur-
thermore, it is likely that also other not yet 
identified proteins bind to the RNase MRP com-
plex via protein-protein and/or protein-RNA 
interactions. Additional experiments designed 
to reveal the putative protein-protein inter-
actions between hPop1 and MRP20, MRP25 
and/or MRP40 are necessary to establish the 
validity of the model.
Our data do not exclude the possibility 
that conformational changes occur in the MRP 
RNA upon binding of MRP20, MRP25 and/or 
MRP40, which might help in creating a proper 
binding site for hPop1 and possibly other pro-
teins. In fact, the much more efficient interac-
tion of MRP40 with mutant MRP67-267 might 
be indicative of changes in the RNA structure 
upon binding of this protein. Interestingly, all 
the proteins found to be associated with the 
RNase MRP complex bind directly or indirectly 
to the 5’ and/or central part of the RNase MRP 
RNA. Neither hPop1, nor MRP20, MRP25 and 
MRP40 require regions in the 3’ part of the 
RNA for association with the MRP complex. 
It is therefore possible that the predicted con-
served pseudoknot structure of MRP RNA is 
not involved in protein binding but might 
be required for the catalytic reactivity of the 
RNase MRP complex. Stemloop I of MRP RNA 
has previously been shown to be required for 
nucleolar localization of MRP RNA (44). It 
will thus be interesting to find out if the stem-
loop I binding proteins, MRP20 and MRP25, 
are involved in the nucleolar targeting of the 
RNase MRP complex.
This study is a further step in resolving 
the complexity of the human RNase MRP par-
ticle. Detailed knowledge on the proteins asso-
ciated with the RNase MRP RNA and their 
interactions may give more insight in the pre-
rRNA processing steps in which RNase MRP is 
involved. Furthermore, detailed information of 
the RNase MRP complex may simultaneously 
lead to a better understanding of the related 
RNase P particle and its function in pre-tRNA 
and pre-rRNA processing.
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Materials and methods
Oligonucleotides
The following oligonucleotides were used for obtain-
ing MRP RNA constructs: MRP-0: GCG-AAT-TCG-
TTC-GTG-CTG-AAG-GCC-TAG-ATC; MRP-1: GCG-AAG-
CTT-ACA-GCC-GCG-CTG-AGA-ATG-AG; MRP-2: GCG-
AAT-TCT-AAT-ACG-ACT-CAC-TAT-AGG-GAA-AGT-C-
CC-CGG-ACC-T; MRP-3: GCG-AAT-TCT-AAT-ACG-ACT-
CAC-TAT-AGG-GCA-GAG-AGT-GCC-ACG-T; MRP-4: 
GCG-AAT-TCT-AAT-ACG-ACT-CAC-TAT-AGG-CTT-
CCC-ACT-CCA-AAG-TCC-G; MRP-5: GAA-AGT-CCC-
CGG-ACC-TCG-AGA-CAT-TCC-CCG-CTT-CCC-AC; 
MRP-6: GAA-AGT-CCC-CGG-ACC-TCG-ACG-TGC-ATA-
CGC-ACG-TAG-ACA-TTC; MRP-7: ACC-TCG-GGC-
AGA-GAG-TGC-CAG-ACA-TTC-CCC-GCT-TCC-CAC; 
MRP-8: GCG-AAT-TCT-AAT-ACG-ACT-CAC-TAT-AGG-
CCT-AGG-CTA-CAC-ACT-GAG-GAC-T; MRP-9: CGA-
AGC-TTC-CTA-GGC-GAA-AGG-GGA-GGA-AC.
MRP constructs and in vitro transcription
A cDNA clone containing the full-length MRP RNA 
(116) was subcloned into the EcoRI/HindIII sites of 
vector pGEM-3Zf(+) and linearized with HindIII, giving 
rise to full-length MRP RNA after in vitro transcription. 
3’ terminally truncated mutants of MRP, i.e. MRP1-197, 
MRP1-176, MRP1-117 and MRP1-82 were obtained by 
linearization of the full-length MRP construct prior 
to in vitro transcription with restriction enzymes 
AluI, HhaI, AccI and AvaII, respectively. 5’ terminally 
truncated mutants of MRP were obtained by PCR 
amplification of the wild-type MRP construct using 
oligonucleotides MRP-2/MRP-1, MRP-3/MRP-1 and 
MRP-4/MRP-1 giving rise to MRP67-267, MRP86-267 
and MRP127-267, respectively. The PCR products were 
digested with EcoRI/HindIII, cloned into pUC19 and 
linearized with HindIII prior to in vitro transcription. 
3’ terminal truncations of these mutants were obtained 
by linearization of the plasmids prior to in vitro tran-
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Figure 8. Model for the human RNase MRP com-
plex. Schematic representation of the presence of 
the MRP20, MRP25, Rpp38 and hPop1 proteins in 
the human RNase MRP complex. The MRP20 and 
MRP25 proteins bind directly to the MRP RNA 
between nucleotides 22 and 67. The exact manner 
in which they bind to this region is unclear and 
the idea depicted is just one of the possibilities. 
Rpp38 binds directly to a region of MRP RNA 
from nucleotides 86-176. hPop1 binds indirectly 
via protein-protein interactions to the RNase MRP 
complex, possibly by binding the MRP20 and/or 
MRP25 proteins and Rpp38.
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scription with restriction enzymes AluI, HhaI, DdeI 
and AccI resulting in MRP67-197, MRP67-176, MRP67-167, 
MRP67-117, MRP86-197, MRP86-176, MRP86-167, MRP86-117, 
MRP127-197, MRP127-176 and MRP127-167, respectively.
MRP22-67 was obtained by PCR amplification of the 
wild-type MRP construct using oligonucleotides MRP-8/
MRP-9. The resulting PCR product was digested with 
EcoRI/HindIII, cloned into pUC19 and linearized with 
HindIII prior to in vitro transcription. MRP mutants 
lacking stemloop II and/or III (MRP∆87-115, MRP∆87-99 
and MRP∆100-115) were constructed using a two step PCR 
reaction. In the first step wild-type MRP was used as 
template in PCR using oligonucleotides MRP-5/MRP-1, 
MRP-6/MRP-1 and MRP-7/MRP-1. The resulting PCR 
products were gel purified and used as primer, together 
with oligonucleotide MRP-0, in a second PCR with 
wild-type MRP as template. The products of this 
second PCR were digested with EcoRI/HindIII, cloned 
in pGEM-3Zf(+) and linearized with HindIII prior to 
in vitro transcription. The integrity of each construct 
was checked by sequence analysis. MRP constructs lack-
ing stemloop II and/or III contained some additional 
mutations due to PCR. In MRP∆87-115, G68 and C145 
were mutated into T68 and T145, in MRP∆87-99 T165 was 
replaced by G165 and in MRP∆100-115, G80 and C126 
were mutated into T80 and G126, respectively.
For in vitro transcription 0.5 µg linearized MRP 
template was incubated for 1 h at 37°C in 25 µl 
of buffer containing 40 mM Tris-Cl pH 7.9, 6 mM 
MgCl2, 2 mM spermidine, 10 mM NaCl, 10 mM dithio-
threitol, 0.1 mg/ml bovine serum albumin, 40 U RNasin, 
1 mM ATP, 1 mM CTP, 1 mM GTP, 2.5 µM UTP, 20 
µCi [α-32P]UTP and 15 U T7 RNA polymerase. After 
transcription, unincorporated nucleotides were removed 
by a Sephadex G50 spin column and the RNA was 
phenol/chloroform extracted and ethanol precipitated. 
The integrity of the 32P-labeled transcripts was checked 
by denaturing polyacrylamide gel electrophoresis.
In vitro reconstitution and immunoprecipitation
Twenty-five µl rabbit serum (anti-hPop1 (77) or 
anti-Ro52 (138)) or 10 µl patient serum (anti-Th/To 
(H248) or normal human serum) were incubated with 
20 µl of a 50% suspension of protein A agarose beads 
in IPP500 (500 mM NaCl, 10 mM Tris-Cl pH 8.0, 0.05% 
NP-40) for 1 h at room temperature. Beads were washed 
twice with IPP500 and once with buffer A (200 mM KCl, 
10 mM Hepes pH 7.9, 2 mM MgCl2, 0.05% NP-40). In 
vitro transcribed 32P-labeled MRP RNA, full-length and 
deletion mutants, were incubated for 45 min. at room 
temperature with 10 µl of total HeLa cell extract (116) in 
a volume of 20 µl containing 200 mM KCl, 10 mM Hepes 
pH 7.9, 2 mM MgCl2, 0.05% NP-40 and 5 mg yeast 
RNA. Protein A agarose coupled antibodies in 500 µl 
buffer A were added, and the mixture was incubated 
for 1 h at 4°C. Beads were washed three times with 
buffer A, and co-precipitating RNAs were isolated by 
phenol/chloroform extraction and ethanol precipitation. 
RNAs were separated on a 8% denaturing polyacryl-
amide gel and visualized by autoradiography.
UV-crosslinking
In vitro transcribed 32P-labeled MRP RNA, full-length 
or deletion mutants (4 pmol), were incubated for 45 min. 
at room temperature with 30 µl of total HeLa cell extract 
(116) in a total volume of 60 µl containing 150 mM 
KCl, 12.5 mM Tris-Cl pH 7.4, 1 mM MgCl2 and 0.05% 
NP-40. For competition experiments 40 pmol of nonra-
dioactive competitor RNA was included in the incuba-
tion of 32P-labeled MRP RNA with HeLa cell extract. The 
mixture was exposed to UV light (254 nm wavelength) 
with an energy of 1 J/cm2 for 20 min. on ice in an Amer-
sham UV crosslinker (RPN2500) to achieve crosslinking 
of RNA to protein. Subsequently, 20 µg of RNase A was 
added and the mixture was incubated for 1 h at 37°C. 
Protein A agarose coupled antibodies (rabbit anti-hPop1 
(77), normal rabbit serum, anti-Th/To (H248) or normal 
human serum or rabbit anti-Rpp30, rabbit anti-Rpp38 
((80), kind gifts of Drs. S. Altman and N. Jarrous (Yale 
University)) in 500 µl IPP150 (150 mM NaCl, 10 mM 
Tris-Cl pH 8.0, 0.05% NP-40) were added, and the mix-
ture was incubated for 1 h at 4°C. Beads were washed 
three times with IPP150 and resuspended in SDS-sample 
buffer. Precipitated proteins were analyzed by 13% SDS 
polyacrylamide gel electrophoresis and visualized by 
autoradiography.
Rpp30 and Rpp38 transfection and immunoprecipita-
tion
Rpp30 cDNA ((78), a kind gift of Drs. S. Altman and 
N. Jarrous (Yale University)) was mutated by PCR to 
introduce a XhoI site before the translational start codon 
and a XbaI site before the stop codon. The PCR product 
was digested with XhoI/XbaI and ligated in a XhoI/XbaI 
digested pCI-neo vector which contains a 3’ VSV-G 
tag encoding sequence (YTDIEMNRLGK-stop) inserted 
between the original XbaI-SalI sites of pCI-neo. The 
resulting construct (Rpp30-VSV) contains the VSV-G 
tag sequence in frame directly behind the last codon of 
Rpp30 and is terminated by the stop codon introduced 
after the tag sequence.
Rpp38 cDNA ((78), a kind gift of Dr. C. Liew (Univer-
sity of Toronto) and Dr. S. Altman (Yale University)) was 
mutated and cloned in pCI-neo containing the 3’ VSV tag 
in the same way, resulting in construct Rpp38-VSV. The 
integrity of both constructs was checked by sequence 
analysis.
Transient transfection of HeLa cells with Rpp30-VSV, 
Rpp38-VSV and pCI-neo DNA followed by immunopre-
cipitation using anti-VSV, anti-fibrillarin and anti-Th/To 
serum (H248) antibodies was performed essentially as 
described (113). Northern blot hybridization with anti-
sense riboprobes specific for P, MRP, U3 and U1 RNAs 
was performed as previously described (116).
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Introduction
Intracellular macromolecular complexes 
are important targets of autoantibodies found 
in the sera of systemic autoimmune disease 
patients. Autoantibodies directed against com-
ponents of the nucleolus are often found in 
patients suffering from scleroderma or sclero-
derma overlap syndromes (139). Examples of 
such nucleolar autoantigens are RNA poly-
merase I, fibrillarin, PM/Scl-100 and Th/To 
(reviewed in ref. (139)).
Abstract
The RNase MRP and RNase P complexes function as endonucleases and cleave the precursors to rRNA and tRNA, respectively. It has been shown that patients suffering from certain systemic autoim-
mune diseases produce autoantibodies directed to both complexes (desig-
nated anti-Th/To autoantibodies). Anti-Th/To positive patient sera have 
been shown to co-precipitate a protein of 40 kDa from cell extracts (Th-40), 
which was suggested to bind to the P3 domain of the RNase MRP and 
RNase P RNAs.
Here we show that Th-40 is identical to the Rpp38 protein. Paradoxically, 
Rpp38 does not bind to the P3 domain and only half of the anti-Th/To sera 
contain anti-Rpp38 reactivity. Two other RNase MRP/RNase P subunits 
Rpp20 and Rpp25, were found to interact with the P3 domain. The previ-
ously reported 40 kDa species associated with this domain appeared to 
consist of Rpp20 and/or Rpp25 associated with a nuclease resistant RNA frag-
ment. Finally, we demonstrate that almost all tested anti-Th/To patient sera 
contain autoantibodies to Rpp25 and hPop1, indicating that these proteins 
harbour the most frequently targeted Th/To determinants. Taken together, 
our data unequivocally define the identity of the Th/To autoantigen and 
demonstrate that Th/To autoepitopes are found on several protein subunits 
of RNase MRP/RNase P.
Anti-Th/To antibodies have been reported 
to occur in 4-13% of scleroderma patients 
(67,68) and are defined as autoantibodies that 
are able to immunoprecipitate the human RNase 
MRP and RNase P ribonucleoprotein particles 
(61,64,68).
The RNase MRP ribonucleoprotein particle 
has originally been identified by virtue of its 
capacity to cleave a mitochondrial RNA in vitro 
to generate RNA primers for mitochondrial 
DNA replication (22). In addition, RNase MRP 
has been shown to cleave at site A3 within the 
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first internal transcribed spacer of the precur-
sor of ribosomal RNA in Saccharomyces cerevi-
siae (28-30). In many respects, the RNase MRP 
complex is related to the RNase P complex. The 
RNase P complex is required for the removal 
of the 5’-end of precursor tRNAs and is sug-
gested to be involved in the processing of the 
precursor rRNA in internal transcribed spacer 
2 (reviewed in ref. (118)). The RNase MRP and 
RNase P complexes both function as site-spe-
cific endonucleases, contain an RNA compo-
nent that has been proposed to adopt a similar 
secondary structure and share several protein 
subunits (reviewed in ref. (118)).
At present, nine proteins have been 
reported to be associated with the human 
RNase MRP and/or RNase P complexes: hPop1, 
Rpp14, Rpp20, Rpp21, Rpp29/hPop4, Rpp30, 
Rpp38, Rpp40 and hPop5 (77-81,120,140). A 
tenth protein subunit of these ribonucleopro-
tein particles, Rpp25, has recently been iden-
tified and cloned in the laboratory of Dr. S. 
Altman (personal communication)
The first autoantigenic polypeptide asso-
ciated with RNase MRP/RNase P was iden-
tified via immunoprecipitations with patient 
sera using 35S-methionine or 3H-leucine labeled 
HeLa cell extracts (68,72,73,135,136) and has 
been designated Th-40, referring to its appar-
ent molecular weight of 40 kDa. Yuan and 
coworkers subsequently showed that a protein 
with a molecular weight of 40 kDa could be 
UV-crosslinked to the P3 domain of RNase P 
and MRP RNA (75), suggesting that Th-40 is 
bound to this domain. In a previous study 
we showed that two proteins with apparent 
molecular weights of 20 and 25 kDa, respec-
tively, can be UV-crosslinked to the P3 domain 
of RNase MRP RNA (nucleotides 22-67, see 
Figure 1) and that a protein with a molecular 
weight of about 40 kDa, Rpp38, is bound to 
a centrally located region of the RNase MRP 
RNA (nucleotides 86-176, see Figure 1) (105).
In this study we have determined the iden-
tity of the Th-40 autoantigen and have identi-
fied the proteins carrying Th/To determinants 
as well as their binding sites on RNase MRP 
RNA.
Results
The Th-40 autoantigen is identical to 
Rpp38
One hundred and seventy two patient 
sera displaying anti-nucleolar reactivities were 
screened for their capacity to co-immuno-
precipitate RNase MRP RNA, RNase P RNA, 
U3 snoRNA, U8 snoRNA, U22 snoRNA, U1 
snRNA and Y1 scRNA (Van Eenennaam et 
al., manuscript submitted for publication). 
Sera that immunoprecipitated RNase MRP and 
RNase P RNA were designated anti-Th/To 
sera. To study the polypeptides precipitated 
by these anti-Th/To sera, immunoprecipi-
tations with biotinylated total HeLa cell 
extracts were performed. Co-precipitating pro-
teins were analyzed by western blot analysis 
and visualization using horseradish peroxi-
dase-conjugated streptavidin. As shown in 
Figure 2A, lanes 1 and 2, anti-Th/To sera 
co-precipitated several polypeptides, the most 
prominent one being a 40-kDa protein. This 
40-kDa protein was not precipitated by con-
trol patient sera (lanes 3-12), which displayed 
other patterns of co-precipitating proteins.
To determine whether the 40 kDa protein 
that was co-precipitated by these anti-Th/To 
sera (lanes 1 and 2) is identical to the previ-
ously described Th-40 autoantigen, similar 
immunoprecipitation experiments were per-
formed with three reference anti-Th/To sera 
(designated P3 (68), Th-ref and Fu). As shown 
in Figure 2B, the precipitation patterns of 
these reference sera (lanes 1, 2 and 3, respec-
tively) were indistinguishable from those 
obtained with the anti-Th/To sera described 
above (lanes 4 and 5). We conclude that the 
40-kDa band co-precipitated by anti-Th/To 
sera by definition represents the Th-40 auto-
antigen.
To shed more light on the identity of 
the co-precipitating proteins, the western 
blot depicted in Figure 2A was stripped and 
reprobed with antibodies directed against 
Rpp40, Rpp38 and hPop4 (protein subunits 
of the RNase MRP and RNase P complexes), 
against the La protein (component of the Ro 
RNPs) and against the U1A protein (compo-
nent of the U1 snRNPs). As shown in Figure 
2C, lanes 1 and 2, Rpp40, Rpp38 and hPop4 
were specifically co-precipitated by the anti-
Th/To sera. The specific immunoprecipitation 
of the La protein by the anti-Ro RNP RNA 
sera (lanes 5 and 6) and of U1A by the anti-U1 
snRNP sera (lanes 11 and 12) further substan-
tiated the specificity of the assay. Overlays of 
the total protein signals (Figure 2A, lanes 1 and 
2) and the immunoblotting signals (Figure 2C, 
lanes 1 and 2) indicated that the Th-40 autoan-
tigen is identical to the Rpp38 protein.
Th-40/Rpp38 does not interact with the 
P3 domain of RNase MRP RNA
Paradoxically, Yuan and coworkers have 
previously demonstrated that the putative 
Th-40 autoantigen could be UV-crosslinked to 
the P3 domain of RNase MRP and P RNA 
(75), whereas we have mapped the binding site 
for Rpp38 to another region of these RNAs 
(105). To clarify this issue, the association of 
Rpp38 with different domains of RNase MRP 
was further investigated. In vitro transcribed 
32P-labeled RNase MRP RNA and U3 snoRNA 
as a control were incubated with a HeLa 
cell extract and reconstituted complexes were 
analyzed by immunoprecipitation using anti-
Rpp38 antibodies. As shown in Figure 3A, 
lane 1, these anti-Rpp38 antibodies were able 
Figure 1. Secondary structure of the human RNase MRP RNA. 
The secondary structure of RNase MRP RNA is based on phy-
logenetic comparison and chemical modification data and is 
adapted from ref. (70). The P3 domain (nucleotides 22-67) and 
the central domain (nucleotides 86-176) are shaded in blue.
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to immunoprecipitate the reconstituted RNase 
MRP complexes, whereas the U3 control RNA 
was not co-precipitated (lane 2). Deletion of 
the 3’ terminal 185 nt of RNase MRP RNA 
resulted in loss of precipitation by anti-Rpp38 
antibodies, which confirmed that the Th-40/
Rpp38 protein does not associate with the P3 
domain (MRP1-82 and MRP22-67, see Figure 3A, 
lanes 4 and 5). In contrast, efficient binding 
of the Th-40/Rpp38 protein to an RNase MRP 
RNA mutant comprising the central domain 
(MRP86-176) was observed (Figure 3A, lane 3). 
The lack of precipitation of U3 RNA and the 
P3 containing RNase MRP RNA mutants was 
not due to instability of these RNAs under the 
experimental conditions used, as evidenced by 
the analysis of the supernatants (Figure 3A, 
lanes 9, 11 and 15). Rpp38 directly binds to 
the central part of the RNA, because the Rpp38 
protein can be UV-crosslinked to this domain 
(105).
To investigate the specificity of anti-Th/To 
patient sera in this reconstitution assay, recon-
stituted complexes were immunoprecipitated 
with twelve anti-Th/To sera (referred to as 
Th1-Th12). As shown in Figure 3B, almost 
all anti-Th/To sera co-immunoprecipitated 
the P3 domain of RNase MRP RNA (mutant 
MRP22-67), whereas none of them immunopre-
cipitated the U3 control RNA. Only five of the 
sera efficiently immunoprecipitated the central 
domain of RNase MRP RNA (lanes 4, 5, 7, 10 
A B
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Figure 2. The Th-40 autoantigen is identical to Rpp38. A. Autoantigens were immunoprecipitated from a biotinylated HeLa cell 
extract using patient sera containing the following reactivities: anti-Th/To (lanes 1 and 2, sera designated Th4 and Th8, respectively), 
anti-U3 snoRNP (lanes 3 and 4), anti-Ro RNP (lanes 5 and 6), anti-U22 snoRNP (lanes 7 and 8), anti-U8 snoRNP (lanes 9 and 10) 
and anti-U1 snRNP (lanes 11 and 12). Co-precipitating proteins were resolved on a 13% SDS-PAGE gel, blotted onto nitrocellulose 
and visualized by HRP-conjugated streptavidin. At the left the positions of molecular weight markers are indicated and the arrow 
points to the band designated Th-40. B. Immunoprecipitation using three anti-Th/To reference patient sera (P3 (lane 1), Th-ref (lane 
2) and Fu (lane 3)) performed as described above. The arrow points to the band designated Th-40. C. The blot shown in panel A 
was probed with antibodies specific for Rpp40, Rpp38, hPop4, La and U1A. Bound antibodies were visualized by incubation with 
HRP-conjugated secondary antibodies followed by chemiluminescence. The arrows point to the position of the band designated 
Th-40 (see panel A).
Figure 3. In vitro reconstitution of RNase MRP complexes. 
A. 32P-labeled RNase MRP RNA, U3 snoRNA and RNase MRP 
RNA mutants (MRP
86-176
, MRP
1-82
 and MRP
22-67
) were incu-
bated in HeLa cell extracts and reconstituted MRP complexes 
were immunoprecipitated using a rabbit anti-Rpp38 antise-
rum. RNAs isolated from the immunoprecipitates, the input 
fractions (10%) and from the supernatants (10%) were ana-
lyzed by gel electrophoresis and autoradiography. RNase MRP 
RNA (lanes 1, 6 and 7), U3 snoRNA (lanes 2, 8 and 9), 
MRP
86-176 
(lanes 3, 12 and 13), MRP
1-82
 (lanes 4, 14 and 15) and 
MRP
22-67
 (lanes 5, 10 and 11). B. 32P-labeled U3 snoRNA, 
MRP
86-176 
and MRP
22-67
 RNAs were incubated in HeLa cell 
extracts and reconstituted complexes were immunoprecipitated using 12 anti-Th/To patient sera (Th1-Th12, lanes 1-12). Co-
precipitating RNAs were isolated from the immunoprecipitates and analyzed by gel electrophoresis and autoradiography. In lanes 
13, RNA isolated from 10% of the input fraction from the Th7 precipitation was loaded. C. Anti-Rpp38 reactivity present in the 
anti-Th/To patient sera (Th1 - Th12) was determined by western blot analysis using recombinant Rpp38 protein (lanes 1-12).
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and control patient antibodies and analysis on 
a high resolution SDS-PAGE gel, showed that 
in addition to the band previously designated 
MRP20 (105), the band referred to as MRP25 
(105) actually is composed out of three bands 
(Figure 5A, lane 4). Both anti-Rpp20 and anti-
Rpp25 antibodies immunoprecipitated these 
four bands, confirming that Rpp20 and Rpp25 
represent the previously identified crosslinked 
proteins (lanes 2 and 3). The multiple bands 
observed in this experiment probably repre-
sent the Rpp20 and Rpp25 proteins covalently 
attached to different nuclease resistant RNA 
fragments. Pre-immune rabbit sera and control 
patient sera did not immunoprecipitate any 
UV-crosslinked proteins (lanes 1 and 5).
The fact that Th40/Rpp38 does not and 
Rpp20 and Rpp25 do bind to the P3 domain of 
RNase MRP RNA raised the question why other 
investigators previously observed a 40-kDa spe-
cies after UV-crosslinking using the P3 domain 
(75). To clarify this issue, we performed a UV-
crosslinking experiment under the conditions 
applied by Yuan and coworkers. The main dif-
ference with the experimental conditions of 
our analyses is the use of RNase T1 rather 
than RNase A to degrade the RNA after UV-
irradiation. RNase T1 cleaves single-stranded 
regions of RNA after a G-residue, while RNase 
A cleaves single-stranded RNAs preferentially 
after a C- or U-residue. As shown in Figure 5B, 
lanes 5 and 6, the RNase T1 digestion resulted 
in a doublet migrating at approximately 40 
kDa, similar to the previously reported results 
(75). UV-crosslinking followed by RNase A 
treatment, which was performed in parallel, 
resulted in the immunoprecipitation of the 
20 and 25 kDa species (lanes 2 and 3), con-
firming our previous results (105). A similar 
result was obtained with rabbit anti-Rpp20 and 
and 11), which would be consistent with the 
presence of anti-Rpp38 reactivity in these five 
patient sera. The presence of anti-Rpp38 auto-
antibodies in these sera was indeed confirmed 
by western blot analysis using recombinant 
Rpp38 protein (Figure 3C).
Taken together, our results show that the 
Th-40/Rpp38 protein binds to the central 
domain of RNase MRP RNA, comprised of 
nucleotides 86-176, and not to the P3 domain. 
The fact that most of the anti-Th/To sera immu-
noprecipitated the reconstituted P3 domain 
strongly suggested that another more fre-
quently targeted autoantigenic component 
interacts with the P3 domain.
Rpp20 and Rpp25 interact with the P3 
domain of RNase MRP RNA
Our previous UV-crosslinking experiments 
showed that two polypeptides with molecular 
weights of 20 and 25 kDa associate with the P3 
domain of the RNase MRP RNA (105). To inves-
tigate whether these two proteins are identical 
to the recently identified Rpp20 (80) and Rpp25 
(C. Guerrier-Takada and S. Altman, personal 
communication) protein subunits, reconsti-
tuted RNase MRP complexes were immuno-
precipitated with rabbit antisera raised against 
Rpp20 or Rpp25. As shown in Figure 4, lanes 
7 and 12, both Rpp20 and Rpp25 efficiently 
reconstituted with the RNase MRP RNA, but 
not with the U3 control RNA (lanes 6 and 11). 
Similar analyses using mutant RNAs MRP22-67, 
MRP1-82 and MRP86-176 showed that Rpp20 is 
able to associate with both the P3 domain and 
the central domain (lanes 8-10), whereas Rpp25 
associated only with the P3 domain (lanes 
13-15). A control pre-immune serum showed 
only background levels of precipitation (lanes 
1-5) and the stability of the RNAs analyzed 
was again established by the comparison of 
the supernatants from the anti-Rpp25 preci-
pitations with the input RNAs (lanes 16-25). 
These results indicate that Rpp20 and Rpp25 
are identical to the two proteins that were 
identified by UV-crosslinking to bind to the P3 
domain.
UV-crosslinking experiments using 
32P-labeled MRP22-67 RNA (the P3 domain), 
followed by immunoprecipitations using Th-7 
Figure 4. Association of Rpp20 and Rpp25 with the P3 domain of RNase MRP RNA. 32P-labeled U3 snoRNA, RNase MRP, MRP
1-82
, 
MRP
22-67
 and MRP
86-176
 RNAs were incubated in a HeLa cell extract and reconstituted complexes were immunoprecipitated with 
pre-immune (lanes 1-5), anti-Rpp20 (lanes 6-10) and anti-Rpp25 (lanes 11-15) antibodies. Co-precipitating RNAs, and RNA from 
10% of the input fractions (lanes 16-20) and from 10% of the supernatants from the anti-Rpp25 precipitations (lanes 21-25) were 
isolated and analysed by denaturing polyacrylamide gel electrophoresis and visualised by autoradiography.
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Figure 5. Rpp20 and Rpp25 can be UV-crosslinked to the 
P3 domain of RNase MRP RNA. A. Reconstituted complexes 
containing 32P-labeled MRP
22-67
 RNA were subjected to UV-
crosslinking and RNase A treatment, followed by an immu-
noprecipitation using pre-immune rabbit serum (lane 1), 
anti-Rpp20 serum (lane 2), anti-Rpp25 serum (lane 3), patient 
serum Th7 (lane 4) and control patient serum (lane 5). Co-
precipitating proteins were resolved on a 15% SDS-PAGE 
gel and crosslinked proteins were visualized by autoradiogra-
phy. B. 32P-labeled MRP
22-67
 RNA was incubated in HeLa cell 
extracts and exposed to UV irradiation to induce crosslinking 
between RNA and cellular proteins. Crosslinked complexes 
were treated with either RNase A (lanes 1-3) or RNase T1 
(lanes 4-6) and subsequently immunoprecipitated with patient 
sera Th7 (lanes 2 and 5) and Th8 (lanes 3 and 6) or control 
sera (lanes 1 and 4). Co-precipitating proteins were analysed 
by 13% SDS-PAGE and visualized by autoradiography. Note 
that the resolution of the gel shown in panel B is lower than 
that of the gel in panel A. The positions of molecular weight 
markers are shown at the left.
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Discussion
The results of previous studies demon-
strated that patient sera containing reactivity 
directed to both the RNase MRP and RNase P 
complexes were able to immunoprecipitate 
a protein of about 40 kDa, named Th-40 
(68,72,73,136). Here, we demonstrate that Th-40 
is identical to the Rpp38 protein. Although 
almost all anti-Th/To patient sera were able to 
(co-) immunoprecipitate the Th-40 autoanti-
gen, only approximately half of the anti-Th/To 
sera actually contain reactivity directed to the 
Rpp38 protein. The immunoprecipitation, even 
under relatively stringent conditions, of Th-40/
Rpp38 by patient sera that do not recognize 
the Rpp38 protein is apparently caused by the 
recognition of other autoantigenic components 
in the RNase MRP and RNase P complexes. The 
RNase P holoenzyme has been shown to be 
stable up to salt concentrations of 500 mM KCl 
(78), suggesting that under these conditions 
the intact complexes rather than individual 
protein subunits are co-precipitated.
The use of either patient sera recognizing 
Rpp38 or polyclonal rabbit sera raised against 
Rpp38 allowed the mapping of the binding-site 
of Rpp38. Rpp38 binds to the region between 
nucleotides 86-176 of the RNase MRP RNA, 
which is in agreement with our previous obser-
vations (105). The binding of Rpp38 to this part 
of the RNase MRP RNA has been suggested to 
be mediated by a so-called two-stranded, helix-
internal loop-helix motif (or Kink-turn motif) 
between nucleotides 145 and 170 (141,142). 
The interaction of Rpp38 with the correspon-
ding domain of the RNase P RNA is suggested 
by the observation that Rpp38 was able to 
interact with the intact RNase P RNA but not 
hPop1 and Rpp25 are the most frequently 
targeted autoantigenic RNase MRP com-
ponents
The results described above demonstrate 
that anti-Th/To sera are frequently reactive 
with proteins associated with the P3 domain 
and that Rpp20 and Rpp25 bind to this frag-
ment of RNase MRP RNA. To investigate the 
antigenicity of these proteins, in vitro trans-
lated, 35S-labeled Rpp20 and Rpp25 were sub-
jected to immunoprecipitations with anti-Th/To 
patient sera and two human control sera. As 
shown in Figure 6, panel G, Rpp20 was only 
detectably immunoprecipitated by Th5 and not 
by the other 11 anti-Th/To sera. In contrast, 
the majority of the anti-Th/To patient sera 
immunoprecipitated in vitro translated Rpp25 
(panel E), indicating that Rpp25 represents an 
important Th/To autoantigen bound to the P3 
domain of RNase MRP RNA.
In addition, all other protein subunits, 
except Rpp38, of the RNase MRP and/or 
RNase P complexes were tested in similar 
immunoprecipitation assays using Th1-Th12. 
As shown in Figure 6, panels A-D, F and H-I, 
these proteins were recognized with variable 
frequencies. Almost all anti-Th/To sera recog-
nized hPop1 (panel A), about half of the sera 
recognized Rpp30 (panel C), hPop5 (panel H) 
and Rpp14 (panel I), and reactivity with Rpp40, 
hPop4 and Rpp21 was observed only in a mino-
rity of these sera (panels B, D, F).
In conclusion, these data indicate that 
patient sera precipitating RNase MRP and 
RNase P complexes (anti-Th/To) most fre-
quently recognize the hPop1 and Rpp25 pro-
teins contained in these complexes.
The resistance of the P3 domain to RNase T1 
digestion was confirmed by incubating in vitro 
transcribed MRP22-67 in a HeLa cell extract, 
followed by treatment with either RNase A 
or RNase T1, immunoprecipitation with anti-
Th/To sera and RNA analysis by gel electro-
phoresis. While the size of MRP22-67 was hardly 
affected by RNase T1 treatment, RNase A 
degraded MRP22-67 to small (oligo)nucleotides 
(data not shown).
anti-Rpp25 as precipitating antibodies instead 
of patient antibodies (data not shown). From 
these data we conclude that the difference in 
apparent molecular weights of the crosslinked 
species is due to the use of different ribonu-
cleases. In the case of RNase T1 the protein(s) 
remain(s) most likely covalently bound to a 
relatively large part of the MRP22-67 RNA, 
whereas in the case of RNase A only a few 
nucleotides remain bound to the protein(s). 
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Figure 6. Immunoprecipitation of RNase MRP proteins by anti-Th/To patient sera. 35S-labeled in vitro translated hPop1 (panel A), 
Rpp40 (panel B), Rpp30 (panel C), hPop4 (panel D), Rpp25 (panel E), Rpp21 (panel F), Rpp20 (panel G), hPop5 (panel H) and 
Rpp14 (panel I) were subjected to immunoprecipitation with patient sera Th1-Th12 (lanes 2-13), two control patient sera (lanes 
14 and 15) and rabbit antisera that were raised against each of these proteins (lane 1). Co-precipitating proteins were visualized 
by SDS-PAGE and autoradiography.
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with a fragment comprising nucleotides 1-74 
(86).
The observation that Th-40/Rpp38 binds 
to the central domain and not to the P3-domain 
of RNase MRP RNA seemed to be in contra-
diction to what has been reported by Yuan 
and coworkers (75,134). However, we demon-
strated that the 40-kDa species that both in 
our and the previous study results from UV-
crosslinking to the P3 domain of RNase MRP 
RNA when RNase T1 is used represents Rpp25 
and/or Rpp20 covalently linked to the (almost) 
complete P3 domain of RNase MRP RNA. Our 
observation that the P3 domain is protected 
against or resistant to RNase T1 cleavage is 
supported by RNase protection experiments as 
described by Liu and coworkers (134) and is 
not surprising in view of the almost complete 
absence of single-stranded guanosines in this 
part of RNase MRP RNA (see Figure 1).
The results of the deletion mutant analyses 
demonstrated that Rpp20 is able to bind both 
to the P3 domain and to an RNase MRP RNA 
fragment comprised of nucleotides 86-176. A 
simultaneous interaction (either directly or 
indirectly) with both the P3 domain and the 
region 86-176 has been suggested for the hPop1 
protein as well (105), although for the efficient 
association of hPop1 both domains seem to 
be required. Taken together, these results sug-
gest that these two RNA regions are positioned 
close to each other in the three-dimensional 
structure of RNase MRP RNA, which may be 
stabilized by Rpp20 and/or hPop1 binding.
RNA-protein interactions in the struc-
turally related human RNase P complex have 
been studied using yeast three-hybrid and UV-
crosslinking experiments. The results indicated 
that Rpp21, Rpp29/hPop4 and Rpp30 interact 
with the P3 domain of RNase P RNA, whereas 
the Rpp38 protein interacts with a more 3’ 
located domain (86). Using our reconstitution 
assay we tried to detect these interactions 
in the reconstituted RNase MRP complex as 
well. However, no detectable reconstitution 
was observed when Rpp14, hPop5, Rpp21, 
Rpp29/hPop4, Rpp30 and Rpp40 were studied 
(our unpublished observations). The RNase P 
reconstitution experiments also indicated that 
no interaction of Rpp20 and hPop1 proteins 
with the RNase P RNA could be demonstrated 
(86). Whether the interactions described for 
the individual RNase P and RNase MRP com-
plexes can be extrapolated to the other com-
plex is at present not clear. A direct interaction 
of Rpp25 with the P3 domain of RNase P RNA 
has been observed as well (C. Guerrier-Takada, 
personal communication).
The observations that almost no anti-Th/To 
serum contains reactivity directed to the Rpp20 
protein and that the majority of the anti-Th/To 
sera contain autoantibodies against Rpp25 
(Figure 6), suggest that Rpp20 is most probably 
co-precipitated with anti-Rpp25 when anti-
Th/To patient sera are used in reconstitution 
and UV-crosslinking experiments.
The ability of patient sera that are able to 
immunoprecipitate the RNase MRP and RNase 
P complexes has been designated anti-Th/To 
reactivity (61,64,68). The availability of cDNA 
clones encoding most, if not all protein sub-
units of these complexes now allowed a more 
detailed analysis of the anti-Th/To autoanti-
body specificities present in patient sera. Our 
study demonstrates that all protein compo-
nents may be targeted by anti-Th/To autoan-
tibodies, albeit some of them only rarely. In 
this study we showed that this reactivity can 
now be subclassified according to the presence 
of autoantibodies against each of the identi-
fied RNase MRP/RNase P protein subunits or 
according to the recognition of a specific com-
bination of these. The analysis of a larger col-
lection of anti-Th/To sera will be required to 
investigate the potential clinical relevance of 
this subclassification and to determine whether 
such a classification may aid in establishing the 
diagnosis and/or prognosis of patients showing 
anti-Th/To reactivity.
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Materials and Methods
Immunoprecipitation using biotinylated HeLa cell 
extracts
Total HeLa cell extract was prepared as described 
before (116). After dialysis against 50 mM NaHCO3 
pH 8.3, 0.5 mM DTE, 0.5 mM PMSF, 1 mg NHS-LC-bio-
tin (Pierce) was added per 20 mg of total protein. After 
incubation on ice for 2 hours, the reaction was stopped 
with 50 mM Tris-HCl, pH 8.0. Finally, the buffer was 
changed to 10 mM Tris-HCl, pH 8.0, 0.5 mM DTE, 0.5 
mM PMSF, 0.1 M KCl, 0.01% NP-40 and 20% glycerol 
by dialysis.
For each immunoprecipitation 20 µl patient serum was 
incubated with 20 µl of a 50% suspension of protein 
A-agarose beads in IPP500 (500 mM NaCl, 10 mM Tris-
HCl, pH 8.0, 0.05% NP-40) for 1 h at room temperature. 
Beads were washed two times with IPP500 and once 
with IPP150 (150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 
0.05% NP-40). Biotinylated HeLa extract was added 
and incubated for 2 hours at 4°C. After 4 washes with 
IPP150, co-precipitating proteins were eluted with SDS-
sample buffer, resolved by 13% SDS-PAGE and blotted 
onto nitrocellulose membranes.
Detection of biotinylated proteins was performed 
using horseradish peroxidase-conjugated streptavidin 
(Dako Immunoglobulins) and visualization by chemilu-
minescence.
In vitro reconstitution
In vitro transcribed 32P-labeled RNase MRP RNA (full 
length and deletion mutants MRP22-67, MRP1-82 and 
MRP86-176), and U3 snoRNA were allowed to associate 
with their protein components in an in vitro reconstitu-
tion assay and analyzed as described previously (105).
UV-crosslinking
UV-crosslinking experiments to study RNA-protein 
interactions were performed as described previously 
(105). After reconstitution and UV-irradiation the recon-
stituted complexes were treated with either 10 µg of 
RNase A for 1 hour at 37 °C or 100 units RNase T1 for 30 
minutes at 30°C per immunoprecipitation. The protein-
RNA complexes were subjected to immunoprecipitation, 
analyzed by SDS-PAGE and visualized by autoradiogra-
phy.
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Immunoblotting analysis
Patient sera were used in a 5000-fold dilution, poly-
clonal rabbit sera were used in a 100-fold dilution and 
mouse monoclonal antibodies SW5 (anti-La) and 9A9 
(anti-U1A and anti-U2B”; Euro-Diagnostica, Arnhem, 
The Netherlands) were used in a 50-fold and 100-fold 
dilution, respectively. Detection was performed using 
horseradish peroxidase-conjugated rabbit-anti-human 
IgG or swine-anti-rabbit IgG or rabbit-anti-mouse IgG 
(Dako Immunoglobulins) as secondary antibodies and 
visualization by chemiluminescence.
Recombinant His6-tagged Rpp38 was obtained by 
expression of Rpp38 cDNA in pQE-30 (Qiagen) in 
M15[pREL4] cells according to the manufacturer’s 
instructions.
In vitro translation
For in vitro transcription-translation of hPop1, hPop4, 
hPop5 the hPop1-pT7-7TT, VSV-hPop4 and VSV-hPop5 
DNA constructs (77,120,140) were linearized using SalI 
and FspI, respectively. The cDNA of Rpp30 (78) was sub-
cloned in pGEM-3Zf(+) and linearized using XbaI. The 
open reading frames of Rpp14, Rpp20, Rpp21, Rpp25 
and Rpp40 were subcloned using a PCR based strategy 
on cDNA constructs as templates (79-81) in pCR4-TOPO 
(Invitrogen) and linearized using SmaI digestion. In vitro 
transcription was performed as described previously 
using either T7 or T3 RNA polymerase (105). In vitro 
translation of these transcripts was performed in the 
presence of [35S]-methionine using rabbit reticulocyte 
lysates (Promega) or wheat germ extracts.
Antisera
Polyclonal rabbit sera against hPop1, hPop4, hPop5 
have been described previously (77,120,140). Polyclonal 
rabbit antibodies raised against Rpp14, Rpp20, Rpp21, 
Rpp25, Rpp30, Rpp38 and Rpp40 (78-81) were kindly 
provided by Dr. S. Altman.
The Th/To reference sera designated P3, Th-ref and 
Fu were kindly provided by Dr. R. Karwan, Dr. J. Craft 
and Dr. T. Mimori, respectively.
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Introduction
Antinuclear antibodies (ANA) have been 
demonstrated to occur frequently in systemic 
autoimmune diseases such as systemic lupus 
Abstract
Sera from patients suffering from systemic autoimmune diseases such as systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) have been shown to contain reactivities to nuclear components. Auto-
antibodies specifically targeting nucleolar antigens are most frequently 
found in patients suffering from SSc or SSc overlap syndromes.
We determined the prevalence and clinical significance of autoantibodies 
directed to nucleolar RNA-protein complexes, the so-called small nucleolar 
ribonucleoprotein complexes (snoRNPs). A total of 172 patient sera with 
anti-nucleolar antibodies were analysed by immunoprecipitation. From 100 
of these patients clinical information was obtained by chart review. Autoan-
tibodies directed to snoRNPs were not only detected in patients suffering 
from SSc and primary Raynaud’s phenomenon, but also in patients suffer-
ing from SLE, rheumatoid arthritis (RA) and Sjögren’s syndrome (SS). Anti-
bodies against box C/D small snoRNPs can be subdivided in anti-fibrillarin 
positive and anti-fibrillarin negative reactivity. Anti-fibrillarin positive 
patient sera were associated with a poor prognosis in comparison with anti-
fibrillarin negative (reactivity with U3 or U8 snoRNP only) patient sera. 
Anti-Th/To autoantibodies were associated with SSc, primary RP and SLE 
and were predominantly found in patients suffering from decreased co-
diffusion and esophagus motility and xerophthalmia. For the first time 
autoantibodies that recognise box H/ACA snoRNPs are described, identify-
ing this class of snoRNPs as a novel nucleolar autoantigen. Taken together, 
our data show that anti-nucleolar patient sera directed to small nucleolar 
ribonucleoprotein complexes are frequently found in other diseases than 
SSc and that categorisation of diagnoses and clinical manifestations based 
on autoantibody profiles seems particularly informative in patient sera 
recognising box C/D snoRNPs.
erythematosus (SLE), systemic sclerosis (SSc), 
Sjögren’s syndrome (SS), polymyositis (PM) 
and dermatomyositis (DM). Antibodies tar-
geted to nucleolar autoantigens such as fibril-
larin, Th/To, PM-Scl, NOR-90/UBF, RNA 
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polymerase I, Ku and DNA topoisomerase I 
(Scl-70) are most frequently found in patients 
suffering from SSc or SSc overlap syndromes 
(reviewed in ref. (68,139,143,144)). The occur-
rence of these antibodies in patient sera is help-
ful in establishing the diagnosis and prognosis 
of the disease. For example, autoantibodies 
directed against DNA topoisomerase I identify 
a subgroup of SSc with early diffuse disease 
and pulmonary involvement (reviewed in ref. 
(139)) and autoantibodies against fibrillarin 
identify a subgroup of SSc with a poor progno-
sis (145).
In the past decade, our understanding of 
nucleolar processes, the most prominent of 
which is the biogenesis of ribosomes, and the 
macromolecular complexes involved increased 
dramatically. It has been shown that the pre-
cursor ribosomal RNA, encoding mature 18S, 
5.8S and 25S rRNA is extensively processed 
and modified (reviewed in ref. (4,5,89)). The 
most important trans-acting factors in these 
processes are the small nucleolar ribonucleo-
protein particles (snoRNPs). These snoRNPs 
can be divided in three groups based on con-
served sequence elements in their RNA compo-
nents: box C/D snoRNPs, box H/ACA snoRNPs 
and RNase MRP/RNase P (3), reviewed in ref. 
(4,5), see Figure 1.
Most of the box C/D snoRNPs have been 
demonstrated to function in the 2’-O-ribose 
methylation of pre-rRNA, whereas U3, U8, U13 
and U22 box C/D snoRNPs have been demon-
strated or suggested to function in the cleavage 
of pre-rRNA at the 5’- and 3’-end of mature 18S 
rRNA (reviewed in ref. (4,5)). Up to now three 
proteins have been identified that are shared 
by this class of snoRNPs: fibrillarin, Nop56 
and Nop5/58 (13-15). The box H/ACA snoRNPs 
have been implicated in the conversion of uri-
dine residues in pre-rRNA to pseudouridines 
(3,17) (see Figure 1). At present, four proteins 
have been shown to specifically associate 
with this class of snoRNPs: hGar1, Nap57/
dyskerin, hNHP2 and hNOP10 (18-20). The 
RNase MRP and RNase P complexes contain 
the still uncharacterised Th/To autoantigen 
(61,63,64)) and are the only representatives of 
the third class of snoRNPs. Both ribonucleo-
protein particles function as endoribonucleases 
and have been shown to function in the clea-
vage of pre-rRNA to mature rRNA and the pro-
cessing of pre-tRNA, respectively (reviewed in 
ref. (118)) (see Figure 1).
The aim of this study was to assess whether 
these three classes of small nucleolar ribonu-
cleoprotein complexes are targeted by autoan-
tibodies present in sera of patients suffering 
from systemic autoimmune diseases. The clini-
cal relevance of the occurrence of these autoan-
tibodies was investigated using chart reviews 
of these patients.
Results
Anti-nucleolar patient sera recognise 
various small nucleolar RNPs
To determine the presence of autoanti-
bodies directed against small nucleolar ribo-
nucleoprotein complexes a random serum 
collection was tested for the presence of anti-
nucleolar antibodies by immunofluorescence 
using HEp-2 cells as described previously (146). 
The 172 anti-nucleolar sera obtained were fur-
ther analysed by immunoprecipitation using 
a total HeLa cell extract. Co-precipitating 
RNAs were isolated and analysed by northern 
blot hybridisation for the presence of RNase 
MRP/RNase P RNA, U3, U8 and U22 (box 
C/D) snoRNAs and U17 and E3 (box H/ACA) 
snoRNAs. We also analysed for reactivities 
directed to the U1 snRNP complex (probing for 
U1 snRNA) and the Ro RNPs (probing for Y1 
scRNA) since these activities are common in 
mixed connective tissue disease and Sjögren’s 
syndrome/SLE, respectively.
A typical example of a northern blot 
analysis is depicted in Figure 2. The upper two 
panels show that in most cases sera that immu-
noprecipitate RNase MRP RNA also precipitate 
RNase P RNA (lanes 2, 4, 13 and 14), although 
one serum appeared to specifically recognise 
RNase MRP (lane 17). The recognition of both 
the RNase MRP and RNase P complexes is 
generally referred to as Th/To specificity. Lane 
11 shows an example of a serum recognising 
U3, U8 and U22 box C/D snoRNPs, suggesting 
Table I. Summary of northern blot hybridisa-
tion data
• A patient is referred to as Box C/D snoRNP 
specific, when U3, U8 and U22 snoRNA are 
immunoprecipitated by the patient serum
•• In addition to the 14 patient sera that 
recognise both RNase MRP and RNase P, 
one serum has been found that appears to 
recognise RNase MRP only.
Small nucleolar  Total group Diagnosed patient
ribonucleoprotein   data group
complexes n=172 (100%) n=100 (100%)
Box C/D snoRNPs • 16 (9%) 8 (8%)
U3 snoRNP only 17 (10%) 5 (5%)
U8 snoRNP only 8 (5%) 6 (6%)
Box H/ACA snoRNPs 1 (0.5%) 1 (1%)
Th/To (RNase MRP/RNase P) 14 (8%) •• 7 (7%)
other specificities  
U1 snRNP specific 15 (9%) 9 (9%)
U1/Y1 overlap 8 (5%) 5 (5%)
Y1 scRNP specific 23 (13%) 15 (15%)
PM/Scl-100 44 (26%) 14 (14%)
no activities found 61 (35%) 47 (47%)
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Figure 1. Schematic representa-
tion of the structure and function 
of autoantigenic small nucleolar 
ribonucleoprotein complexes. In 
the nucleolus (light blue) the 
biogenesis of ribosomes takes 
place. Three of the four ribosomal 
RNAs (18S, 5.8S and 25/28S) 
are synthesised as one large pre-
cursor. This precursor rRNA is 
modified at specific positions by 
2’-O-ribose methylation (Me) and 
conversion of uridines to pseu-
douridines (Ψ). Ribose methyl-
ation is mediated by box C/D 
snoRNPs (bottom left), whereas 
pseudouridylation is mediated by 
box H/ACA snoRNPs (bottom 
middle). The Th/To autoantigen 
(RNase MRP and RNase P) 
cleaves the precursor rRNA 
between the 18S and 5.8S and 
between the 5.8S and 25/28S 
rRNA sequences, respectively 
(bottom right). For a more 
complete overview see 
(5,12,89,162).
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that a polypeptide that is common to this 
class of snoRNPs is autoantigenic. Lane 17 sug-
gests that a protein common to the box H/ACA 
snoRNPs is autoantigenic as well, because both 
box H/ACA snoRNPs E3 and U17 are immuno-
precipitated by this patient serum.
Table I summarises the results of the nor-
thern blot analyses and the occurrence of auto-
antibodies against PM/Scl-100, as detected by 
ELISA analyses of this group of 172 anti-nucleo-
lar patient sera. These data will be described 
below in more detail for each of the snoRNPs.
Anti-nucleolar activity is found in patients 
suffering from SLE, SSc, RA and primary RP
Clinical information of 100 patients with 
anti-nucleolar activity was obtained by chart 
review. The recognition of nucleolar complexes 
by autoantibodies in this patient group is speci-
fied in Table I. A comparison of the occurrence 
of these autoantibodies in this group (n=100) 
with that in the total group (n=172) shows that 
the patient data group is a good representation 
of the total group.
Table II shows the diagnoses of the patients 
in this group. As expected, based on literature 
data, patients with anti-nucleolar antibodies 
suffer from SSc (n=14), PM (n=2), DM (n=2), 
primary RP (n=10) and SSc-overlap syndromes 
(n=2). Surprisingly, anti-nucleolar antibodies 
were also found in patients diagnosed with 
SLE (n=11), SS (n=4), RA (n=20), MCTD 
(n=4) and a group of different other diseases 
(n=27), including gout, M. Buerger, M. Kahler, 
M. Reiter, Crohn’s disease, ankylosing spondy-
litis.
Fibrillarin is autoantigenic in patient 
sera recognising box C/D snoRNPs
In 9% of the anti-nucleolar patient sera 
(see Table I), autoantibodies co-precipitating 
box C/D snoRNAs were found (a serum is 
designated anti-box C/D snoRNP, when U3, U8 
and U22 snoRNAs are all immunoprecipitated). 
10
%
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t
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Figure 2. Northern blot analysis of anti-nucleolar sera. Immunoprecipitations using total HeLa cell extract with 21 patient sera 
(lanes 1-21) are shown. Co-precipitated RNAs were isolated and analysed by northern blot hybridisation with probes specific for 
RNase P RNA, RNase MRP RNA, U3 snoRNA, U17 snoRNA, E3 snoRNA, U8 snoRNA and U22 snoRNA as indicated on the 
right of each panel. RNA isolated from total cell extracts (10% input) was analysed in the left and right lanes. Table II. Diagnoses of patients with anti-nucleolar autoantibodies
 Total  Box C/D U3 only U8 only  Box H/ACA  Th/To
      (RNase MRP/P)
 n=100 n=8 n=5 n=6 n=1 n=7
Syndromes
SLE 11 3    1
SSc 14 1    2
SS 4     
PM 2   1  1
DM 2  1   
RA 20 1 2 2  
MCTD 4     
primary RP 10 2    2
Overlap syndromes
RA/SLE 1     
RA/SS 2     
SLE/SS 1     
SSc/SS 1     
DM/SSc 1     
Other 27 1 2 3 1 1
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appear to be associated with two patients 
groups with different manifestations. The group 
of anti-fibrillarin positive sera seems to be asso-
ciated with a more poor prognosis than the 
anti-fibrillarin negative patient sera, suggest-
ing that such analyses may contribute to a 
more reliable prognosis for these patients.
Identification of box H/ACA snoRNPs as 
a new nucleolar autoantigen
One anti-nucleolar patient serum was found 
to co-immunoprecipitate both U17 and E3 box 
H/ACA snoRNAs, indicating that also compo-
nents of this class of snoRNPs (albeit with low 
frequency) can be autoantigenic in patients 
suffering from connective tissue diseases (see 
Figure 2, lane 17, and Table I). At this 
moment, four proteins have been identified 
that are known to associate with all box H/ACA 
snoRNPs: hGar1, NAP57/dyskerin, hNHP2 and 
hNOP10 (18-20). Immunoprecipitation of these 
four proteins, translated in vitro, did not 
generate conclusive data on the direct target of 
the autoantibodies (our unpublished observa-
tions). It is possible that the autoantibodies 
in this serum react with another, yet unidenti-
fied, common subunit of box H/ACA snoRNPs. 
Chart review of this patient learned that this 
patient suffered from gout and polyarticular 
non-erosive arthritis.
Anti-Th/To autoantibodies are associ-
ated with different connective tissue dis-
eases
The Th/To autoantigen (RNase MRP/RNase 
P) has been reported to be recognised by 
SSc patients with a frequency of 10-14% 
(62,67,68,139,148). In this population of random 
Three proteins have been reported to be asso-
ciated with all box C/D snoRNPs (fibrillarin, 
Nop56 and Nop5/58) suggesting that one or 
more of these proteins is targeted by these 
sera. Previous studies indicated that sera with 
anti-nucleolar activity frequently contain auto-
antibodies against fibrillarin (145,147). To 
investigate the recognition of fibrillarin by the 
patient sera precipitating the box C/D snoRNPs, 
western blot analyses were performed using 
recombinant fibrillarin. As shown in Figure 
3, lanes 11-18, all patient sera that are able 
to immunoprecipitate box C/D snoRNPs effi-
ciently recognise fibrillarin, whereas with sera 
that recognise merely U8 or U3 snoRNP only 
background levels of reactivity were observed 
(lanes 1-10). The former group will now be 
referred to as anti-fibrillarin positive patient 
sera.
Anti-fibrillarin antibodies have been 
reported to occur in patients suffering from 
primary RP, SSc and SSc-overlap syndromes 
(68,145). Chart review confirmed that anti-
fibrillarin positive sera (n=8) can be found in 
SSc (n=1) and primary RP (n=2), see Table II. 
In addition, anti-fibrillarin positive sera were 
found in patients suffering from SLE (n=3), RA 
(n=1) and UCTD (n=1). Clinical manifestations 
of anti-fibrillarin positive patients were studied 
in more detail, see Table III. Anti-fibrillarin 
positive patient sera appeared to be particu-
larly associated with manifestations suggest-
ing a more poor prognosis, such as pleuritis, 
pericarditis, renal failure and myocarditis.
Identification of reactivity to U3 and U8 
snoRNPs only
The analyses of this cohort of anti-nucleo-
lar sera showed for the first time that 5-10% 
of these sera contained reactivity to either U3 
snoRNP only or to U8 snoRNP only, see Table I. 
These sera do not show detectable reactivity to 
fibrillarin, as illustrated in Figure 3, lanes 1-10. 
The anti-U3 snoRNP only antibodies (n=5) 
were found to be present in patients suffering 
from DM (n=1), RA (n=2), RA with sicca com-
plaints (n=1) and fibromyalgia (n=1), see Table 
II. Anti-U8 snoRNP only antibodies (n=6) 
are found in patients suffering from similar 
diseases, i.e. PM (n=1), RA (n=2), deforming 
osteoarthritis (n=1), arthralgies (n=1) and JCA 
(n=1). In more detail, the patient sera that 
recognise U3 or U8 snoRNP only (n=11) are 
associated with arthritis (n=7), polymyositis 
(n=2), RP (n=2) and sicca complaints (n=4, e.g. 
xerostomia and xerophthalmia), see Table III. 
In addition, anti-U8 snoRNP only patient sera 
associate with pleuritis (n=1), anemia (n=3) 
and lymphopenia (n=3), diabetes (n=1) and 
vasculitis (n=1).
In summary, anti-fibrillarin positive and 
negative anti-box C/D snoRNP patient sera 
U8 specific U3 specific Box C/D
1 2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 185 19 20 21 22
control sera
43 kDa-
30 kDa-
Figure 3. Recognition of fibrillarin by anti-nucleolar sera. Recombinant fibrillarin was separated by SDS-PAGE and transferred to 
nitrocellulose membranes. Strips of these membranes were incubated with patient sera that co-immunoprecipitate either U8 
snoRNA (lanes 1-5) or U3 snoRNA (lanes 6-10) or all box C/D snoRNAs analysed (U8, U3 and U22 snoRNAs) (lanes 11-18) or 
control sera (lanes 19-22). The position of molecular weight markers is indicated on the left.
Table III. Clinical manifistations per group of anti-nucleolar patient sera
Clinical manifistations Total  Box C/D  U3 only  U8 only  Box H/ACA  Th/To
      (RNase MRP/P)
 n=100 n=8 n=5 n=6 n=1 n=7
      
Butterfly rash 9 1    
discoid lupus 3 1    1
increased photosensitivity 6     
arthritis 44 3 3 4 1 
pleuritis 5 2  1  
pericarditis 5 2    
renal disease 13 2    
neurologic disorders 5     
anemia 33 3  3  1
lymphopenia 20 2  3  2
prox scleroderma 6     
bilat basale longfibrose (X-thorax) 9 1    1
pulmonal hypertension 2     
Raynaud’s phenomenon 45 4 1 1  5
decreased co-diffusion 17 2  1  4
decreased esophagus motility 16 2    4
decreased intestine motility 4     
sclerodactyly 16 2    2
digital pitting scars 17 4    3
sicca complaints 48 4 3 1  6
polymyositis 8  1 1  2
diabetes mellitus 3   1  
vasculitis 18   1  2
myocarditis 3 1    
116 C h a p t e r  7 117
7
C h a r a c t e r i z a t i o n  o f  A u t o a n t i b o d i e s  a g a i n s t  s n o R N P s
have been reported not only in SSc, but also 
in MCTD, SLE, RA and SS (145,147). Our data 
indicate that two types of anti-box C/D snoRNP 
autoantibodies exist, one that recognises fibril-
larin (i.e. precipitating the whole group of 
box C/D snoRNPs) and another that recognises 
individual box C/D snoRNPs such as U3 and 
U8 snoRNP (this group is also referred to as 
U3 only or U8 only). This distinction may be 
important for the diagnosis and prognosis of 
these patients. Our data and the work of Arnett 
and coworkers (145) indicate that antibodies 
directed to fibrillarin are associated with severe 
SSc, whereas antibodies directed to individual 
box C/D snoRNPs appear to be associated with 
arthritis and polymyositis.
The presence of autoantibodies against 
fibrillarin in the group of sera targeting box 
C/D snoRNPs does not implicate that auto-
antibodies directed to other protein subunits 
shared by all box C/D snoRNPs do not exist. 
These putative autoantigens include Nop5/58 
and Nop56 (14,15). Possible targets of patients 
sera directed against U3 snoRNP only include 
U3-55K, Mpp10 and human homologues of 
IMP3 and IMP4 (113,150,151). Other patient 
sera could be identified as U8 snoRNP only. 
At this moment, only one protein is known 
that specifically binds U8 snoRNP: X29 (152). 
The X29 protein has been identified in Xeno-
pus laevis, but a homologous human protein 
is likely to exist as well. The identification of 
the primary targets of box C/D snoRNP spe-
cific autoantibodies awaits a better and more 
complete characterisation of the composition 
of these ribonucleoprotein complexes.
Autoantibodies against box H/ACA 
snoRNPs were detected in one patient suffer-
ing from gout and arthritis. The existence of 
autoantibodies against this class of snoRNPs 
has never been reported before. Four proteins 
are known to specifically associate with this 
class of box H/ACA snoRNPs: hGar1, NAP57/
dyskerin, hNHP2 and hNOP10 (18-20). We 
were unable to obtain conclusive data on which 
of these proteins is autoantigenic. We also can 
not exclude the possibility that post-trans-
lational modifications are important for the 
recognition of (one of) these proteins by autoan-
tibodies. Post-translational modifications (e.g. 
methylation or deimination of arginines) have 
been shown to be of critical importance for the 
efficient recognition of Sm proteins and RA-
specific autoantigens (153,154). Alternatively, 
a yet unidentified box H/ACA snoRNP associ-
ated protein may be targeted by these auto-
antibodies. The generation of autoantibodies 
directed to box H/ACA snoRNPs appears to be 
a rare phenomenon. Northern blot analysis, 
however, may not be sensitive enough to detect 
low-titered autoantibodies in anti-nucleolar 
sera, because box H/ACA snoRNPs are much 
less abundant than for example U3 and U8 
snoRNPs. Both the further characterisation of 
the composition of box H/ACA snoRNPs and 
the identification of more patient sera with 
anti-box H/ACA snoRNP reactivities will be 
required to shed more light on the specificity 
of this new class of autoantibodies.
The observed prevalence of autoantibodies 
directed against the Th/To-autoantigen in SSc 
patients is in accordance with reported fre-
quencies (8-14%) ((67,145,148,149), reviewed 
in ref. (139,143)). Because we analysed anti-
nucleolar patient sera rather than SSc sera, 
the present results demonstrate that anti-Th/To 
antibodies are also present in other autoimmune 
diseases: e.g. SLE and PM. Both Yamane and 
coworkers and Okano and coworkers showed 
that anti-Th/To antibodies are associated with 
anti-nucleolar sera, we detected autoantibo-
dies with anti-Th/To specificity in 8% of the 
cases (n=14). Co-precipitation of RNase MRP 
and RNase P RNAs was also observed in 15 
other anti-nucleolar patient sera, but these sera 
precipitated Ro RNP complexes as well. This 
strongly suggests that anti-La antibodies are 
responsible for the precipitation of the RNase 
MRP and RNase P RNAs by these sera, because 
the La autoantigen is known to associate 
(transiently) with all RNA polymerase III pro-
ducts, including the RNAs associated with 
RNase MRP, RNase P and Ro RNPs.
The well known association of the anti-
Th/To specificity with SSc (n=2) and primary 
RP (n=2) is supported by our data. In addi-
tion, anti-Th/To antibodies were found in one 
patient with SLE, one patient with PM and one 
patient with severe weight loss. Chart review 
of these seven patients showed that the Th/To 
autoantigen is primarily associated with mani-
festations of RP (n=5), decreased co-diffusion 
(n=4), esophagus hypomotility (n=4) and with 
sicca complaints (n=6, of which 5 suffered 
from xerophthalmia).
40% of anti-nucleolar reactivity remains 
uncharacterised
In addition to antibodies targeted to small 
nucleolar ribonucleoprotein complexes, anti-
bodies to the PM/Scl-100 autoantigen, which 
are also known to result in nucleolar staining 
in immunofluorescence, were detected as well 
(n=44, see Table I). PM/Scl-100 reactivity was 
found in patients suffering from DM, PM, SSc 
and DM/SSc overlap syndromes, as has been 
reported before ((149) and references therein). 
In addition, reactivity against PM/Scl-100 was 
detected in sera from patients suffering from 
RA, SLE, SS and MCTD, see Table I.
All anti-nucleolar patient sera were further 
tested for the presence of reactivity against 
the non-nucleolar U1 snRNP and Ro RNPs. 
Antibodies directed against U1 snRNP were 
detected in 23 sera, whereas 31 contained 
anti-Ro RNP reactivity. The presence of these 
antibodies associated with SLE, MCTD and 
SLE, SSc and SS, respectively. However, in 61 
of the anti-nucleolar sera none of the tested 
activities could be detected, suggesting that 
these sera recognise other (possibly yet unchar-
acterised) autoantigens.
Discussion
This study describes the analysis of a group 
of 172 anti-nucleolar sera from autoimmune 
patients for the presence of autoantibodies 
directed against small nucleolar ribonucleo-
protein particles. Other investigators have 
previously reported that the existence of anti-
nucleolar reactivities is particularly associated 
with SSc (68,139,143,145). In the present study 
a random collection of patient sera was screened 
for the presence of anti-nucleolar reactivities 
and chart review of 100 of these patients indi-
cated that the occurrence of anti-nucleolar 
reactivity is not restricted to SSc, but is also 
found in patients suffering from other disea-
ses. The association of anti-nucleolar reactivi-
ties with SLE, PM/DM and RA has not been 
reported before and thus lowers the relevance 
of anti-nucleolar autoantibody detection for 
diagnostic purposes.
Autoantibodies precipitating U3 snoRNA 
and possibly other box C/D snoRNPs have been 
reported in 5-10% of sera from patients suf-
fering from primary RP, SSc and SSc-overlap 
syndromes (68). Anti-fibrillarin autoantibodies 
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localised SSc (67,148). In our study, anti-Th/To 
antibodies are associated with Raynaud’s phe-
nomenon, decreased co-diffusion, esophagus 
hypomotility and xerophthalmia, supporting 
the previous findings. The major autoantigen 
associated with the Th/To antigen is referred to 
as Th-40. This 40 kDa protein has been iden-
tified using immunoprecipitation of proteins 
from radioactively labelled cell extracts and 
UV-crosslinking analysis (42,72,75). Although 
three proteins (hPop1, Rpp30 and Rpp38) of 
the RNase MRP and RNase P complexes have 
been reported to be recognised by Th/To-sera, 
none of them seems to represent the Th-40 
autoantigen ((77,78), reviewed in ref. (118)), 
leaving the question on the identity of this 
autoantigen unanswered.
Surprisingly, a large group of patient sera 
(35-47%) did not recognise any of the tested 
small (nucleolar) ribonucleoprotein complexes. 
It seems likely to assume that in these sera auto-
antibodies are present directed to other nucleo-
lar autoantigens such as Ku, NOR-90/UBF, RNA 
polymerase I or DNA topoisomerase I. These 
proteins/complexes have been reported to be 
autoantigenic in 10-25% of SSc sera (reviewed 
in ref. (139,143)). Future research will have to 
evaluate whether these or other as yet uniden-
tified autoantigens are recognised by patient 
sera that do no recognise small nucleolar ribo-
nucleoprotein complexes.
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Patients and methods
Patients
Most patient sera were obtained from the department 
of Rheumatology of the University Medical Centre St. 
Radboud, Nijmegen and the St. Maartens Hospital, 
Nijmegen and routinely tested for the presence of anti-
nucleolar autoantibodies by indirect immunofluores-
cence on HEp-2 cells in a 40-fold dilution (146).
A total of 172 sera that displayed anti-nucleolar reacti-
vity were collected. From 100 patients clinical informa-
tion could be obtained by chart review (26 from the St. 
Maartens Hospital and 74 from the University Medical 
Centre St. Radboud). The patients’ age and sex were 
recorded along with clinical findings, which include all 
signs, symptoms and serology contributing to the clas-
sification criteria of RA (155), SLE (156), SSc (157), SS 
(158) and diagnostic criteria of DM and PM by Peter 
and Bohan (159,160). Also often occurring non-specific 
signs such as RP, sicca complaints, pulmonary function 
test abnormalities, pulmonary hypertension, motility 
abnormalities of esophagus and gut, myocarditis and 
other (autoimmune) diseases such as diabetes, vasculitic 
disorders, thyreoiditis, spondyalarthropathies and gout 
were recorded.
snoRNP immunoprecipitation analysis
Total HeLa cell extracts were prepared as described 
previously (116). For each immunoprecipitation with 
patient serum, 20 µl serum was incubated with 20 µl of 
a 50% suspension of protein A-agarose beads in IPP500 
(500 mM NaCl, 10 mM Tris-HCl pH 8.0, 0.05% NP-40) 
for 1 h at room temperature. Beads were washed two 
times with IPP500 and once with IPP150 (150 mM NaCl, 
10 mM Tris-HCl pH 8.0, 0.05% NP-40). HeLa extract 
was added, the mixture was incubated for 2 hours at 4°C 
and the beads were washed three times with IPP150. To 
analyse co-precipitating RNAs, the RNA was isolated by 
phenol-chloroform extraction and ethanol precipitation. 
RNAs were resolved on a denaturing polyacrylamide 
gel and blotted onto Hybond-N membranes (Amersham 
Pharmacia Biotech). Northern blot hybridisations with 
32P-labeled oligonucleotides was performed as described 
by Sambrook et al. (161). The following oligonu-
cleotides were used to analyse the following RNAs: 
RNase P: 5’-GGG-AGA-GCC-CTG-TTA-GGG-CCG-CCC-3’; 
RNase MRP: 5’-CCC-CGT-GTG-GTT-GGT-GCG-CGG-
ACA-C-3’; U3: 5’-CGA-AGC-TTG-TAC-CAC-TCA-GAC-
CGC-GTT-CTC-3’; U8: 5’-CAT-GTT-CTA-ATC-TGC-CCT-
CCG-GAG-GAG-G-3’; U22: 5’-ACA-GGC-TCT-GGG-ACT-
AGG-ACA-GAG-AG-3’; U17: 5’-AGA-GCC-CTA-TGC-
TCC-CCT-ACG-CCA-C-3’; E3: 5’-GCA-GGG-GGA-ACG-
ACA-ACA-CAG-CAC-3’; U1: 5’-GCG-CGA-ACG-CAG-
TCC-CCC-ACT-ACC-AC-3’; Y1: 5’-CTA-AGC-TTA-AAA-
GAC-TAG-TCA-AGT-GCA-GT-3’.
Western blot analysis of hFib
Recombinant His6-tagged human fibrillarin was 
expressed in and purified from Sf-9 cells using the Bac-
to-Bac baculovirus expression system according to the 
manufacturer’s protocol (Gibco-BRL). For western blot 
analysis approximately 1 ng of recombinant protein 
was loaded on a 13% SDS-PAGE and transferred to 
nitrocellulose. Patient sera were used in a 5000-fold 
dilution. Detection was performed using horseradish 
peroxidase-conjugated rabbit-anti-human IgG (Dako 
Immunoglobulins) as secondary antibody and visualisa-
tion by chemiluminescence.
Anti PM/Scl-100 autoantibodies
Reactivity with PM/Scl-100 was determined by ELISA 
as described previously (149).
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Introduction
Pleiotropy, that is, multiple phenotypic 
manifestations of a single genetic defect, is a 
hallmark of McKusick-type metaphyseal chon-
drodysplasia or cartilage-hair hypoplasia (CHH) 
[MIM #250250] (163). The most prominent 
characteristic of this recessively inherited dis-
order is disproportionate short stature with 
adult heights ranging from 104 to 149 cm. 
Other common features include hypoplastic 
hair, ligamentous laxity, defective immunity, 
hypoplastic anemia, and neuronal dysplasia 
of the intestine. Manifestations occurring in 
a smaller proportion of affected individuals 
include congenital megacolon (Hirschsprung’s 
disease), and predisposition to lymphoma and 
other cancers. The variation in clinical sever-
Abstract
The recessively inherited developmental disorder, cartilage-hair hypoplasia (CHH) is highly pleiotropic with manifestations inclu-ding short stature, defective cellular immunity, and predisposition 
to several cancers. The endoribonuclease RNase MRP consists of an RNA 
molecule bound to several proteins. It has at least two functions, namely, 
cleavage of RNA in mitochondrial DNA synthesis and nucleolar cleaving of 
pre-rRNA.
We describe numerous mutations in the untranslated RMRP gene that 
cosegragate with the CHH phenotype. Insertion mutations immediately 
upstream of the coding sequence silence transcription while mutations in 
the transcribed region do not. The association of protein subunits with 
RNA appears unaltered. We conclude that mutations in RMRP cause CHH 
by disrupting a function of RNase MRP RNA that affects multiple organ 
systems.
ity is remarkable both between and within sib-
ships (163-165). CHH was first described in the 
Old Order Amish where it is a common cause 
of short-limbed short stature (163,166). The 
incidence among the Amish was calculated as 1 
in 1340 implicating a carrier frequency as high 
as 1:19 (167). Another founder population, the 
Finns, displays a similar gene enrichment with 
a calculated carrier frequency of 1:76 (164). 
Cases have been described in numerous other 
populations; however, there is no precise mea-
sure of its worldwide incidence (164). A locus 
responsible for CHH was mapped to a region on 
the short arm of chromosome 9 eight years ago 
(168), and subsequently shown to account for 
most or all CHH (locus homogeneity) (167,169). 
The critical region has been reduced to less 
than 1 Mb of DNA by linkage and linkage dis-
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equilibrium analysis (170) and physical map-
ping (171). However, in spite of intensive study 
of candidate genes in the critical region ((172); 
unpublished data by the present authors) the 
gene has been elusive (166). Here we describe 
mutations in the RMRP gene causing CHH. 
This study describes disease-causing muta-
tions in a nuclear gene encoding a structural 
RNA molecule. The untranslated RMRP gene 
is transcribed by RNA polymerase III, encodes 
the RNA component of a ribonucleoprotein 
endoribonuclease (66), and is located in the 
CHH critical region ((173), and results shown 
here). Normally the RNase MRP complex is 
involved in multiple cellular and mitochon-
drial functions. In the nucleolus this endonu-
clease partakes in the processing of pre-rRNA 
whereas in the mitochondrion it cleaves the 
RNA primers responsible for DNA replication 
((27,174), reviewed in ref. (118)). As we did 
not find any disturbances in the association 
of specific proteins with RNase MRP RNA 
from CHH patients, the disease-causing func-
tional impairment of the RMRP gene product 
remains to be characterized. The existence of 
one or more elusive additional substrates for 
this endonuclease has been postulated (5,41). 
Our findings provide a first step toward an 
improved understanding of these processes 
leading to the pleiotropic phenotypic manifes-
tations of CHH.
Results
Genetic map of the CHH region
To refine the genetic map of the CHH region 
in chromosome 9p13 beyond our previous map 
(171), we developed new polymorphic markers 
(Table 1). Haplotypes were constructed of 116 
affected chromosomes from 16 multiplex and 
42 uniplex Finnish CHH families using 23 poly-
morphic markers. Among the 116 haplotypes, 
96 (83%) shared alleles with the presumptive 
ancestral haplotype, suggestive of a prevalent 
shared founder mutation. A graphic representa-
tion of those 78 haplotypes in which all alleles 
could be unequivocally assigned to the 23 
markers is shown in Figure 1A. The “ancestral” 
haplotype shown uppermost was observed 
in 18 chromosomes, whereas all other chro-
mosomes showed a reduction in the length 
of the shared haplotype as evidence of histori-
cal recombinations. These historical recombi-
nations allowed us to tentatively narrow the 
critical CHH region to the interval between the 
TESK1 A/G and D4S markers. This region was 
later shown to represent 145 kilobases of DNA. 
The degree of linkage disequilibrium between 
markers and the disease phenotype can give a 
hint about the precise location of the sought 
gene (175) and has proven a powerful tool in 
the positional cloning of numerous genes in 
the Finnish population (176). The higher the 
Pexcess value, the stronger is the linkage dis-
equilibrium and the closer is the marker to the 
disease gene (177). Within the above critical 
region, Pexcess varied between 0.70 and 0.92 
being highest at the adjacent markers TP2A 
and TA13S (Figure 1A).
Genomic and transcript map of the 
CHH region
The CHH critical region as defined above 
was contained in three overlapping BAC clones, 
468J10, 199G9, and 497J14 as determined pre-
viously (Figure 2 in (171)). The region was 
known to contain several genes and transcripts; 
however, in an effort to study all genes, we 
shotgun-sequenced the three BAC clones and 
assembled the middle part of the sequence 
into three contigs, 71.6 kb, 187.6 kb, and 
122.7 kb in length (accession nos. AF334828 to 
AF334830). The 145 kb CHH critical region was 
fully covered by the largest contig and con-
tained at least 11 genes as shown in Figure 1B.
Mutational analysis in CHH patients
Using available bioinformatics tools and 
existing databases, we mapped and assembled 
11 genes in the critical region that we had 
sequenced (Figure 1B). We analyzed all 11 
genes by a combination of reverse transcrip-
tase PCR cDNA sequencing, single-strand con-
formational polymorphism (SSCP), and direct 
genomic PCR sequencing in a panel of 7 
CHH patients and one noncarrier control. 
No potentially disease-causing mutations were 
found in the coding regions of TESK1, CD72, 
SIT, AK001187, MN/CA9, TPM2, TLN, LZIP, 
AAF53384 homolog, and KIAA0258 genes (data 
not shown). However, the finding of an inser-
tion in the RMRP gene in one CHH patient 
focused our attention on RMRP.
Mutations in the RMRP gene
The primary transcript of RMRP (accession 
no. M29916) comprises 267 nucleotides and 
Name Location Type of PCR Primer Sequences (5’-3’) PCR Product SSCP
  Polymorphism  Size (bp) Conditions
16P1 Centromeric to dup TGCATGCA AAGGATCCTCGCAGCTTTC 182/190 6% Sequagel
 AB002373  GCACCCTGGTCAATGTTTTC
AB12GS AB002373 A/G AGTGGGCCCATATGAAACAC 118 0.7 x MDE
   CCCCTTTGAGTGGTTGCTTAC  4 W 15 hr
Del13 CD72 13 nt deletion GAGGCATGGGGAGTCCAG 103/90 2% SeaKem
   GTGGAGGAACTTTCATCCCAG
SIT45S SIT intron 3 T/C GGCTGTGACGCTGCTATTTC 223 0.5 x MDE
   AATGCAGGTTCCCATACAGC  3 W 17 hr
TP2A TPM2 exon 2A G/A CGCTTCTCTCCCCTACAATAG 270 0.7 x MDE
   GACAGAGGGGACTTGGTCAG  5 W 18 hr
TA13S nt 3806 in TLN cDNA C/T CTGTGTCAGCTGCCTACCTG 143 1 x MDE
   AGAGGCCTGGCATTCTTTG  6 W 18 hr
D4S KIAA0582 G/A CATCCTCCTCCAAGAATGGAC 187 0.8 x MDE
   AAACCTCAGCCCTGGCAC  6 W 18 hr
D6S KIAA0582 G/A AATCAGGATCCATTACACCCTC 137 0.7 x MDE
   CAGCTTCTCCCTCCCAATC  4 W 17 hr
CA1 Between AC repeat TTCCTTCTGTGTTGGGTGTG ~140 6% Sequagel
 37D7T7 and Z38966  TTCCTATTGAGCCCGATTTG
XL6S Telomeric to EST-C G/A AAGGCTGAGTCTGGGTGATTC 152 0.8 x MDE
   AAGGCAAACAGGGGATTTTC  5 W 17 hr
XL2S Telomeric to EST-C G/A AGACTGAGGTCAGAGGGGGAAG 145 0.8 x MDE
   CGCAAGGCTGGTTCTCTGAG  5 W 17 hr
XL1S Telomeric to EST-C T/C CAAAAGCCCGTGTTGTTCATC 166 0.8 x MDE
   GGTGGAGACAGAGGAGCTGTC  5 W 18 hr
CCS EST-C G/A CATTCGGCACATGAGATACG 145 1 x MDE
   CAGGACTGTGACGTGGAGAG  6 W 17 hr
TG2S T64224 C/T CAGAACCAGCATCATAG 187 1 x MDE
   GGATCCTTGTTATTGGGACAG  5 W 17 hr
Table 1. The new polymorphic markers used in genetic mapping. The order is from the telomere to the centromere.
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is present in the genome as a single copy 
(27). RMRP is transcribed by RNA polymerase 
III, which is active within the nucleoplasm 
(178). The RMRP promoter is a type III pro-
moter lacking intragenic promoter elements 
(178,179). A TATA box is located between -33 
and -25, and additional type III promoter ele-
ments are found between -67 and -57 (PSE 
element), -215 and -208 (octamer element), 
and between -231 and -225 (SP1 binding site) 
(180). We PCR amplified the entire ~1 kb 
RMRP region in four overlapping fragments, 
and searched for sequence variants by direct 
sequencing. The mutations are of two distinct 
types. The first category consists of insertions 
or duplications between 6 and 30 nucleotides 
long residing in the region between the TATA 
box and the transcription initiation site. As 
shown below, these mutations interfere with 
the transcription of RMRP. The second category 
consists of single nucleotide substitutions and 
other changes involving at most two nucleo-
tides. These reside in highly conserved resi-
dues of the transcribed sequence. Table 2 
summarizes the mutations found in those CHH 
patients and families in which a mutation of 
both alleles has been identified so far. Figure 
2 summarizes the location of these mutations. 
Of note is that while the insertion mutations are 
of somewhat different length and location, they 
all result in a lengthening of the important dis-
tance between the TATA box and the transcrip-
tion initiation site. Regarding the 4 different 
mutations in the transcribed sequence, we note 
that all are located at sites that are conserved 
in human, cattle, mouse, rat, and some even 
in Xenopus, Arabidopsis, or Saccharomyces sug-
gesting that they are functionally important 
(70,181). Moreover, nucleotides 98 and 262 
reside in positions predicted to show double-
stranded structure (70) whereas position 98 can 
be important for MRP40 (recently shown to 
be identical to Rpp38) protein binding (105). 
These features suggest that the mutations are 
extremely likely to cause functional distur-
bances. Among 70 CHH patients that have 
been studied for mutations so far, 55 harbor 
a mutation in both alleles of the RMRP 
gene. In all instances where samples from seve-
ral family members were available, the muta-
tions cosegregated with the disease phenotype 
assuming recessive inheritance. In 13 families 
with more than one affected child, all affected 
individuals had identical mutations. All 26 
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Figure 1. Genetic, physical, and transcript map of the chh region. A. Haplotypes of 78 affected chromosomes from Finnish CHH 
patients are shown. Alleles of the polymorphic markers are arbitrarily numbered. The uppermost haplotype encountered in 18 
chromosomes is considered “ancestral.” Portions of this haplotype that are shared on the remaining 60 chromosomes are shown 
in blue. The region shared by all haplotypes extends between markers TESK1 A/G and D4S and is depicted as the “CHH region.” The 
telomere is to the left. On top are shown the P
excess
 values depicting the degree of linkage disequilibrium between each marker and 
the disease phenotype. A peak at markers TP2A and TA13S is seen. An arrow indicates the location of the RMRP gene. B. Shown 
here is the middle region of the genetic map depicted in (A). Above the line are the 9 polymorphic markers; below the line are 
the transcripts. Among the genes in the CHH critical region the ones that were mapped there before the genomic sequence was 
obtained are marked in light blue, whereas the ones marked in dark blue were localized there based on the sequence we genera-
ted. RMRP is depicted in black. In addition to these genes, exon prediction and homologies to human and mouse coding sequences 
suggested one novel gene immediately centromeric to AK001187 (MG homolog). A promoter region near the 3’ end of TLN and 
several non-TLN ESTs were found to overlap the 3’ end of TLN. These findings may suggest an unknown gene overlapping TLN 
(TU region). After repeats were masked, exons of the putative genes were searched using FGENES and GRAIL-1.3 programs. Four 
exons were predicted for the MG homolog whereas three exons were predicted for the TU region. Using reverse transcription PCR, 
we determined that AK001187 and MG homolog belong to the same gene.
A
B
Patient Number Nationality Mutation in the Paternal Allele Mutation in the Maternal Allele
 1 •a Finnish 70A→G •b 70A→G
 2 •a Finnish •c 70A→G
 3 Finnish 70A→G 262G→T •d
 4 Finnish 262G→T •d 70A→G
 5 Finnish 70A→G dupTACTCTGTGA at –13 •e
 6 Finnish dupTACTCTGTGA at –13 •e 70A→G
 7 •a Swiss Two times dupACTACTCTGTGAAGC at -10 •f 98dupTG •f
 8 •a German 70A→G insCCTGAG at –6 •f
 9 Canadian 98dupTG •f 70A→G
10 English dupTCTGTGAAGCTGAGGAC at –3 •f 193G→A •g
Table 2. Mutations in the RMRP gene in CHH patients. •a Patients 1, 2, 7, and 8 refer to the ones described in Figures 3 and 4. 
•b Homozygosity for the 70A→G mutation has been diagnosed in a total of 42 Finnish CHH families, including 12 with more than 
one affected child and 30 with a single affected child. All of these carry modifications of the “ancestral” haplotype described in 
Figure 1. The 70A→G mutation has been detected in heterozygosity in 1 Finnish control sample out of 120 and in 2 out of 160 
non-Finnish control samples. •c This patient has uniparental disomy for chromosome 9 with two copies of the maternal, mutation-
carrying chromosome, and no paternal chromosome 9. •d The 262G→T mutation has been found in compound heterozygosity 
(with 70A→G) in a total of 6 Finnish CHH families, one of which has two affected children. The chromosomes carrying 262G→T 
share a haplotype that differs from that of the main “ancestral” one. The 262G→T mutation has not been detected in any of 
120 Finnish and 160 non-Finnish control individuals. •e The 10-nucleotide TACTCTGTGA duplication at position –13 occurs in 
heterozygosity in two Finnish families (patients 5 and 6). The chromosomes carrying this mutation share a haplotype that differs 
from the “ancestral” one. This and all other duplication-insertions have been searched for in 120 Finnish and 160 non-Finnish 
controls and not found. •f None of these mutations have been found in 120 Finnish and 160 non-Finnish controls. •g The 193G→A 
mutation has not been found in any of 112 Finnish and 93 non-Finnish controls.
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parents studied so far were heterozygous for 
one of the mutations found in the affected 
child(ren). Among 6 unaffected siblings of 
affected individuals either heterozygosity for 
a mutation (n=1) or homozygosity for the wild 
type sequence (n=5) was seen. Notably, in 
Finnish patients and parents the chromosomes 
carrying the main 70A→G mutation all had the 
main “ancestral” haplotype or modifications 
thereof (n=110). All 6 chromosomes carrying 
the 262G→T mutation shared a haplotype that 
differed from the main one, and both chro-
mosomes carrying the 10 bp duplication had 
another, “private” haplotype. In searching for 
these mutations in control individuals compris-
ing 120 anonymous blood donors from Finland, 
a panel of 61 non-Finnish controls representing 
various nationalities, and 99 Centre d’Etude 
du Polymorphisme Humain (CEPH; http://
www.cephb.fr) grandparents were screened. 
A single case of a control sample with one 
of these mutations was detected in Finland; 
a blood donor was heterozygous for 70A→G. 
As the carrier frequency of CHH in Finland 
is of the order of 1:76 (164), this finding was 
expected. Among 160 non-Finnish controls, it 
was found in two samples. These were grand-
parents of a CEPH family in which kinship 
between grandparents is likely. None of the 
other mutations were found in any control 
sample.
Reduced expression levels of RNase MRP
RNA expressed in some CHH patients 
cells derived from two patients with single 
nucleotide mutations in the transcribed region 
(patients 1 and 2; Table 2) and two patients 
with insertions (patients 7 and 8) were studied. 
As is shown in Figure 3, expression of RNase 
MRP RNA was found in all CHH patients. 
Using the level of expression of U3 snoRNA 
and U1 snRNA as references, RNase MRP RNA 
was less abundantly present in patients 7 and 
8 as compared to control cells. Quantitative 
analysis using a phosphorimager showed that 
the level of expression of RNase MRP RNA in 
patients 7 and 8 was reduced to 35-40% of the 
level expression in control cells. By contrast, 
MRP RNA was expressed in patients 1 and 2 
at a level comparable to that in the controls. In 
conclusion, these results suggest that the level 
of expression of RNase MRP RNA is reduced 
in the CHH patients with 5’ region insertions 
but not in CHH patients with merely intragenic 
mutations.
The reduced kevel of RNase MRP RNA 
is caused by silencing of one RMRP allele
Next we investigated whether the reduced 
expression seen in patients 7 and 8 was due 
to the silencing of one allele or a lower acti-
vity of both alleles. Both patients are com-
pound heterozygous for mutations (Table 2). 
In patient 7, the transcript was noted to be 
slightly larger than in the other CHH patients 
and the controls, as seen in lane 3 of Figure 
3. As the slight increase in transcript size 
suggested an addition of ~2 nucleotides, we 
hypothesized that the transcript emanated 
from the maternal allele that has a 2 bp duplica-
tion at position 98 (Table 2). To further study 
this phenomenon, we reverse transcribed RNA 
from patients 7 and 8 and a healthy control and 
then cloned and sequenced the cDNAs. The 
sequence of RMRP RNA in control cells was 
identical to that published by Topper and Clay-
ton (66) (accession no. M29916). In patient 7, 
all 10 clones analyzed showed the duplication 
of TG at position 98, while in patient 8, all 10 
clones sequenced showed the 70A→G muta-
tion. Thus, in these two patients, the alleles 
with 5’ region insertions were not expressed. 
Taken together with the fact that total expres-
sion levels in these two patients were only 
35-40% of the controls (Figure 3), it follows 
that only the alleles with intragenic mutations 
were expressed.
RNase MRP protein subunits associate 
with RNase MRP RNA in CHH patients
To study protein binding to MRP RNA, 
we performed immunoprecipitations on cell 
extracts derived from the four CHH patients 
described in the preceding paragraph, and two 
controls. As shown in Figure 4, hPop1 and 
hPop4 were clearly associated with the RNase 
MRP complex in patients 1, 2, 7, and 8. Simi-
lar experiments were done using antibodies 
against the Rpp30 and Rpp38 protein subunits 
(78) yielding similar results (data not shown). 
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Figure 2. Localization of the RMRP mutations in CHH patients. 
Depicted in the upper part is the RNase MRP RNA gene 
as published in ref. (66). Shown is the TATA box at position 
–33 to –25 and the transcription initiation site (represented 
by +1). Depicted in the box is the transcribed region of the 
RNase MRP gene. All mutations listed in Table 2 are shown. 
The lower part depicts the secondary structure of the RNase 
MRP RNA shown as adapted from ref. (70). The mutations are 
shown in dark blue.
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from CHH patients. Total RNA was analyzed by northern 
blotting using riboprobes directed against RNase MRP RNA, 
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expressed in patient 7. Control-F, fibroblasts from a normal 
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heterozygous do occur. It might not be surpris-
ing if CHH patients with a leaky/leaky geno-
type were less severely affected than patients 
who are null/leaky. Both mild and severe cases 
occur among the numerous patients who are 
homozygous for the main 70→G mutation 
(“leaky/ leaky”). However, it is too early to 
firmly assess any genotype-phenotype corre-
lations. Indeed, we (165) and others (163) are 
impressed with the great phenotypic variabi-
lity seen even within sibships. This suggests 
that other factors than (or in addition to), the 
RMRP mutation status contribute to the phe-
notype. These questions may best be addressed 
by studying experimental mutations in animal 
models. The first description of CHH by Victor 
McKusick et al. (163) established its major 
characteristics: recessive inheritance of a condi-
tion characterized by disproportionate, short-
limbed dwarfism associated with numerous 
other manifestations. The multi-organ, multi-
tissue manifestations of CHH, including cancer 
stimulated speculations about the nature of 
the mutated gene (164,182-184). In the largest 
series of CHH patients studied for cancer, a 
significant excess of cancer was seen, and 
it was mainly attributable to non-Hodgkin’s 
lymphoma (185). Our results are compatible 
with the hypothesis that the basic defect may 
involve many cellular functions. The RNase 
MRP complex is one of a large population of 
small nucleolar ribonucleoproteins (reviewed 
in ref (5)). In yeast the RNase MRP complex 
cleaves pre-rRNA (28). The RNA gene that is 
mutated in CHH was first described as a nuclear 
gene whose RNA product contributes to the 
endonuclease activity needed for mitochon-
drial DNA replication (22,26,27). By immuno-
precipitation we showed that the association of 
four protein subunits with RNase MRP RNA 
was undisturbed. We have attempted to mea-
sure the RNase MRP activity in CHH cells but 
available methods developed in yeast (28) do 
not appear to be sensitive enough for human 
cells (data not shown). In yeast, inhibition of 
RNase MRP results in the accumulation of a 
long form of precursor 5.8S rRNA (28). We used 
primer extension and northern blot hybridiza-
tion in search of this precursor in CHH cells 
but found none (data not shown). As far as we 
know, such long forms have not been docu-
mented in humans.
Thus a clear-cut disturbance of one of the 
two known functions of RNase MRP has not 
yet been documented in CHH cells. It may even 
be that the RNA product of RMRP has other 
functions in addition to the ones characterized 
so far, and that the mutations found in CHH 
patients disrupt these. The fact that mutations 
in the transcript were found only in the highly 
conserved positions may eventually yield clues 
in this regard. In analogy with other small 
nuclear and small nucleolar ribonucleoprotein 
particles, these residues might be located in 
regions that are involved in substrate RNA 
recognition by direct base pairing interactions 
(5). Alternatively, they might be part of the 
catalytic center of the enzyme, a possibility 
supported by the structural homology with 
RNase P, one of the first RNAs for which a cata-
lytic activity has been identified (50). Interest-
ingly phylogenetic comparison of RNase MRP 
and RNase P RNA between human and E. coli 
supports this idea. The sequence element 
68-GGAA-71 in human RNase MRP RNA is 
found to be fully conserved (69). The functional 
significance of these residues is suggested by 
recent studies on the E. coli RNase P complex, 
in which the two adenosine residues at compa-
rable positions (70 and 71) in RNase MRP RNA 
transcription initiation cause a lengthening of 
this interval and, at least in two cases, silencing 
of the corresponding RMRP allele. These we 
may call “null” promoter mutations. By con-
trast, mutations in the transcribed part of the 
gene do not cause inhibition of transcription, 
and may well be “leaky”. These assumptions 
are based on the fact that no patients have been 
found that are homozygous for the putative 
null mutations, and therefore this condition 
might be lethal as could be deduced from stu-
dies in yeast (98). By contrast, patients who 
are homozygous “leaky” and others who are 
In summary these immunoprecipitation data 
suggest that none of the mutations analyzed 
abolish the association of these four protein 
subunits with the MRP RNA.
Discussion
As shown here, mutations in RMRP can 
lead to CHH. Genetic evidence suggests the 
following model for the effect of RMRP muta-
tions. Duplications and insertions in the region 
between the TATA box and the point of 
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Figure 4. Association of hPop1 and hPop4 protein 
subunits with the RNase MRP complex. A. Immu-
noprecipitation with anti-hPop1 and anti-hPop4 anti-
bodies on extract of two CHH patients, a control 
cell line and HeLa cell extract. The control antibody 
is preimmune serum. Lanes 1-4 represent 10% input 
fraction, lanes 5-8 the coprecipitating MRP RNA 
using anti-hPop1 antibodies, and lanes 9-12 the 
coprecipitating MRP RNA using anti-hPop4 antibod-
ies. The signal with preimmune serum in HeLa cells 
is background due to overloading of cell extract. 
B. Immunoprecipitation performed using anti-hPop1 
antibodies on extract of CHH patients 7 and 8 and 
control cells. Lanes 1-3 represent the 10% input frac-
tion, lanes 4-6 the coprecipitating MRP RNA with 
antibodies. C. Immunoprecipitation performed using 
anti-hPop4 antibodies on extract of CHH patients 7 
and 8 and control cells. Lanes 1, 4, and 7 represent 
the 10% input fraction, lanes 2, 5, and 8 the copre-
cipitating MRP RNA with antibodies.
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are important for substrate binding and cataly-
sis (reviewed in ref. (186)). Thus, it is temp-
ting to speculate that the A→G substitution 
at position 70 found in the major haplotype of 
CHH interferes with the optimal activity of the 
RNase MRP enzyme. An unknown function 
has been previously alluded to by Tollervey 
and Kiss (5) who suggested the existence of 
yet undetected additional substrates for RNase 
MRP. As reviewed in ref. (118), a function in 
cell cycle control is possible. In yeast cells 
having RMRP mutations, defects in plasmid 
segregation believed to be caused by telo-
phase arrest have been documented (41). Dis-
turbances in the mitotic process would seem 
to fit the T cell deficiency described in CHH 
patients. The immune deficiency, together with 
the hypoplastic anemia, and the failure of 
skeletal growth in CHH, would seem to be logi-
cal effects of, for example, mitotic arrest.
Acknowledgements
We dedicate this paper to Dr. Victor A. 
McKusick. We thank our colleagues Teresa 
Costa, M.D., (Halifax, Canada), Peter Freisinger, 
M.D., (München, Germany), Andrea Superti-
Furga, M.D., (Zürich, Switzerland), and Robin 
M. Winter, M.D. (London, England) for giving 
us an opportunity to study their patients. We 
are grateful to Drs. S. Altman and C. Guerrier-
Takada (Yale University) for kindly providing 
rabbit anti-Rpp30 and anti-Rpp38 antibodies, 
and to Dr. Pertti Sistonen and Dr. C. L. Harte-
veld for control samples. Niina Ali-Varpula, 
Miina Ollikainen, Eija Rintala, Johanna Tom-
miska, and Reetta Vierumäki are acknowledged 
for laboratory assistance. Supported by grants 
CA16058, and CA67941 from the National Insti-
tutes of Health, and the Academy of Finland, 
the Ulla Hjelt Fund, the Sigrid Juselius Founda-
tion, The March of Dimes Birth Defects Foun-
dation (1-FY98-32 and 1-FY99-586), and the 
Helsinki University Central Hospital Research 
Fund. The work of H.v.E., W.v.V. and G.P. was 
supported in part by the Netherlands Founda-
tion for Chemical Research with financial aid 
from the Netherlands Organization for Scien-
tific Research (NWO-CW).
Materials and Methods
Genetic mapping of the CHH region
Only Finnish CHH patients with a carefully verified 
diagnosis were studied for the purpose of refining the 
genetic map. There were 16 families with more than one 
affected individual (multiplex), and 42 families with 
one affected individual (uniplex). Several individuals 
per family were genotyped for 23 polymorphic markers. 
From each family only 2 affected haplotypes (one mater-
nal, one paternal) were considered in the analysis. 
Haplotypes were constructed manually. The presump-
tive ancestral founding haplotype was reconstructed 
assuming the minimum number of historical recombina-
tions. A measure of linkage disequilibrium between a 
marker and the disease phenotype (Pexcess) is calculated 
using the formula
Pexcess = (Paffected - Pnormal)/(1 - Pnormal),
where Paffected is the frequency of the allele in affected 
chromosomes and Pnormal is the frequency of the allele 
in unaffected chromosomes (177). For these calculations 
most of the 116 affected haplotypes were used that 
were judged to descend from the putative shared major 
founder mutation. The corresponding normal haplo-
types (n > 100 at each marker) were taken from the unaf-
fected maternal and paternal chromosomes. The number 
of haplotypes (affected and normal) varied slightly 
between markers because of occasional uncertainty in 
allele assignment.
Analysis of polymorphic markers
Most of the novel polymorphic markers were found 
during SSCP analyses or sequencing of candidate genes 
in patient samples. 16P1 and AC1 were found based 
on the genomic BAC sequence. Primers for the SSCP 
markers and the genomic 13 nt deletion (Del13) 
were designed using the Primer 3 program at the White-
head Institue for Biomedical Research/MIT Center for 
Genome Research at http://www.genome.wi.mit.edu 
(Table 1). Primers 5’-TCC-TTG-GAC-AAG-TAC-CAA-
CA-3’ and 5’-GGG-AAA-CACA-GTG-CCT-CT-3’ were 
used for D9S1878 (http://www.cephb.fr/mail.html). 
Primers for the other polymorphisms were listed in 
Table 2 in ref (171). For the SSCP analyses, the PCR pro-
ducts were loaded on MDE (FMC BioProducts) gels and 
run overnight at room temperature (Table 1). Markers 
D9S1878, D9S163, D9S1804, 99AC, 89AC, and AC1 were 
separated in 6% Sequagel (National Diagnostics) gels at 
50°C. Bands on the polyacrylamide gels were visualized 
by silver staining as described in detail in ref. (187).
Genomic sequencing of the CHH region
Three BAC clones (497J14, 199G9, and 468J10) from 
the previously assembled contig (171) covering the CHH 
critical region were shotgun sequenced. Libraries were 
prepared in pCR-BluntII-Topo vector (Invitrogen) using 
the GATC GmbH service (Konstanz, Germany). Forty 
96-well plates were sequenced, in both directions, using 
the BigDye Terminator AmpliTaq FS Cycle Sequencing 
Kit (PE Applied Biosystems). Cycle Sequencing was per-
formed using the PE9700 Thermal Cycler (Perkin Elmer). 
The cycling protocol was 30 cycles of 95°C for 30 s, 50°C 
for 20 s, and 60°C for 4 min. Cycling was performed using 
10 µl reactions and reactions were purified by filtration 
plate. Custom vector primers TOPO2 5’-AGATG CAT-
GCTCGAGCGG-3’ and TOPO1 5’-TCGGATCCACTAGTA-
ACG-3’ designed by GATC GmbH, were used. Sequences 
were processed through a series of programs in UNIX. 
After quality assessment using Phred, 72% of subclone 
sequences were passed for use in assembling contigs 
using Phrap. Gap filling was performed using a combina-
tion of primer walking from the contig ends and PCR 
across the gaps. Primer sequences and PCR conditions are 
available on request. Finishing was facilitated by using 
MIT’s Finish program (http://www.genome.wi.mit.edu). 
The genomic sequence of the 187.6 kb CHH region was 
analyzed using the Genotator program package.
Patients and controls
Mutational analyses have so far been done on 51 CHH 
families from Finland and 4 families from other coun-
tries. With few exceptions both parents and all affected 
children have been studied. In addition a small number 
(n=7) of unaffected children have also been studied. The 
diagnostic criteria were as outlined previously (165). To 
search for the observed sequence variants in controls, 
120 anonymous blood donors from Finland, a panel of 
61 control individuals of various ethnicities (Chinese, 
Iranian, Indian, Indonesian, South European, British, 
German, Danish, Dutch) and 99 grandparents of CEPH 
families were studied. The number of controls studied is 
shown for each sequence variant (Table 2).
Mutation detection in RMRP
The RMRP gene (accession no. M29916) was sequenced 
in four PCR fragments RM1-RM4.
The primers were: RM1F: 5’-CTG-GCA-CCC-TCA-
TGG-GAG-3’; RM1R: 5’-GCA-CAC-CCA-GGT-ACC-AGC-
TAG-3’; RM2F: 5’-GGA-GGA-TAC-AGG-CGA-GTC-AG-3’;
RM2R: 5’-GCA-GAA-TAG-CTA-ATA-GAC-ACG-AAA-
TG-3’; RM3F: 5’-GGC-CAG-ACC-ATA-TTT-GCA-TAA-
G-3’; RM3R: 5’-CGG-ACT-TTG-GAG-TGG-GAA-G-3’;
RM4F: 5’-AGA-GAG-TGC-CAC-GTG-CAT-AC-3’; RM4R:
5’-CTT-CAT-AGC-AAG-GCC-AAG-AAC-3’.
Primers for RM3I fragment inside RM3 were 5’-CTT-
AGA-AAG-TTA-TGC-CCG-AAA-AC-3’ and 5’-GAA-
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AGG-GGA-GGA-ACA-GAG-TC-3’; 5% Sequagel (Natio-
nal Diagnostics) gels were used for separation. Deletions 
and insertions in the 5’ region of RMRP were searched 
for within 1.5 kb from the M29916 sequence by running 
PCR fragments in 5% Sequagel (National Diagnostics) 
and LongRanger (FMC BioProducts) gels at 50°C. The 
primer sequences and PCR conditions are available on 
request from the authors.
Extraction and analysis of total RNA
Lymphoblast (Control-L, patient 1 and patient 2) and 
fibroblast (Control-F, patient 7 and patient 8) cells were 
pelleted and total RNA isolated using Trizol (Gibco-BRL) 
as suggested by the manufacturer. RNAs were resolved 
on 5% denaturing polyacrylamide gels and blotted 
to Hybond-N+ membranes (Amersham). Northern blot 
hybridizations with riboprobes specific for human RNase 
MRP, U3 snoRNA, and U1 snRNA were performed as 
previously described (116). Quantitative analysis of the 
levels of transcription was done with a Phosphorimager 
(Biorad).
Synthesis and Analysis of cDNA
First strand cDNA synthesis and 5’ RACE were per-
formed using a SMART RACE cDNA amplification kit 
(Clontech) as described by the manufacturer. For first 
strand synthesis MRP-1 oligo 5’-GCG-AAG-CTT-ACA-
GCC-GCG-CTG-AGA-ATG-AG-3’ was used. RACE was 
done using MRP-1 and MRP-0 5’-GCG-AAT-TCG-TTC-
GTG-CTG-AAG-GCC-TAG-ATC-3’) and products were 
cloned using the TOPO-TA cloning kit (Invitrogen) and 
sequenced using the dideoxynucleotide chain termina-
tion method.
Immunoprecipitation
Anti-hPop1 (77) and anti-hPop4 (120) antibodies were 
coupled to protein A-agarose beads (Biozym) in IPP500 
(500 mM NaCl, 10 mM Tris-HCl pH 8.0, 0.05% NP-40) 
by incubation for 2 hr at room temperature. Beads 
were washed twice with IPP500 and once with IPP150 
(150 mM NaCl, 10 mM Tris-HCl pH 8.0, 0.05% NP-40). 
For each immunoprecipitation the cell extract was incu-
bated with the antibody-coupled beads for 2 hr at 
4°C. Subsequently, beads were washed three times with 
IPP150. To analyze coprecipitating RNAs, the RNA was 
isolated by phenol-chloroform extraction and ethanol 
precipitation. RNAs were analyzed by northern blot 
hybridization as described above.
Part IV
General discussion
Chapter 9
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Novel protein components 
of the RNase MRP 
complex
In the last decade, ten proteins were shown 
to be associated with the RNase MRP and/or 
RNase P complex in yeast Saccharomyces cere-
visiae: Pop1p, Snm1p, Pop3p, Pop4p, Rpp1p, 
Rpp2p/Pop7p, Pop5p, Pop6p, Pop8p and Rpr2p 
(32-38). Biochemical and genetic analyses have 
shown that all of these proteins, except Snm1p 
and Rpr2p, are associated with both RNase 
MRP and RNase P. The Snm1p protein was 
shown to be specifically associated with the 
RNase MRP complex, whereas the Rpr2p pro-
tein was found to be specifically associated 
with the RNase P complex (32,38).
Abstract
The human RNase MRP complex is an RNA-protein complex functio-ning in the cleavage of RNA. Two substrates of this endoribonucle-ase have been identified sofar. The cleavage of a mitochondrial 
transcript into small RNA primers needed for mitochondrial DNA replica-
tion was the function by which this enzyme was first identified. A few years 
later it was shown that the RNase MRP complex was involved in the cleavage 
of precursor ribosomal RNA. The RNase MRP complex was shown to be 
related to the RNase P complex, an RNA-protein complex involved in the 
processing of precursor tRNA.
The aim of the project underlying this thesis was to characterise the compo-
sition of the RNase MRP complex, to study its assembly and to investigate its 
relation to certain human diseases. The results obtained in this project are 
described in Part I, II and III, respectively. In this Chapter, the contribution 
of the studies described in this thesis to our knowledge on the human RNase 
MRP complex will be discussed.
The first protein subunit of the human 
RNase MRP complex was identified by virtue 
of its homology with the Pop1p protein com-
ponent of the yeast RNase MRP/P complex 
(77). In Part I of this thesis the identification 
of two additional protein components of the 
human RNase MRP and RNase P complexes is 
described (Chapters 2 and 3, (120,140)). These 
two proteins, referred to as hPop4 and hPop5, 
were identified as the human homologues of 
yeast Pop4p and Pop5p, respectively. Simulta-
neously, the human RNase P complex has been 
purified in the laboratory of Dr. S. Altman, 
resulting in the identification and character-
isation of seven additional protein subunits: 
Rpp14, Rpp20, Rpp25, Rpp29, Rpp30, Rpp38 
and Rpp40 ((78-80), Guerrier-Takada, personal 
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communication). Sequence comparison showed 
that Rpp29 is identical to the hPop4 protein 
and therefore this protein will be referred to as 
Rpp29/hPop4 (79,120). Rpp20 represents the 
human homologue of Rpp2p/Pop7p and Rpp30 
is homologous to Rpp1p (33,36). Recently, the 
human homologue of the yeast protein compo-
nent that was shown to be specifically associ-
ated with the RNase P complex was identified: 
Rpp21 (81). Four of the identified proteins have 
been shown to have homologues in archae bac-
teria as well: hPop4, hPop5, Rpp21 and Rpp30, 
suggesting that these eukaryotic and archaeal 
proteins share a common ancestor (51,121).
To elucidate whether the recently identi-
fied human RNase P proteins are also associated 
with the RNase MRP complex, immunoprecipi-
tations using rabbit antibodies raised against 
the RNase P proteins were performed. As 
shown in Figure 1, at least eight of the cur-
rently identified proteins are shared by the 
RNase MRP and RNase P complexes (lanes 3, 
5-10, 13). Surprisingly, these results also indi-
cate that the human homologue of the yeast 
protein that was found to be specifically associ-
ated with the RNase P complex (Rpr2p) is asso-
ciated with both RNase P and RNase MRP (lane 
9). The failure of the rabbit antisera against 
Rpp14 and Rpp40 to co-precipitate RNase P 
RNA implies that no conclusions can be drawn 
on their association with the RNase MRP com-
plex. In conclusion, up to date no human pro-
teins that are specifically associated with either 
RNase MRP or RNase P have been identified.
The currently described protein compo-
nents of the human and yeast RNase MRP and 
RNase P complexes are summarised in Table I.
The RNase MRP and P complexes in 
human cells differ from their yeast coun-
terparts
Our current knowledge on the composi-
tion of the human and yeast RNase MRP and 
P complexes and the results from biochemical 
and genetic analyses of both complexes indi-
cate that the human complexes are not simply 
homologues of the yeast complexes. A major 
difference between the human and yeast com-
plexes concerns their protein composition. 
Although most of the human and yeast proteins 
are homologous, homologues of some of the 
yeast proteins do not appear to exist in human 
cells (i.e. Snm1p, Pop3p, Pop6p and Pop8p). 
Vice versa, counterparts of some human RNase 
MRP/RNase P proteins are not evident in 
yeast (e.g. Rpp14, Rpp25, Rpp38 and Rpp40). 
Although it can not be completely excluded 
that homologues of these proteins are present, 
but have not been identified yet, scanning of 
the yeast and human genomes (which have 
been completely sequenced) did not reveal 
obvious homologues, strongly suggesting that 
they do not exist.
Another difference between the yeast and 
human complexes is the existence in yeast 
of proteins specifically associated with either 
RNase MRP or RNase P, whereas these have 
not been identified in human. Moreover, as 
described above, it was found that the human 
homologue of the RNase P specific protein in 
yeast is also associated with the human RNase 
MRP complex and no human homologue of 
the yeast RNase MRP specific protein could be 
identified.
Furthermore, the human and yeast com-
plexes show a different behaviour during bio-
chemical purification. It yeast, it has been 
shown that the RNase MRP and RNase P acti-
vities can be physically separated using classi-
cal biochemical purification methods (30,38). 
In humans, separation of the majority of the 
RNase MRP and RNase P complexes can also 
be achieved, when the RNA component was 
used to monitor their fractionation ((80), our 
unpublished observations). However, a small 
part of the RNase MRP complex co-fraction-
ated with the RNase P complex and RNase 
MRP activity could only be detected in these 
fractions (our unpublished observations). This 
suggests that active RNase MRP might exist in 
one large complex together with RNase P. How-
ever, our data are contradicted by the results 
of Karwan and co-workers, who published that 
both fractions of RNase MRP contained endo-
nuclease activity (135). On the other hand, 
our results are supported by the findings of 
Lee and co-workers who showed, using RNA 
selections with antisense oligonucleotides, that 
a small fraction of the RNase MRP complex 
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Figure 1. Association of protein subunits with RNase MRP and RNase P complexes. Immunoprecipitations were performed using 
antibodies raised against hPop1 (lane 3), Rpp40 (lane 4), Rpp38 (lane 5), Rpp30 (lane 6), hPop5 (lane 7), hPop4 (lane 8), Rpp21 
(lane 9), Rpp20 (lane 10), Rpp14 (lanes 11) and Rpp25 (lane 13) with partially purified RNase MRP and RNase P (lanes 1-11) 
((140) and our unpublished observations) or a HeLa cell extract (lanes 12 and 13). Co-precipitating RNAs and RNAs from 10% 
of the input fractions (lanes 1 and 12) were isolated, resolved by denaturing gel electrophoresis and analysed by northern blotting 
using riboprobes specific for RNase MRP and RNase P RNA (116).
Table I. Composition of human RNase MRP and RNase P complexes. •a Association with complex is indicated by + ; no association 
with – ; nd: not determined. •b The yeast homologue of Rpp21 (Rpr2p) has been shown to associate specifically with RNase P.
Protein Molecular Predicted pI Yeast RNase MRP RNase P Reference
 weight (cal/app)  homologue •a •a
  
hPop1 115/115 9.8 Pop1p + + (37,77)
Rpp40 34/40 5.3  nd + (80)
Rpp38 32/38 9.9  + + (78,105, this thesis)
Rpp30 30/30 9.4 Rpp1p + + (78,33,105, this thesis)
Rpp29/hPop4 25/30 10.9 Pop4p + + (34,79,120, this thesis)
Rpp25 21/25 9.7  + + (78, Guerrier-Takada, pers. comm.)
Rpp21 18/21 9.6 Rpr2p +/– •b + (38,81) 
Rpp20 16/20 8.7 Rpp2p/Pop7p + + (80,38,36) 
hPop5 19/19 7.9 Pop5p + + (38,140, this thesis)
Rpp14 14/14 7.6  nd + (79) 
   Snm1p + – (32) 
   Pop3p + + (35) 
   Pop6p + + (38) 
   Pop8p + + (38)
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forms higher order structures with the RNase 
P complex (57). Because the only obvious dif-
ference between the human RNase MRP and 
RNase P complex is the RNA component, a 
purification strategy based on an RNA-tag 
fused to the RNase MRP RNA, rather than 
purifications based on the biochemical features 
of these complexes, may solve this paradox. 
The RNA-tag approach will not only shed more 
light on whether the RNase MRP is associated 
with the RNase P complex but also on whether 
the currently identified protein subunits are 
associated with each individual complex or 
with a combined RNase MRP/RNase P com-
plex.
Finally, recent experiments indicated that 
components of the RNase MRP and RNase P 
complexes have co-evoluted. Swapping of the 
P3 domain from human RNase MRP RNA with 
that from the yeast RNase MRP RNA showed 
that this hybrid RNA is not functional, sug-
gesting that for a proper function of this com-
plex human proteins are required (71).
In conclusion, all these data suggest that 
the human RNase MRP and RNase P complexes 
are at least partially different from the yeast 
enzymes.
Assembly of the human 
RNase MRP complex
Subcellular localisation and assembly of 
the RNase MRP complex
The RNase MRP and RNase P RNA are 
transcribed by RNA polymerase III. In-situ 
hybridisation experiments showed that RNase 
MRP and RNase P RNAs, like other RNA 
polymerase III products, can be detected in 
the so-called perinucleolar compartments (59). 
However, at these sites no protein subunits of 
the RNase MRP and RNase P complexes can 
be detected, suggesting that the RNase MRP 
and RNase P RNAs are not assembled into the 
mature ribonucleoproteins at these sites and 
that these RNAs are first relocalised in the 
nucleus before they are assembled (57).
It has been thought for a long time that 
transport of RNA-protein complexes to the 
nucleolus is a two-step process: first proteins 
are imported into the nucleoplasm, where they 
associate with their cognate RNA, followed by 
the actual transport to the nucleolus (107-109). 
In Chapter 4, we describe that RNase MRP/
RNase P proteins are capable of entering the 
nucleolus independent of their association with 
RNA. In addition, we showed that clusters of 
basic residues in these proteins appear to be 
required for their nucleolar accumulation. Our 
data and recent work from other groups sug-
gest that nucleolar localisation occurs by diffu-
sion and retention in the nucleolus, the latter 
mediated by interactions with nucleolar com-
ponents (Chapter 4, (188)). This idea is also 
supported by the observation that RNase MRP/
RNase P protein subunits relocalise after shut-
down of RNA polymerase I, which is respon-
sible for the synthesis of rRNA, suggesting 
that the synthesis of substrate is coupled to 
the nucleolar accumulation of these enzymes 
(81). Chen and Huang showed that Rpp29/
hPop4 and other factors involved in rRNA 
transcription and processing, shuttle between 
the nucleoplasm and nucleolus (188). In addi-
tion, they showed that these factors move faster 
when RNA polymerase I transcription in inhi-
bited, suggesting that the lack of substrates 
leads to dissociation from the nucleolus and 
enhancement of their mobilities. The under-
lying mechanism of this dynamic process for 
the RNase MRP and other complexes is at pre-
sent unclear and forms an interesting topic for 
future research.
Architecture of the RNase MRP complex
With the goal to identify the Th-40 auto-
antigen we studied the architecture of the 
RNase MRP complex. The Th-40 autoantigen 
was originally described as a 40 kDa protein 
that is immunoprecipitated from labelled 
cell extracts using patient sera that contain 
reactivity against RNase MRP and RNase P 
(68,72,73,135,136). Later, it was shown that 
proteins that are recognised by these patient 
sera bind the P3 domain of RNase MRP and 
RNase P RNA, suggesting that the Th-40 auto-
antigen is bound to the P3 domain (75,134). 
However, the identity of the Th-40 autoanti-
gen was never elucidated. In Chapters 5 and 
6 the identification of the Th-40 autoantigen 
is described and evidence that the immuno-
precipitated 40 kDa protein is identical to 
the Rpp38 protein is presented. However, the 
Rpp38 protein does not bind to the P3 domain, 
but is associated with the central domain of the 
RNase MRP RNA. Recently, it was shown that 
Rpp38 is homologous to a ribosomal protein 
called L7AE, which was shown to bind a so-
called Kink-turn motif present in rRNA. The 
observation that a Kink-turn motif is present 
in the central domain of RNase MRP RNA 
strongly suggests that this motif is involved in 
the association with Rpp38 (141).
This raised the question why previous data 
suggested that Th-40 binds to the P3 domain 
(75). Our data showed that two proteins associ-
ate with the P3 domain: Rpp20 and Rpp25. In 
addition, we obtained evidence that the Rpp20 
protein interacts with the central domain as 
well and that the hPop1 protein needs both 
RNA domains to associate with the RNase MRP 
complex, indicating that Rpp20 and hPop1 
form a molecular bridge between these two 
RNA domains. The observation that almost all 
patient sera with reactivity against RNase MRP 
and RNase P contain autoantibodies directed 
to Rpp25, strongly suggested that Rpp25 is 
the autoantigenic component bound to the 
P3 domain. The paradoxical appearance of a 
40-kDa species in UV-crosslinking with the 
P3 domain appeared to be due to the choice 
of the ribonuclease applied in these experi-
ments. RNase T1, which was applied by Yuan 
and coworkers, did not degrade the crosslinked 
RNA efficiently, thereby increasing the appa-
rent molecular weight of the cross-linked pro-
teins (75).
More data on the architecture of the 
RNase MRP complex were provided by yeast 
two-hybrid experiments using Rpp14, Rpp20, 
Rpp21, Rpp29, Rpp30, Rpp38, Rpp40 and 
hPop1 (82). These experiments identified two 
strong interactions: Rpp30 interacts with 
Rpp14 and Rpp40 with Rpp21. In addition, 
multiple weaker interactions (for example 
between hPop1 and Rpp38, and between Rpp20 
and hPop1) were observed between the other 
proteins. However some of the observed inter-
actions could not be confirmed when DNA 
binding and activation-domains in the yeast 
two-hybrid experiments were swapped, thus 
complicating the interpretation of these obser-
vations. Finally, preliminary results indicate that 
hPop5 interacts with Rpp30 (our unpublished 
observations). In Figure 2 a model for the 
RNase MRP complex based on the described 
RNA-protein and protein-protein interactions 
is presented (82).
Recently, the RNA-protein interactions in 
the RNase P complex were studied using a 
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yeast three-hybrid assay and UV-crosslinking 
analysis. This work shows that Rpp29/hPop4, 
Rpp30, Rpp21 and Rpp25 interact with the 
P3 domain, whereas the Rpp38 protein inter-
acts with another part of the RNase P RNA 
((86), Guerrier-Takada personal communica-
tion). How these data relate to the data obtained 
for the RNase MRP complex is not clear yet. 
The latter interactions might be typical for the 
human RNase P complex, although these pro-
teins have been shown to associate with both 
complexes (see above).
At this moment, three proteins have been 
proposed to be involved in substrate binding 
by RNase P: hPop1, Rpp14 and Rpp21 (81,189). 
These proteins are the first to be implicated 
in actual substrate binding and/or catalysis of 
pre-tRNA cleavage.
RNase MRP in human 
disease
RNase MRP in systemic autoimmune 
diseases
Patients suffering from systemic autoim-
mune diseases frequently produce autoanti-
bodies, which are directed to a large variety 
of cytoplasmic, nuclear and nucleolar autoan-
tigens. The occurrence of these autoantibodies 
can be helpful in diagnosis and prognosis of the 
different autoimmune diseases (190). For exam-
ple, anti-nucleolar reactivity has been demon-
strated to occur frequently in patients suffering 
from systemic sclerosis ((68), reviewed in 
ref. (139,143,190)). Among the identified 
autoantigens targeted by patient sera dis-
playing anti-nucleolar reactivity are the 
RNase MRP and RNase P complexes. This 
reactivity is referred to as anti-Th/To-speci-
ficity (61,62,64,65,68,73,136,191). Although 
the occurrence of anti-nucleolar reactivities 
including anti-Th/To autoantibodies have been 
reported to be specific for patients with sys-
temic sclerosis, our analyses of 172 anti-nucleo-
lar patients sera showed that these reactivities 
are also found in patients suffering from other 
systemic autoimmune disease like systemic 
lupus erythematosus and polymyositis (Chap-
ter 7). These observations reduce the relevance 
of this autoantibody system for diagnostic pur-
poses.
The Th/To autoantigen has been studied 
in more detail during the past decade and 
it has been demonstrated that a protein of 
40 kDa (designated as Th-40) is the most 
frequently recognised autoantigenic protein 
(68,72,73,135,136). In Chapter 6, evidence is 
presented that the Th-40 autoantigen is identi-
cal to Rpp38. However, immunoprecipitations 
of in vitro translated recombinant proteins and 
western blot analyses showed that not Rpp38, 
but hPop1 and Rpp25 are the most frequently 
recognised Th/To autoantigens (Chapter 6). 
In addition, we demonstrated that some anti-
Th/To patient sera (also) contained autoanti-
bodies reactive with hPop5, Rpp14 and Rpp30. 
Based upon these findings, I suggest that the 
term Th-40 to refer to the most frequently 
recognised Th/To autoantigen should not be 
used anymore, because this is misleading. In 
fact, six of the ten known RNase MRP/RNase P 
associated proteins are frequently targeted by 
anti-Th/To positive patient sera. All together, 
these represent the Th/To autoantigen.
Although the etiology of systemic auto-
immune diseases is at present unclear, it is 
hypothesised that modification of proteins 
during cell death contributes to the bypass of 
tolerance to ‘self antigens’ (reviewed in ref. 
(192,193)). During apoptotic or necrotic cell 
death most key enzymes and complexes essen-
tial for cell survival are post-translationally 
modified or cleaved. These modified “self” 
proteins translocate to the cell surface of the 
apoptotic cell or leak from the necrotic cell 
and become accessible for the immune system. 
Because of the modification, which may lead to 
a change in the tertiary structure, these anti-
gens are not longer recognised as “self” and 
may trigger an autoimmune response (reviewed 
in ref. (192,193)). Whether the hPop1, Rpp38, 
Rpp30, Rpp25, hPop5 and Rpp14 proteins 
are modified during apoptotic or necrotic cell 
death remains to be determined.
RNase MRP in cartilage-hair hypoplasia
While the anti-Th/To autoantibodies proved 
to be extremely helpful in determining the 
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Figure 2. Structural model for the RNase MRP complex. Schematic representation of the binding of hPop1, Rpp38, Rpp25 and 
Rpp20 to the RNase MRP RNA. The Rpp25 and Rpp20 were shown to bind directly to the P3 domain of RNase MRP RNA 
(Chapter 6). The Rpp38 protein has been demonstrated to bind to the centrally located domain (Chapter 5 and 6), which was also 
shown for the Rpp20. The observation that hPop1 binds these two RNA domains as well, strongly suggests that the hPop1 and 
Rpp20 proteins form a molecular bridge between these two RNA domains. To generate this model the protein-protein interac-
tions observed by yeast two-hybrid analyses (82) are included as well. Only interactions that were confirmed when DNA binding 
and activation domains were swapped were taken into account. The exact manner in which these proteins interact with each other 
or with the RNA is still unclear and the model depicted is just one of various possibilities.
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architecture of the RNase MRP complex, the 
genetic defect in the RNase MRP RNA may 
aid in elucidating the function(s) of the human 
RNase MRP. In Chapter 8 we describe the iden-
tification of mutations found in the gene enco-
ding the RNase MRP RNA, which was shown 
to cause a pleiotropic disease called cartilage-
hair hypoplasia (CHH). For the first time it 
was found that mutations in a nuclear 
gene encoding an untranslated RNA molecule 
could cause a disease. Recently, mutations 
in the nuclear gene encoding the telomerase 
RNA component were shown to cause dyskera-
tosis congenita, indicating that disease-causing 
mutations in genes encoding structural RNAs 
may be a more widespread phenomenon than 
initially thought (194).
The absence of patients homozygous for a 
so-called null mutation strongly suggests that 
RNase MRP RNA is essential for viability, as 
has been reported previously for yeast RNase 
MRP (28,29,98). The disease causing mutations 
in CHH are most likely leading to a (partial) 
functional impairment of the RNase MRP com-
plex. A yet unresolved question is which func-
tion is impaired.
The RNase MRP complex has been impli-
cated to function in two processes: the cleavage 
of a mitochondrial transcript to RNA primers 
that function in mitochondrial DNA replica-
tion and the cleavage of precursor rRNA at the 
5’-end of 5.8S rRNA (reviewed in ref. (118)). 
To detect whether the mutations in the RNase 
MRP RNA associated with CHH had any effect 
on the maturation of the 5.8S rRNA, total 
RNA was analysed from cell lines derived from 
CHH patients. Analysis of the 5.8S rRNA using 
northern blot hybridisation did not reveal any 
difference in the relative abundance of 5.8S(S) 
and 5.8S(L) rRNA, suggesting that the matu-
ration of 5.8S rRNA is not or hardly affected 
(our unpublished observations). It is unclear 
whether the processing of rRNA is not affected 
by the mutations in RNase MRP RNA or 
whether there is another control mechanism 
that regulates the relative steady-state levels 
of the short and long forms of 5.8S rRNA. Evi-
dence for a direct role of RNase MRP in rRNA 
processing in human cells is not available, but 
the evolutionary conservation of the rRNA 
processing machinery as well as its nucleolar 
accumulation strongly support such a role. 
Therefore, it is more likely that the apparently 
normal expression levels of both forms of 5.8S 
rRNA in patient cells are due to a sufficient 
overall RNase MRP activity in the nucleoli of 
these cells, in spite of the possibly reduced 
activity per particle, or to a compensatory 
change that maintains normal expression levels. 
In addition to the processing of the 5.8S rRNA 
the mitochondrial function of the RNase MRP 
complex was studied in cells of patients suffer-
ing from CHH.
A first attempt to study the mitochondrial 
function in CHH and control cells was made 
by assaying the ability of the RNase MRP com-
plex to cleave a mitochondrial RNA, spanning 
the mitochondrial origin of DNA replication 
(22,24,135). Unfortunately, these experiments 
did not result in conclusive data, which is 
probably due to the limited amount of CHH 
cell extracts available.
A reduction of the RNase MRP activity 
might decrease the efficiency of mitochondrial 
DNA replication, and as a result might lead 
to a reduced amount of mitochondrial DNA 
in CHH patients. However, Southern blotting 
analysis of total DNA showed that no signifi-
cant decrease in the amount of mitochondrial 
DNA could be detected in CHH cells. In agree-
ment with these observations western blotting 
analyses using extracts from isolated mito-
chondria demonstrated that proteins encoded 
by mitochondrial DNA were expressed to 
normal levels, using nuclear encoded mito-
chondrial proteins as an internal reference (our 
unpublished observations). Taken together, our 
preliminary data suggest that in CHH patients 
no obvious biochemical mitochondrial defect 
can be observed.
The third function that has been described 
for the RNase MRP complex in yeast is its 
involvement in the breakdown of the mitotic 
spindle and the closing steps of mitosis (41). As 
suggested before, the inhibition of such a func-
tion would negatively affect cell proliferation 
and thus might very well explain the growth 
defects and T-cell deficiencies observed in CHH 
patients (Chapter 8, (195)). Interestingly, the 
cell division rates of the available CHH patient 
derived cell lines are significantly lower than 
those of control cells. The establishment of new 
(better defined) cell lines of CHH patients will 
enable the further study of the role of RNase 
MRP in the cell cycle.
It should be noted that studies on the func-
tion of the RNase MRP complex using cells 
derived from CHH patients may be suboptimal 
in view of another aspect. Cartilage-hair hypo-
plasia is a disease that already manifests at 
birth, indicating that during embryogenesis 
a RNase MRP defect is already evident. The 
RNase MRP dependent process that is inhi-
bited in the embryo can be any of the processes 
described above or another yet unidentified 
process. For example, in yeast it has been 
shown that depletion of RNase MRP RNA 
results in a different protein expression pattern, 
suggesting that RNase MRP somehow regulates 
the expression of certain proteins (29). Dif-
ferential expression, mediated by RNase MRP, 
may in higher eukaryotes be important during 
embryogenesis and when abrogated by muta-
tion in the RNA component may cause CHH.
Future perspectives
In this thesis studies on the composition 
and assembly of the RNase MRP complex 
are described. Its relevance as an autoantigen 
in systemic autoimmune diseases was also 
addressed and its functional importance was 
substantiated by the identification of its role in 
cartilage-hair hypoplasia.
Although many questions asked at the start 
of this project were answered, many more ques-
tions were raised by these answers.
Because the present data suggest that the 
RNA component is the only difference between 
the human RNase MRP and RNase P com-
plexes, it will be a challenging and important 
task to purify the RNase MRP complex by 
introducing an RNA tag in the RNase MRP 
RNA. This may enable the selective isolation of 
the single RNase MRP complex and will pro-
vide information on whether the RNase MRP 
and RNase P complexes form one large com-
plex or exist as two separate complexes. This 
approach can be also used to further explore 
the existence of complex specific proteins.
Another interesting area of research is the 
identification of protein-protein interactions 
in the RNase MRP complex. Although some 
information on this subject has been obtained 
using the yeast two-hybrid system, more reli-
able data may be generated in a mammalian 
two-hybrid system as well as by co-immuno-
precipitation studies with recombinant pro-
teins.
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The involvement of the RNase MRP RNA in 
the genetic disease called cartilage-hair hypo-
plasia raises numerous interesting questions. 
New cell-lines derived from CHH patients will 
be essential tools before we can answer them. 
Such well-defined cell lines could for example 
be used to study proliferation rates of CHH 
cells and compare them with control cells. 
In addition, in vivo cell labelling followed by 
RNA analysis could generate information as to 
which RNAs are substrates for the RNase MRP 
complex. Identification of these substrates and 
developing new in vitro assays may contribute 
to the understanding of the molecular mecha-
nism of the enzymatic activity of the RNase 
MRP complex.
Another approach to study the mechanism 
underlying cartilage-hair hypoplasia is the 
generation of mice in which CHH-specific muta-
tions are introduced in the RNase MRP RNA 
genes and study the effects of these changes.
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Eukaryotische cellen bevatten verschil-
lende soorten RNA, onder andere messenger 
RNA, transfer RNA en ribosomaal RNA. Direct 
na synthese van voorlopers van deze RNAs 
(de zgn. pre-RNAs) worden deze gekliefd en 
gemodificeerd. Klieving en modificatie van pre-
transfer RNA en pre-ribosomaal RNA wordt 
gereguleerd door RNA-eiwit complexen die 
in de nucleolus voorkomen, de zogenaamde 
small nucleolar ribonucleoprotein complexes (of 
snoRNPs). SnoRNPs kunnen ruwweg worden 
ingedeeld in drie groepen: box C/D snoRNPs, 
box H/ACA snoRNPs en RNase MRP/RNase P.
Het RNase MRP complex is geïdentificeerd 
door haar betrokkenheid bij de klieving van 
een mitochondrieel RNA tot kleine RNA mole-
culen, die nodig zijn bij de synthese van het 
mitochondrieel DNA. Later bleek het RNase 
MRP complex ook betrokken te zijn bij de 
rijping van het nucleolaire 5.8S ribosomaal 
RNA.
Het RNase MRP complex bestaat uit één 
RNA molecuul en meerdere eiwit componenten. 
De RNA component van het RNase MRP com-
plex vertoont structurele gelijkenis met de 
RNA component van het RNase P complex, 
waarvan is aangetoond dat het betrokken is 
bij de rijping van transfer RNA. Verder weten 
we dat de meeste eiwit componenten van het 
RNase MRP complex ook onderdeel zijn van 
het RNase P complex en dat patiënten die 
lijden aan bepaalde systemische auto-immuun-
ziekten een afweerreactie ontwikkelen tegen 
een aantal van deze eiwitten.
Het doel van het onderzoek beschreven in 
dit proefschrift was de identificatie van nieuwe 
eiwit componenten van het RNase MRP com-
plex (Deel I), het bestuderen van de opbouw 
van het RNase MRP complex (Deel II) en het 
bestuderen van de rol in humane ziekten van 
het RNase MRP complex (Deel III).
De algemene inleiding, Hoofdstuk 1, geeft 
een overzicht van de huidige kennis over de 
snoRNPs, met speciale aandacht voor de RNase 
MRP en RNase P complexen.
In Deel I worden enkele nieuwe eiwit 
componenten van het RNase MRP complex 
gepresenteerd. De Hoofdstukken 2 en 3 behan-
delen de identificatie en karakterisatie van de 
humane homologen van de gist Pop4 en Pop5 
eiwitten. Beide eiwitten blijken zowel in het 
RNase MRP als het RNase P complex aanwezig 
te zijn.
Deel II bevat enkele studies over de assem-
blage van het RNase MRP complex. In Hoofd-
stuk 4 is met behulp van mutagenese en 
transfectie studies de subcellulaire lokalisatie 
van drie eiwitten geanalyseerd. Positief geladen 
domeinen in deze eiwitten blijken belangrijk 
te zijn voor hun accumulatie in de nucleolus. 
Deze eiwitten blijken ook onafhankelijk van 
associatie met het RNase MRP complex naar de 
nucleolus te kunnen migreren. Onze resultaten 
suggereren dat nucleolaire accumulatie van 
deze eiwitten via diffusie en retentie plaats-
vindt. In de Hoofdstukken 5 en 6 worden 
data beschreven die de basis vormen voor een 
model van de architectuur van het RNase MRP 
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complex. Het Rpp38 eiwit blijkt een centraal 
domein van het RNase MRP RNA te binden, 
terwijl Rpp25 associeert met het zogenaamde 
P3 domein van het RNase MRP RNA. De hPop1 
en Rpp20 eiwitten blijken beide domeinen 
nodig te hebben. Verder werd bestudeerd welke 
RNase MRP/P eiwitten herkend worden door 
patiënten sera die reactiviteit tegen de RNase 
MRP/RNase P complexen bevatten. Hieruit 
bleek dat Rpp25 en hPop1 het meest frequent 
herkend worden door patienten auto-antlicha-
men. We konden ook aantonen dat Rpp38 iden-
tiek is aan het zgn. Th-40 auto-antigen.
In Deel III is de relatie tussen het RNase MRP 
complex en bepaalde humane ziekten bestu-
deerd. In Hoofdstuk 7 wordt de klinische rele-
vantie van auto-antilichamen tegen snoRNPs 
bestudeerd. Analyses van patiënten sera die 
reactiviteit tegen nucleolaire componenten 
vertonen, tonen aan dat anti-nucleolaire 
auto-antilichamen niet alleen voorkomen bij 
sclerodermie, zoals voorheen gedacht werd. 
Eukaryotic cells contain several classes of 
RNA: messenger RNA, transfer RNA and ribo-
somal RNA. After transcription of these RNAs, 
cleavages and modifications have to occur to 
generate the mature RNAs. The cleavage and 
modification of transfer RNA and ribosomal 
RNA is mediated by RNA-protein complexes 
that are primarily found in the nucleolus. These 
complexes which are designated small nucleo-
lar ribonucleoprotein particles (snoRNPs). 
SnoRNPs can roughly be divided into three 
groups: box C/D snoRNPs, box H/ACA snoRNPs 
and RNase MRP/RNase P.
Originally, the RNase MRP complex has 
been identified by virtue of its capacity to 
cleave a mitochondrial transcript to small RNA 
molecules that function in the priming of mito-
chondrial DNA synthesis. However, the RNase 
MRP complex also functions in the maturation 
of the 5’-end of the 5.8S ribosomal RNA, which 
occurs in the nucleolus.
The RNase MRP complex contains one 
RNA molecule and several protein components. 
The RNA component of the RNase MRP com-
plex displays structural similarity to the RNA 
component of the RNase P complex, which has 
been shown to function in the cleavage of pre-
cursor transfer RNAs. In addition, it has been 
demonstrated that most of the protein sub-
units associated with the RNase MRP complex 
are also present in the RNase P complex and 
that patients suffering from certain systemic 
autoimmune diseases develop an autoimmune 
response directed to some of these proteins.
The goal of the research underlying this 
thesis was to identify new protein components 
of the RNase MRP complex (Part I), to obtain 
information on the architecture of the RNase 
MRP complex (Part II) and to study the auto-
antigenicity of the RNase MRP complex in sys-
temic autoimmune diseases (Part III).
The general introduction presented in 
Chapter 1 reviews our current knowledge on 
snoRNPs with emphasis on the RNase MRP 
and RNase P complexes.
In Part I the identification of new protein 
subunits of the human RNase MRP and RNase 
P complexes is presented. In Chapters 2 and 3 
the identification and characterisation of the 
human homologues of the yeast Pop4 and Pop5 
proteins is described. These proteins are associ-
ated with both the RNase MRP and RNase P 
complexes.
Part II contains various data on the assem-
bly of the RNase MRP complex. First (Chapter 
4) the subcellular localisation was studied by 
mutagenesis and transfection studies of three 
protein components of the RNase MRP com-
plex. Basic domains of these proteins appeared 
to be important for their nucleolar accumu-
lation, which appeared to proceed indepen-
dently of complex association. These data led 
to the hypothesis that proteins are accumulat-
ing in the nucleolus by a mechanism of diffu-
sion and retention. In Chapters 5 and 6 data are 
described that provide the basis for a model of 
the architecture of the RNase MRP complex. 
It was found that Rpp38 binds to a centrally 
Deze analyses hebben tevens tot identificatie 
van nieuwe auto-antilichaam specificiteiten 
geleid, gericht tegen ofwel box C/D ofwel box 
H/ACA snoRNPs in het algemeen of exclusief 
tegen de U3 of U8 snoRNPs. In Hoofdstuk 8 
wordt de relatie van het RNase MRP RNA met 
een genetische ziekte, cartilage-hair hypoplasie 
genaamd, beschreven. Voor het eerst blijkt een 
genetische ziekte te worden veroorzaakt door 
een mutatie in een niet getransleerd gen dat 
door DNA in de kern gecodeerd wordt. Twee 
soorten mutaties zijn gevonden in patiënten 
die lijden aan cartilage-hair hypoplasie: een 
insertie/duplicatie in de promoter van het 
gen, wat een uitschakeling van dat gen tot 
gevolg heeft, of een substitutie in de code-
rende sequentie, wat tot de productie van een 
gemuteerd RNase MRP RNA leidt.
In het laatste hoofdstuk (Hoofdstuk 9) 
worden de resultaten verkregen binnen dit 
project bediscussieerd.
 
Summary
154 S u m m a r y 155R e f e r e n c e s
located domain, that Rpp25 binds to the P3 
domain, whereas hPop1 and Rpp20 are asso-
ciated with both domains of the RNase MRP 
RNA. In addition, the reactivity of patient sera 
that recognise the RNase MRP and RNase P 
complexes with individual proteins was tested. 
The results indicated that the Rpp25 and 
hPop1 proteins are most frequently targeted by 
the autoantibodies of these patients. We also 
showed that Rpp38 is identical to the so-called 
Th-40 autoantigen
In Part III we studied relations between the 
RNase MRP complex and some human diseases. 
In Chapter 7 the clinical relevance of the detec-
tion of autoantibodies directed to snoRNPs was 
studied. Analyses of patient sera showing anti-
nucleolar reactivity showed that this reacti-
vity is not specifically associated with systemic 
sclerosis, as has been thought before, but can 
also be found in other systemic autoimmune 
diseases. Novel autoantibody reactivities spe-
cifically directed against either box C/D or box 
H/ACA snoRNPs or exclusively against the U3 
or U8 snoRNPs were identified. In Chapter 8 
the intriguing role of the RNase MRP RNA in 
a genetic disorder, called cartilage-hair hypo-
plasia, is described. For the first time it was 
found that mutations in a nuclear gene enco-
ding an untranslated RNA molecule can cause 
a disease. Patients suffering from cartilage-hair 
hypoplasia may contain two types of muta-
tions in this gene: an insertion/duplication 
in the promoter region, leading to abrogation 
of transcription, or substitutions in the 
coding region, leading to the expression of a 
mutated RNase MRP RNA. The latter mutations 
impair an as yet unidentified function of the 
RNase MRP complex.
In the last chapter (Chapter 9) of this thesis 
the results obtained in this project are dis-
cussed.
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zoek betrokken. In het begin nog betrokken 
bij het bediscussiëren of alle geopperde ideeën 
van mijn promotor wel praktisch uitvoerbaar 
waren, later ben je uitgegroeid tot een grote 
steun binnen mijn project. Vele uren heb ik bij 
je op je kamer gezeten, over proefjes en over 
hoe het op het lab eraan toeging…. Een enorme 
waardering heb ik voor al het werk dat je voor 
me hebt gedaan, ook al heb ik misschien iets te 
vaak gezegd dat je liep te neuzelen. Wat betreft 
het hPop5 verhaal en mijn vakantie naar Banff, 
je hebt helemaal gelijk.
Zonder de hulp van 3 studenten en 2 anali-
sten zou mijn proefschrift er een stuk dunner 
uit hebben gezien. Rolf, jij was mijn eerste 
student en jij kreeg een op het eerste gezicht 
makkelijk project. Niets bleek minder waar, 
moeder natuur had de dingen anders bedacht 
dan door mij verwacht. Jij hebt veel werk 
verzet, waarvan een deel de basis is geworden 
van hoofdstuk 4. 
Judith, het toppertje van de klas. Dat heb 
je waar gemaakt! Je was een harde werker en 
je zei waar het op stond. Kortom dat klikte! 
Mijn lange afwezigheid heeft geen invloed op 
je afstuderen gehad en ik was dan ook blij te 
horen dat je na je afstuderen als collega terug 
zou komen. Misschien waren 172 immuun-
precipitaties voor de eerste week in je nieuwe 
baan iets teveel van het goede, maar ze zagen 
er in ieder geval alle 172 prachtig uit! Bedankt 
voor al je steun bij de totstandkoming van 
hoofdstuk 3, 6 en 7. Ik ben blij dat je mij van-
Zoals Ronald Plasterk waarschijnlijk terecht 
opmerkte in zijn column “Gods baan in 
Leiden”, zijn het dankwoord, het curriculum 
vitae en de stellingen het enige dat de jonge 
promovendus geheel op eigen kracht heeft 
geschreven. Het is ook zo. Want vele anderen 
hebben aan de rest van dit proefschrift een bij-
drage gehad, die in dit dankwoord een plaats 
verdienen.
Als eerste wil ik Petra Bindels en Helma 
Pluk bedanken. Jullie enthousiasme voor de 
wetenschap, wat jullie op mij hebben overge-
dragen, heeft mij uiteindelijk overgehaald om 
na mijn studie verder te gaan in de weten-
schap. 
Mijn promotor, Walther van Venrooij, u wil 
ik bedanken voor het creëren van een mooie 
leerschool. Wie weet dat ik u later nog eens 
bijval dat “mijn promotietijd de mooiste tijd 
van mijn carrière” is geweest, ik sta nu nog aan 
het begin. U heeft me bijgebracht om te denken 
in artikelen en doelgericht te werken. Verder 
heeft u mij vertrouwen geschonken bij het 
opzetten van de verschillende samenwerkin-
gen en bij het regelen van mijn verblijf bij 
Sidney Altman. Tenslotte dank voor de enorme 
kluif aan corrigeerwerk welke u heeft door-
gewerkt voor mij, want het moest natuurlijk 
altijd snel…..
Mijn co-promotor, Ger Pruijn. Ik heb je al 
in één van mijn eerste weken bij mijn onder-
Helma Pluk, Hans van Eenennaam, Saskia A. Rutjes, Ger 
J.M. Pruijn and Walther J. van Venrooij (1999). RNA-
protein interactions in the human RNase MRP ribonu-
cleoprotein complex. RNA 5: 512-524
Hans van Eenennaam, Ger J.M. Pruijn and Walther J. 
van Venrooij (1999). hPop4: a new protein subunit of 
the human RNase MRP and RNase P ribonucleoprotein 
complexes. Nucleic Acids Research 12: 2465-2472
Hans van Eenennaam, Nayef Jarrous, Walther J. van Ven-
rooij and Ger J.M. Pruijn (2000). Architecture and func-
tion of the human endonucleases RNase P and RNase 
MRP. IUBMB Life 49: 265-272
Maaret Ridanpää, Hans van Eenennaam, Katarina Pelin, 
Robert Chadwick, Cheryl Johnson, Bo Yuan, Walther 
van Venrooij, Ger Pruijn, Riika Salmela, Susanna 
Rockas, Outi Mäkitie, Ilkka Kaitila and Albert de la 
Chapelle (2001). Mutations in the RNA component of 
RNase MRP cause a pleiotropic human disease, Carti-
lage-Hair Hypoplasia. Cell 104: 195-203.
Hans van Eenennaam, Dorien Lugtenberg, Judith H.P. 
Vogelzangs, Walther J. van Venrooij and Ger J.M. Pruijn 
(2001). hPop5, a protein subunit of the human RNase 
MRP and RNase P endoribonucleases. Journal of Bio-
logical Chemistry 276: 31635-31641.
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het blauwe zeiltje etc.) en jullie vermogen mijn 
gevoelens een beetje te relativeren.
De secretaresse-met-pit, Els, jij verdient 
hier ook een plaats! Jij vond dat het af en toe 
meer op een gesticht leek dan op een univer-
sitaire instelling en voor mij was het in ieder 
geval duidelijk dat jij fungeerde als de Bioche-
mie-psychotherapeut. We hebben dus ook heel 
wat afgekletst, over de organisatie, werktijden, 
attitude, Marktzicht en andere dingen daarom-
heen. Maar je was er ook om me te vertellen 
dat ik “liep te fluimen”, dat ik te snel met mijn 
mening klaarstond of om me mijn schoenen na 
te brengen als ik daar naast dreigde te gaan 
lopen. En wat dit proefschrift betreft, je hebt 
helemaal gelijk, uiteindelijk is dat van mij ook 
gelayout!
Arjan, Ernest, Max en Sander voor jullie 
ligt het resultaat van 4 jaar met blauwe vloei-
stof schudden, wat je daar allemaal niet over 
kunt schrijven! Jullie hebben ook heel wat 
te horen gekregen over mijn promotie. Jullie 
steun en jullie “poep, lekker belangrijk” had ik 
zo af en toe nodig en jullie zorgden er ook voor 
dat ik me ondanks mijn werkend bestaan 
nog student voelde. Ernest, jij staat vandaag 
symbool voor mijn vriendschap met de Bun-
di’s. Ik ben blij dat je mijn paranimf wilt zijn, 
vooral omdat onze vriendschap teruggaat naar 
1976 in Nieuw- en Sint Joosland en is blijven 
bestaan op de C.S.W. te Middelburg en tijdens 
onze studie aan de K.U.N.. Voor jou is een pro-
motie not-done, toch wil ik op deze manier 
samen met jou mijn opleiding afsluiten.
Ton en Ria, jullie wil ik bedanken voor alle 
steun die ik vooral in het vervolg van mijn pro-
motie heb gekregen. De gesprekken over welke 
kant ik op wilde, het commentaar op mijn sol-
licitatiebrieven en natuurlijk de correcties van 
een aantal nederlandse stukken van dit proef-
schrift. 
Marieke, jij hebt bijna mijn gehele aio-tijd 
meegemaakt en je hebt van dichtbij gezien dat 
het niet altijd even makkelijk was. “Want jij 
gelooft in mij, jij ziet toekomst in ons allebei”. 
Onder dat motto accepteerde je dat mijn werk 
na 18:00 uur of op vrijdag niet ophield. En: 
“Zou je me laten gaan, als het nodig was,” 
ik weet dat dat zo is. Jij hebt mijn trip naar 
Amerika alleen maar aangemoedigd en dat 
heeft bij ons alleen maar bevestigd wat we 
eigenlijk al wisten.
En nu mijn ouders, Leo en Jannie, aan 
jullie heb ik dit proefschrift opgedragen. Voor 
jullie is gaan studeren en promoveren altijd 
een beetje een zwarte doos geweest. Dankzij de 
waarden en normen, die jullie aan mij hebben 
overgedragen en de familietrekjes die kennelijk 
in mijn genen gecodeerd liggen heb ik mijn 
studie en deze promotie succesvol kunnen 
afronden. Mijn opleiding zit erop, bedankt 
voor hoe ik nu de wereld in kan. Voor jullie dit 
proefschrift!
Tenslotte dank aan alle belastingbetalers. 
Bedankt voor 4 jaar salaris, voor het uitbetalen 
van mijn resterende vakantiedagen en voor 
fl. 21703,- aan genoten subsidies, waardoor ik 
een bezoek heb kunnen brengen aan Wye (UK), 
Edinburgh (UK), New Haven (USA) en Banff 
(Canada).
daag als paranimf bij wilt staan, ook al vind je 
het maar een stom toneelstukje.
Dorien, jou heb ik in de Xenos gestrikt 
om bij mij je afstudeerproject te doen. Jij zou 
het two-hybrid werk van Rolf en het hPop5 
werk van Judith afmaken. Met als gevolg dat 
je de eerste vrijdag direct tot 20:00 uur op 
het Trigon zat. Je hebt goed werk verricht en 
dat terwijl je liever thuis tussen de koeien zat. 
Twee co-auteurschappen (hoofdstuk 3 en 6) 
heeft jouw hoofdvak opgeleverd, niet slecht!
Annemarie, jij zou mijn proefjes, beschre-
ven in hoofdstuk 4, even herhalen, terwijl ik in 
Amerika zat. Dat even, was wat te optimistisch, 
want het zat op alle fronten tegen. Uiteindelijk 
was toch alles af voor de grote verhuizing en 
hebben we beiden van elkaar geleerd. 
Ben, jij hebt niet alleen proefjes voor mij 
gedaan, maar met jou heb ik ook 4 jaar lang op 
1.87 gezeten, het lab, voorheen bekend als het 
vrijgezellen-lab, nou dat hebben we mooi eens 
even rechtgezet. Ups en downs hebben we daar 
meegemaakt, wel jammer dat jouw ups vaak 
kwamen als ik op vakantie ging. 149 ELISA 
platen heb jij voor mij er doorheen gejaagd, 
dus 7450 patiënten sera getest, helaas is dit 
nooit in een paper terechtgekomen.
Ook wil ik Frank van den Hoogen bedan-
ken. Als reumatoloog begeleidde je mijn onder-
zoek naar de klinische relevantie van het 
bepalen van het anti-Th/To reactiviteit. Jij 
was meteen enthousiast voor dit onderzoek en 
wist dat enthousiasme ook telkens weer op 
mij over te dragen. Bovendien wist jij Laurens 
en Liane te motiveren meer dan 100 patiënten 
statussen door te werken. Frank, Laurens en 
Liane, Bedankt!
Onderzoekers buiten Nederland hebben ook 
aan dit onderzoek bijgedragen: Dr. S. Altman, 
Dr. C. Guerrier-Takada, Dr. N. Jarrous, 
Dr. A. de la Chapelle, Dr. M. Ridanpää en 
Dr. I. Kaitila, bedankt voor deze samenwerkin-
gen.
En dan de mensen die niet hebben mee-
onderzocht, maar op een andere wijze bij 
hebben gedragen aan dit onderzoek. 
Erik en Michael, wij vormden samen de 
drie musketiers van het Trigon. Na onze studie 
zijn we alle drie bij de VRT als aio begonnen, 
samen niet lunchen in het Trigon. Heerlijk 
afblazen, zeiken over dingen en ‘dat het niet 
leuk is als experimenten in één keer lukken’. 
Maar vooral ook veel lachen, ‘errrruuug 
bedankt’ voor een geweldige vriendschap en 
grote collegialiteit. 
Erik, jou wil ik nog in het bijzonder 
noemen. Jij bent hartstikke gek! Eerst heb je 
me overgehaald mijn proefschrift toch te gaan 
lay-outen. Vervolgens ben jij helemaal uit je 
dak gegaan en heb je alle figuren die niet aan 
jouw lay-out eisen voldeden (lees ALLE figu-
ren) aangepast. Ook heb je me gekker gemaakt 
dan dat ik al was, wat uitvoering van dit proef-
schrift betreft, maar goed het ziet er dan nu ook 
echt prachtig uit! Bedankt, bedankt, bedankt!
Alle andere collega’s en ex-collega’s wil 
ik verder bedanken voor de hand-en-span 
diensten, maar vooral eigenlijk de gezelligheid 
en discussies. In het bijzonder wil ik de vol-
gende mensen noemen: Rick, ex- en huidige 
collega, bedankt voor de steun als ‘oudere 
aio’, maar vooral voor de leuke tijd op het 
Trigon en in Schotland. Reinout, jij was de 
‘jongere aio’, bedankt voor de gezelligheid op 
onze Banff trip. De oudere ex-collega’s: Frank, 
Saskia, Helma, Jacqueline, Christel, Yvonne, 
jullie bedankt voor de mooie verhalen (over 
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Hans van Eenennaam is geboren op 3 
november 1973 te Nieuw- en Sint Joosland, 
gemeente Middelburg, als zoon van Jannetje 
Johanna Baas en Leendert van Eenennaam. In 
1992 behaalde hij zijn V.W.O. diploma aan de 
Christelijke Scholengemeenschap Walcheren te 
Middelburg en begon hij aan zijn studie schei-
kunde aan de Katholieke Universiteit Nijmegen 
(KUN). Tijdens deze studie heeft hij een bijvak-
stage doorlopen op de afdeling Moleculaire- en 
Ontwikkelingsgenetica (Drs. P. Bindels en Prof. 
Dr. W.H.G. Hennig) van de KUN. Zijn hoofd-
vak-stage heeft hij doorlopen op de afdeling 
Biochemie van de KUN onder begeleiding van 
Dr. H. Pluk en Prof. Dr. W.J. van Venrooij. 
Het doctoraal examen Scheikunde is cum laude 
behaald in augustus 1997. Hij ontving voor 
zijn afstudeeronderzoek bij de afdeling Bio-
chemie in 1998 de Universitaire scriptieprijs op 
het gebied van de Natuurwetenschappen.
Tijdens zijn studie is hij lid geweest van de 
Nijmeegse Studenten Roei Vereniging Phocas 
en is hij politiek commissaris geweest in het 
Bestuurlijk Overleg Studentenverenigingen. 
Verder is hij van 1996 tot 2001 lid van de Raad 
van Toezicht van de Stichting Studenten Huis-
vesting Nijmegen geweest.
Vanaf oktober 1997 tot oktober 2001 was 
hij werkzaam als Onderzoeker in Opleiding 
op de afdeling Biochemie van de KUN onder 
begeleiding van Dr. G.J.M. Pruijn en Prof. Dr. 
W.J. van Venrooij. Tijdens deze periode werd 
het onderzoek verricht dat is beschreven in 
dit proefschrift. Hij heeft gedurende deze peri-
ode drie studenten begeleid en een bijdrage 
geleverd aan het praktisch biochemie-onder-
wijs voor tweedejaars scheikunde studenten. 
Voor zijn onderzoek heeft hij een 4 maanden 
durend werkbezoek gebracht aan de groep 
van Prof. Dr. S. Altman (Yale University, New 
Haven, USA).
Hij heeft zijn onderzoeksresultaten gepre-
senteerd tijdens ‘the fourth annual meeting of 
the RNA Society’ in Edinburgh (1999) en ‘the 
sixth annual meeting of the RNA society’ in 
Banff (2001).
Sinds 1 januari 2002 is hij werkzaam bij de 
sectie Fertility van de Target Discovery Unit, 
Organon N.V. te Oss.
Dear Nayef, with you I started my collabo-
ration with the Altman group. Although in the 
beginning our collaboration was difficult, as 
we were working on highly related subjects, 
trust grew in time. Thanks for the trust you 
put in me, for all the materials you sent us and 
all the information you shared with us. I will 
never forget meeting you in person and still 
hold good memories to the talks we had over a 
glass of beer. I wish you all the best with your 
own group in Jerusalem. Finally, I would like 
to thank you for introducing to Sid my idea 
to work for some time in New Haven. Which 
brings me to you, Sid. I would like to thank 
you for the opportunity you have created for 
me to come and work in your lab for 4 months. 
You and your group gave me a warm welcome 
in a snow-covered New Haven. You taught me 
biochemical purifications, to be an enzymo-
logist and to think in terms of functionality. 
More importantly, you have learned me to keep 
Acknowledgements
an open mind and not to think in dogmas, but 
to look at the experimental data every time. 
To my surprise, you also told me that life is 
more than working in the lab and that gave me 
the opportunity to visit much of New York’s 
beauty. Cecilia and Donna, you two were my 
lab-mothers. You both took care of me and 
taught me everything about biochemical puri-
fications. Cecilia, special thanks to you, you 
supervised my work and encouraged me daily. 
You and Sid made me a better scientist!! 
Finally, I would like to thank Albert, Ilkka 
and Maaret. You contacted us and explained 
you had found a genetic defect, but needed 
biochemical help to understand your findings. 
I would like to thank you for all the trust 
you put in me and for the things you learned 
me about genetics. I enjoyed our collaboration 
very much.
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